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Abstract
The development of fully automated and high-throughput systems for proteomics is
now in demand because of the need to generate new protein-based disease biomarkers.
Unfortunately, it is difficult to identify protein biomarkers that are low abundant when in the
presence of highly abundant proteins, especially in complex biological samples like serum,
cell lysates, and other biological fluids. Membrane proteins, which are in many cases of low
abundance compared to cytosolic proteins, have various functions and can provide insight into
the state of disease and serve as targets for new drugs making them attractive biomarker
candidates. Traditionally, proteins are identified through the use of gel electrophoretic
techniques and two-dimensional protein profile patterns have been used as potential
diagnostic tools for biomarker discovery and the profiles from protein content of body fluids
or cells are available in databases.
However, gel electrophoretic methods are not always suitable for particular protein
samples. Microfluidics offers the potential as a fully automated platform for the efficient
analysis of complex samples, such as membrane proteins and do so with performance metrics
that exceed their bench top counterparts. In recent years, there have been various applications
and improvements to microfluidics and their use for proteomic analysis reported in the
literature. In addition, microfluidics offers the potential of a disposable, low cost, and easily
fabricated method to perform analysis on complex samples. In this work through the use of
microfluidic devices, we demonstrate the ability to effectively extract and purify biotinylated
cell surface membrane proteins from the cell lysate of MCF-7 human breast carcinoma. In
addition, we also attempt to separate membrane proteins from MCF-7 cells.

xxi

Our on-chip assay (µ-solid-phase extraction, µSPE) allows us to extract membrane
proteins and rid the sample of contaminating cytosolic proteins (purification) in order to do
further analysis on the membrane proteins. We also attempted to separate a complex
biological sample using a microchip that is suitable for multidimensional techniques that
employed sodium dodecyl sulfate micro-capillary gel electrophoresis (SDS µ-CGE) in the 1st
dimension and micro-micellar electrokinetic capillary chromatography (µ-MEKC) in the 2nd
dimension. Proteins were detected by laser-induced fluorescence following their labeling with
dyes. Because our overall goal of this work is the development of a completely integrated
system for the analysis of complex protein samples, we also discuss the integration of the
extraction module with the separation module along with fabrication steps toward the
integration of modules for the digestion of proteins on chip and interfacing the device with
MALDI-MS.
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Microfluidics for the Analysis of Integral Membrane Proteins: A Top-down
Approach

1.1

The Study of Proteins

1.1.1 The Proteome and Proteomics
The field of proteomics is focused on the determination of structures, expressions,
interactions, and functions, which includes activities, roles and localizations of the proteome a catalogue of the proteins in a specific organism coded by the genome. The original
definition of the proteome views it as the protein complement of the genome, thereby not
accounting for the numerous post-translational modifications and the varying state of
proteins.1,2 Proteomics involves a comprehensive analysis, including the determination of
structure, modifications, expression levels, localization and protein-protein interactions,
within a given organism, cell, biological fluid, or tissue. Schramm et al.3, reported that
proteomics involves the functional analysis of the full set of proteins by high-throughput
technologies in a given system. This definition suggests that proteomics goes beyond
identification and that protein analysis requires advanced technologies, such as highthroughput processing techniques. Proteomics attempts to tackle three main areas of interest:
(1) protein expression; (2) protein structure; and (3) protein function.4
1.1.2 Challenges in Proteomics
Various populations of proteins perform the higher biological functions in the cellular
network making proteomics an attractive tool for research and scientists alike.5 In cancer
research, particularly in identifying biomarkers for new drugs and drug discovery, proteomics
is vital because proteins have been selected for investigation as biomarkers because of their
past performance as biomarkers for other disease states or other cancers or because of their

1

function or family relationships.6 Throughout the past twenty years, there has been a growing
interest in approaches toward discovering new biomarkers that may allow early diagnosis,
prognosis, classification of disease subtypes, prediction of treatment response, and
identification of potential targets for drug therapy. For most of these applications, a single
marker is likely insufficient for stratification, and a panel of markers, i.e. molecular profiles or
biosignatures can be more useful. Such biomarker profiles can be identified at different
molecular levels, such as DNA, RNA, microRNA, and protein. A significant portion of the
biomarker discovery efforts using -omics approaches has been in the area of cancer, and
several markers are already in routine clinical practice, such as K-Ras mutation and HER-2
amplification. A particular area of interest is the cell surface proteome due to its ease of
accessibility and the possibility to serve as an ideal target for novel protein drugs. Most
acknowledge the importance of proteomics as procuring extensive information required for
the entire supplement of proteins comprising the proteome.
Traditionally, proteomic analyses of complex protein samples involve the resolution of
proteins using two-dimensional (2D) gel electrophoresis that includes isoelectric focusing
(IEF) coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and followed by the identification of resolved proteins by mass spectrometry.7,8 The idea of
building protein databases was proposed using subtractive pattern analysis of these gels.9-11
Over time, with the advances in analytical protein technologies and advancements in mass
spectrometry, it became possible for many proteins to be resolved by 2D-PAGE. However,
the disadvantages of 2D-PAGE include a large amount of sample handling, a limited dynamic
range, and difficulties resolving low abundance proteins12-14 with extreme pI and molecular
weights,15,16 and hydrophobic proteins such as membrane proteins.7 The solubility of
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hydrophobic proteins (membrane proteins) is problematic due to incompatibility with the IEF
buffers, and if the proteins are solubilized, they are prone to precipitation at their isoelectric
point (pI). To alleviate the issue of solubility with IEF buffers, many investigators have used
1D gel coupled with mass spectrometry for identification of the proteins.17-19 Yet, the
limitation of this approach is the increased protein complexity in each 1D gel band.
Shotgun methods provide a powerful alternative to 2D gels. Shotgun proteomics is
analogous to shotgun sequencing where DNA is broken into small fragments; these fragments
are sequenced, and recombined in silico to determine the DNA sequence of an organism. In a
general shotgun proteomic pipeline, a mixture of proteins is digested into peptides (using
proteases such as trypsin), the peptides are loaded onto at least a two-dimensional
chromatography based separation system, peptides are eluted into a tandem mass
spectrometer in an automated fashion, and the resulting tandem mass spectrometry data is
analyzed by powerful computational systems. Proteins are first digested with proteases into a
more complex peptide mixture that is then analyzed directly by LC/MS and protein
identifications are determined by database searching software.
This general approach is rapid and readily automated, but requires significant
computing resources for data analysis. Moreover, as with gel-based methods, the solubility of
membrane proteins is also a major challenge for non-gel shotgun approaches. Large scale
shotgun proteomics effectively began with the introduction of multidimensional protein
identification technology (MudPIT) in which a microcapillary column is packed with reversed
phase (RP) and strong cation exchange (SCX) packing material, loaded with a complex
peptide mixture and placed in line between an HPLC and a tandem mass spectrometry
system.20-22 In addition to 2D gel and shotgun proteomic techniques, industrial-scale (liters)
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approaches have also been reported for sample pooling of smaller proteins < 40,000 Da and
fragments of large proteins. Using over 12,000 plasma fractions, Rose et al.23 reported
thousands of peptide identifications, which permitted the identification of 502 different
proteins and polypeptides from a single pool.
Given the cost (liter-scale amounts of protein) and labor intensiveness (2D gel
techniques) of such methods, they are clearly not applicable to routine clinical tests and are of
marginal use in confirming candidate biomarkers where thousands of individual samples must
be analyzed separately to placate statistical criteria for diagnostic specificity and sensitivity.
Regrettably, proteomics is still burdened with numerous challenges that hinder its goals.
These challenges can be categorized as; (a) the sample type; (b) limitations of bench-top
approaches; and (c) analysis of data.
1.1.3 Complexity of Protein Sample
The proteome is very complex. The human genome is composed of approximately 3 x
104 genes.24,25 Proteins sizes can range from a few amino acids to several thousands making
them a very diverse and distinct class of molecules. They possess wide pI ranges and can be
hydrophilic or extremely hydrophobic to the point where they are almost irretrievable from
aqueous media.26 For example, proteins associated with the cell membrane contain
hydrophobic domains that make them particularly difficult to analyze using traditional
methods such as isoelectric focusing (IEF). Because of their hydrophobic and basic (as in
charge) nature, and frequently large size, their isolation is not easy.
A primary difficulty encountered in the study of membrane proteins is that of
obtaining the protein of interest. Membrane proteins are usually present at low levels in
biological membranes, and it is rare that a single protein species is a major peptidic
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constituent of the membrane.27 In addition most membrane proteins cannot be readily
obtained in sufficient amounts from their native environments and thus attempts are made to
overexpress them. A second difficulty is that membrane proteins are naturally embedded in a
lipid bilayer, which in even the simplest organism is a complex, heterogeneous and dynamic
environment. This limits (but does not exclude) the use of many standard biophysical
techniques to determine structure and function such as X-ray crystallography, circular
dichroism, NMR, ligand-binding studies, classical kinetic characterization, the identification
of structure–function relationships and also restricts applications since they require the protein
to be extracted from its native membrane and studied in a detergent or lipid environment in
vitro.27 This necessity leads to difficulties in sample preparation and spectral contributions
from lipids. Finally, membrane proteins are not generally soluble in aqueous media.
The need for membrane proteins to inhabit surroundings that satisfy their
hydrophobicity therefore requires special synthetic systems for in vitro work. Unfortunately,
reconstituting purified proteins into such systems has proven to be very difficult. Despite the
problems of working with membrane proteins, they remain an important area for study due to
their role in the control of fundamental biochemical processes and their importance as
pharmaceutical targets. Conventional methods for membrane isolation such as gradient
separation,28 polymer partitioning,29 and chemical treatment30 typically result in high purity
but are often cumbersome and protein yields are poor. The dynamic range (i.e. abundance,
size, function) of proteins within a single cell can span close to six orders of magnitude.31 It
has been estimated that between 100,000 to 250,000 proteins are encoded by roughly 25,000
human genes through post-translational modifications and differential splicing, which can
produce an additional 5 to 10 different proteins from each gene.32,33
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1.1.4 Limitations of Bench-top Approaches for Proteomic Analyses
Proteomics attempts to simultaneously determine the identities, functions, and
quantities of proteins.34 The need for large sample volumes, poor performance and laborintensive demands are all challenges associated with available bench-top techniques used in
proteomics.
For example, IEF-PAGE coupled with SDS-PAGE is a common strategy used to form
2D electrophoresis platforms, providing a dynamic range of 102 – 104 and a limit-of-detection
(LOD) ~10-6 M. This technique can routinely resolve >2,000 spots per gel, which is well
below the amount of proteins present in a proteomic sample. Moreover, it requires welltrained personnel, has limited automation potential, and can be time consuming.35 Mass
spectrometry (MS), on the other hand, provides better LOD (~10-15 mole for peptides) and
high specificity, however, 2D-PAGE cannot be coupled on-line with MS to achieve a fast
multidimensional protein separation and identification.36 As a result, multi-dimensional liquid
phase-based separation methods using different electrophoretic and chromatographic
techniques have been greatly developed as complementary methodologies because they can
be coupled on-line with mass spectrometers for protein identification. The feasibility of multimodular combinations of high-performance liquid chromatography (HPLC), isoelectric
focusing (IEF), chromatofocusing (CF), capillary electrophoresis (CE) as well as
combinations of different HPLC modes provides numerous options for the separation of
protein complexes and peptides.37

Ion-exchange chromatography (IEX) together with

reversed-phase (RP) liquid chromatography (RPLC) is one example of orthogonal 2D-LC
analysis.38 The total peak capacity in this 2D separation can be greater than 5000 and high-
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sensitivity peptide identification may therefore be achieved because of increased resolution
and the resultant decrease in peptide overlap.39
Among various kinds of 2D-LC techniques, the combination of strong cation
exchange (SCX) mode separation in the first dimension and RP separation in the second
dimension has become a dominant separation technology. As a classical proteome research
strategy, this SCX–RPLC approach provides a large amount of biological information as a
complement to traditional 2D-PAGE approach. Fujij et al.40 described an on-line SCX–RPLC
workflow involving stepwise salt elution using ammonium formate that was employed for
SCX separations and the resulting fractions were subjected to RPLC-MS analysis after
concentration and desalting. Vitali and co-workers41 also employed SCX–RPLC with tandem
MS (MS/MS) strategy to identify proteins from Bifidobacterium infantis. Digested proteins
were first separated through a SCX column and the fractions were collected every minute.
After drying and resuspension, protein fractions were further separated and identified through
a homemade RPLC coupling with a quadrupole time-of-flight (Q-TOF) mass spectrometer.
However, there is no amplification technique in proteomics similar to PCR in
genomics and therefore, proteins must be analyzed in their native concentrations. Also,
because of the inability to amplify protein targets using techniques employed in genomics,
proteome analysis can be much more challenging. This can be compounded by the high
complexity of proteome samples. No single chromatographic or electrophoretic procedure todate possesses the peak capacity required to resolve a complex mixture, such as that found in
a single proteome, to resolve all of its individual components.
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1.1.5 Complications of Protein Data Analysis
Measurable parameters in proteomics are large in number, and require many
biological and methodological replicates, which may not be so easy to attain. Bias in protein
data analysis is widespread and can be viewed as a threat to the validity of protein biomarkers
where results have been unclear or irreproducible.42,43 This issue is apparent when handling
large data sets, such as those presented in proteomic analyses. It is intrinsically easier to find a
correlation irrespective of real cause and effect due to false positive probably outnumbering
true positives.34 Lay et al. 34 pointed out that the failure of many proteomic studies correlates
with the failure to consider the analytical need to define quality standards, including method
validation and standardization. Also, due to a lack of quality standards, it is difficult to
compare results generated from various laboratories.
The analysis of a full proteome presents a formidable task and, in spite of recent
technical developments, remains to be achieved for any species. The task is challenging
because proteomes have a sizeable and undetermined complexity. What is certain is that the
number of proteins in a species proteome exceeds by far the number of genes in the
corresponding genome. This diversity arises from the fact that a particular gene can produce
numerous distinct proteins as a result of alternative splicing of primary transcripts, the
presence of sequence polymorphisms, posttranslational modifications, and other protein
processing mechanisms.44 Moreover, proteins span a concentration range that surpasses the
dynamic range of any single analytical method or instrument.
Peripheral membrane proteins do not interact with the hydrophobic core of the
phospholipid bilayer; they are usually bound to the membrane indirectly by interactions with
integral membrane proteins or directly through ionic interactions with the lipid polar head
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groups. Membrane proteins are, in some cases, amphipathic and can contain both hydrophobic
and hydrophilic domains. These characteristics render them extremely difficult to analyze.7
As a result, even though 20-30% of the human genome may encode for membrane proteins,45
they are underrepresented in most analyses.46
A central goal of proteomics has been the complete and, in most instances,
quantitative analysis of the proteome of a species or, in multicellular organisms, a particular
cell or tissue type. Although this goal has remained tenuous, significant progress has been
made in the development of an array of technologies for proteome analysis and their
application to biological and clinical research. At the present time, MS is generating the
majority of proteomic data, more specifically by tandem MS (MS/MS) with increasing
performance.47 The instrumentation and diverse workflows share a commonality in that they
generate hundreds to thousands of fragment ion spectra per hour of data acquisition. However,
the assignment of fragment ion spectra to peptide sequences, the interference of the proteins
represented by the identified peptides, and the determination of their abundance in the sample
being analyzed present complex statistical and computational challenges. Therefore, it is
essential that tools and solutions that provide both accurate and reproducible results and can
be generally applied to these problems be developed for proteomic studies.47 The
determination of function and abundance of individual proteins is also critical.
The correct assignment of the fragment ion spectrum to a peptide sequence is the first
key step in proteomic data processing. A plethora of software tools and computational
approaches have been developed to automatically assign peptide sequences to fragment ion
spectra and can be classified into three categories: (i) Database searching; (ii) De novo
sequencing; and (iii) alternative “hybrid” strategies. Database searching involves peptide
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sequences being identified by correlating the fragment spectra that are acquired with
theoretical spectra predicted for each peptide contained in a protein sequences database. In de
novo sequencing, peptide sequences are clearly read out directly from fragment ion spectra. In
addition, the alternative approaches that combine both database searching and de novo
sequencing offer the option of performing “error-tolerant” database searching after the
extraction of short sequence tags of 3-5 residues in length.
Several MS/MS database search programs have been developed and take the fragment
ion spectrum of a peptide as input and score it against theoretical fragmentation patterns
constructed for peptides from the searched database. The group of candidate peptides is
restricted based on user-specified criteria such as proteolytic enzyme constraint and mass
tolerance.47 The output from the program is a list of fragment ion spectra matched to peptide
sequences that have been ranked according to each score and, typically, the best scoring
peptide match is considered during the subsequent statistical analysis step. The search score
measures the degree of similarity between the experimental spectrum and the theoretical
spectrum, and therefore serves as the primary discriminating parameter for separating correct
from incorrect identifications.
There are numerous scoring schemes available including spectral correlation functions
(SEQUEST) or related concepts such as shared fragment counts and dot product (TANDEM,
OMSSA, MASCOT).47 Scoring functions can also be based on empirically observed rules or
statistically derived fragmentation frequencies. The score actually reported by the tool can be
based on an arbitrary scale or converted to a statistical measure known as the expectation
value, E, which refers to the expected number of peptides with scores equal to or better than
the observed score under the assumption that peptides are matching the experimental
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spectrum by random chance. The E value is computed by assuming that the database search
score follows a particular distribution, i.e. Poisson, or by empirical fitting of the observed
distribution of scores.48-50 This score is largely unchanged under different scoring methods
and gives a clearer interpretation of quality of the match across different instrument platforms
and search algorithms. However, it should be noted that neither the best match nor a high
search score (or low E value) are reliable indicators for a true match. Discriminating true from
false matches is therefore a critical next step in proteomic data analysis.
Spectral identification can be done using spectral matching with a library of spectra
representing the peptide sequences contained in the proteome map.51-53 The spectral library is
compiled from a large collection of experimentally observed mass spectra of correctly
identified peptides. An unknown spectrum can then be identified by comparison to candidates
in the spectral library to determine the match with the highest spectral similarity.54 Although
the method of spectral matching outperforms database searching in speed, error rate, and
sensitivity characteristics of the results, no peptides will be identified that were not previously
entered into the respective spectral library. In the de novo sequencing approach, the amino
acid sequence of a peptide is read from a fragment ion spectrum with the main advantage over
database searching being that it allows identification of spectra for which the exact peptide
sequence is not present in the searched sequence database, such as those peptides that contain
sequences with modified peptides or polymorphisms.
Yet, de novo analysis is computationally intensive and requires high quality fragment
ion spectra. Furthermore, peptide sequences extracted using de novo algorithms need to be
matched against sequences of known proteins present in the sequence databases because
researchers are more interested in knowing the proteins present in the sample. Hybrid
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strategies that combine both database searching and de novo sequencing start with the
interference of short sequence tags (partial sequences) from MS/MS spectra, followed by an
error-tolerant database search, which will allow for one or more mismatches between
sequence of the peptide that produced the spectrum and the database sequence.55-57 By
limiting the search to only those database peptides that contain the sequence tag extracted
from the spectrum, the database search time can be reduced significantly.
Although proteome analysis has seen various improvements over the last decade with
respect to sample processing, data analysis, and data acquisition, many challenges remain.
And are primarily associated with the complexity of the proteome itself. There are also
challenges related to the analysis of the information contained in proteomic datasets. Inferring
the identities of proteins, protein isoforms, and differentially modified proteins in a sample
from confidently identified proteins is also a challenge. Two alternatives that are being
utilized more frequently is top-down proteomics, which is focused on the analysis of intact
proteins rather than the peptides and has the potential to resolve populations of proteins into
their components,58-60 and the targeted analysis of specific peptides of high information
content (proteolytic peptides) that collectively represent the proteome, thus eliminating the
redundancy of current methods that are available now.47,61,62 Although substantial progress
has been made in the effort to improve the analysis of proteomic data, the development of
new algorithms and analysis tools still remain before these technologies can be implemented
routinely.
1.2

Membrane Proteins: Organelle-specific Sub-population of the Proteome
A strategy to overcome the challenges associated with full proteome analysis is to

target proteomes of certain organelles, for example membrane proteins. Conventional
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proteome analysis can include fractionation of biological cell components and performing the
analysis on individual organelles63 such that only a sub-population of the full proteome is
analyzed. Organelle pre-fractionation normally involves cell homogenization, density gradient
separation of organelles, detergent extraction of membrane proteins, and two-phase
partitioning with high-salt and high-pH washes. These processes can be lengthy, laborintensive, and may result in poor yields.63-65
A principal sub-population of the proteome is membrane proteins, which provide
important cellular functions such as controlling transport into and out of the cell and
communication and regulating responses to external stimuli. Membrane proteins are normally
classified into one of two categories, integral and peripheral and are based on the nature of
their association with the cell membrane (see Figure 1.1).

Figure 1.1 Various membrane proteins and their associations with the biological membrane
(Reproduced from Cordwell, S. J.; Thingholm, T. E. Proteomics 2010, 10, 61166 with
permission, Copyright 2013, John Wiley & Sons).
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Integral membrane proteins have domains embedded in the phospholipid bilayer and
contain hydrophobic amino acid side-chain residues that interact with fatty acyl groups of the
phospholipids, anchoring the protein to the membrane. They function primarily in signal
transduction. Proteins that have domains that span the entire phospholipid bilayer are called
transmembrane proteins. These molecules can possess several hundred amino acid residues
that extend both into the aqueous medium on either side of the bilayer and multiple
transmembrane domains (TMDs) within the membrane.67 Integral membrane proteins are, in
most cases, amphipathic and can contain both hydrophobic and hydrophilic domains. These
characteristics render them extremely difficult to analyze,7 and as a result, they are
underrepresented in most analyses.46 Peripheral membrane proteins do not interact with the
hydrophobic core of the phospholipid bilayer; they are usually bound to the membrane
indirectly by interactions with integral membrane proteins or directly through ionic
interactions with the lipid polar head groups.
The isolation of sub-populations of the proteome can be combined with specific
protein tagging strategies to reduce cross-contamination. For example, immobilized
antibodies against membrane proteins were utilized for the purification of a membrane
fraction using magnetic beads, but were limited to proteins for which a specific antibody was
available.68 Protein radioactive labeling has been employed in different protein studies for the
isolation of membrane proteins

69

and quantitative analysis of proteins by MS is often

performed with isotope-coded affinity tags.14 Surface-protein biotinylation strategies with
affinity purification using avidin or streptavidin columns, avidin-modified magnetic beads or
visualized by hybridization with streptavidin-HRP complexes have been reported and new
surface membrane proteins identified.70-76
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1.2.1 Importance of Integral Membrane Proteins
Integral (or peripheral) membrane proteins act as major gateways into the intracellular
environment. All cells and most intracellular organelles are enclosed in an impermeable lipid
bilayer and the integral membrane proteins are embedded in these membranes. They are the
entry and exit routes for many ions, nutrients, waste products, hormones, drugs and large
molecules such as proteins and DNA. They are also responsible for much of the
communication between cells and their environment. Additionally, these proteins provide
responses to external stimuli. Cells can make a huge variety of membrane proteins.
Approximately, 38% of all proteins encoded by the mammalian genome and more than onethird of the current list of potential biomarkers are classified as membrane proteins.77-79
The medical importance of this enormous family of proteins cannot be undervalued.
Integral membrane proteins have been reported to play key roles in host-pathogen
interactions77,80-82 and cell regeneration after injury.83 Cardiovascular diseases, cancer, and
diseases caused by degeneration of cells within the central nervous system are major health
problems in the United States.77,84-86 Proteomic investigations into Integral membrane proteins
have the potential to identify new biomarkers that ensure early disease diagnosis, offer targets
for new therapeutics, and provide an indication of response to therapy.
Integral membrane proteins are localized on the cell surface and are the first to be
impacted by pathological changes in the cellular microenvironment. As part of the cellular
response to a pathological insult, Integral membrane proteins may be secreted or shed from
the cell surface into biological fluids (plasma, cerebrospinal fluid, or urine).

87

The level of

Integral membrane proteins in these fluids can provide valuable diagnostic and/or prognostic
information about disease, disease severity, and the progress of the therapy for the disease.88
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As stated previously, membrane and membrane-associated cell surface proteins
represent more than one-third of the proteins encoded by the human genome, however, they
also account for more than two-thirds of the targets for existing drugs.89 They are also an area
of special interest because of their accessibility to new drugs for treatment of the abovementioned diseases.86,89,90 Therefore, it is critical that advances toward the isolation and
identification of Integral membrane proteins continue, especially those with multiple transmembrane domains (TMDs) and post-translational modifications (PTMs) due to their
expansive roles as possible disease biomarkers and target molecules in disease treatment.
1.2.2 Difficulties in Handling Integral Membrane Proteins
Membrane proteins are unique within proteome research due to their diversity and
behavior during the process of purification and separation.66,79 Membrane proteins are
embedded in the lipid bilayer and the composition of these lipids varies among the systems.
The nature of the lipids can affect the stability of the protein. Several post-translational
modifications (PTMs) of membrane proteins can produce extreme micro-heterogeneity that
can reduce the efficiency of electrophoretic and chromatographic separations. The PTMs and
hydrophobicity of Integral membrane proteins also cause complications with their
identification by MS.79,91 Membrane proteins are extracted from the host cell membrane by
the addition of detergents, which cover the hydrophobic surface of the protein, allowing
solubilization.
The choice of detergent is a crucial part of the purification process. Often a series of
detergents are tested and the detergent that extracts the largest quantity of soluble, active,
homogeneous, stable protein is used; however, it should be noted that just because a detergent
is successful with extracting membrane proteins, it does not mean that they will be
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solubilized. Despite advances in methods to analyze hydrophobic proteins, integral membrane
proteins are still under-represented in most membrane proteomes.79,92 Contamination of the
membrane protein fraction by other organelles and non-membrane proteins, which interact
with the plasma membranes during the purification process, is a serious issue. It is paramount
that problems such as these be alleviated or eliminated to guarantee the purest membrane
protein fraction for further downstream analysis.
1.3

Current Methodologies in Integral Membrane Protein Analysis
The study of membrane proteins using high resolution and throughput proteomics

remains challenging. While membrane proteins are generally low in abundance, the foremost
impediment in their analysis is poor solubility. Integral membrane proteins, in particular,
contain both hydrophobic and hydrophilic domains, which makes them difficult to purify and
characterize on a proteomic scale. In order to undertake a comprehensive analysis of
membrane proteins, several areas need to be considered. The analysis can be divided into four
main experimental steps: (i) enrichment and purification of membrane proteins; (ii)
solubilization of membrane proteins; (iii) separation; and (iv) identification and
characterization (analytical techniques). Each of these steps provides experimental challenges
and influences the success of the experimental design and the interpretation of the results.
1.3.1 Enriching and Purifying Integral Membrane Proteins
There are several strategies available to probe targets that are in low abundance,
including detection methods with single-molecule sensitivity that utilize fluorescence and/or
electrochemistry. Mutch et al. developed a technique to count low-copy-number membrane
proteins in synaptic vesicles.125,126 They used this approach to quantify proteins in isolated,
single synaptic vesicles and they were able to quantify seven major membrane proteins of rat
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brain synaptic vesicles. The method combined organelle purification with immunolabeling,
microfluidics, and total-internal-reflection fluorescence (TIRF) microscopy. The enrichment
and purification of integral membrane proteins is one of the most critical components of the
experimental approach, with the major challenge being the presence of contaminating, higher
abundance cytosolic proteins in the final protein extract prior to solubilization and analysis.
Some of the strategies for the enrichment of membrane proteins are summarized in Table 1.1
and will be discussed in the next few sections.
Table 1.1 Strategies for Membrane Protein Enrichment
Membrane
Protein
Enrichment
Strategy
Two-phase
purification

Principle

Isolation of
membrane proteins
from soluble
proteins according
to hydrophobicity

Sample
Origin

Results

Drawbacks

Rat liver

67% were
integral
membrane
proteins

Actin
contamination
in membrane
protein fraction,
laborious

81% were
classified
as
membrane
proteins

High detergent
conc. affects
protein stability
& further
analysis

Efficiently
removed
peripheral
membrane
proteins
50% of the
proteins
were
integral
membrane
proteins

Only loosely
bound cytosolic
proteins
removed,
protein cleavage
Contamination
of cytosolic
proteins, sample
handling,
laborious

Enrichment using
a solution of
cationic colloidal
silica particles

Electrostatic crosslinking to silica
particles

Rat lung,
microvascular
endothelial
cells

Wash with high
salt or high pH
conditions

Removal of
loosely bound
cytosolic proteins

Rat Liver

Differential
centrifugation or
density
sedimentation

Isolation of
membrane proteins
from sub-cellular
organelles based
on difference in
organelle densities

Mouse liver
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Ref.

94

95

96

97

Table 1.1 Strategies for Membrane Protein Enrichment (continued)
Membrane
Protein
Enrichment
Strategy
Enrichment using
secondary
antibody superparamagnetic
beads

Combination of
sucrose
centrifugation and
sodium carbonate
extraction

Principle

Beads coated with
antibodies against
known membrane
proteins

Purification of
membrane
proteins and
removal of
cytosolic proteins
loosely bound to
membrane

Sample
Origin

Mouse liver

hMSC

Results

67% were
membrane
proteins or
proteins
associated
with
plasma
membrane
57.3%
were
integral
membrane
proteins

Drawbacks

Ref.

Antibodies must
be specific for
membrane
proteins

98

Time
consuming, pH
conditions have
negative effects
on proteins

99

Many of the membrane protein fractions are obtained from tissue samples or cells that
have been lysed by physical or chemical means.66 Membrane protein fractions with high
purity and stringency are also hard to obtain from samples where little material exists to begin
with.66,93 In studies with membrane proteins in which cell culture systems are utilized, often
only Integral membrane proteins of the highest abundance are identified; and of those
identified, many have poor reproducibility due to the presence of contaminating proteins from
other organelles.66 Listed below are some the bench top techniques used for the enrichment
and isolation of membrane proteins along with a short description as to their implementation.
1.3.1.1 Precipitation and/or Density Gradient Centrifugation of Integral Membrane
Proteins
Sub-fractionation is a means for reducing the complexity of an initially complex
sample, improving the dynamic range, and consequently enhancing the identification of low
abundance proteins or those specific to a research problem of interest.96,97,100-104 Traditionally,
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the purification of membrane proteins involves density gradient ultra-centrifugation and/or
chemical precipitation. Using chemical precipitation requires aqueous two-phase purification,
where membrane and membrane proteins are separated from cytosolic (soluble) proteins
according to their hydrophobicity, such as PEG 3350 or dextran T-500.105,106 Aqueous twophase purification has also been utilized for the fractionation of membrane proteins prior to
MS analysis, resulting in the identification of 42% and 67% of integral membrane proteins of
rat brain and liver proteins, respectively, as an example.105,107
Density sedimentation or differential centrifugation of whole cell lysates, tissue
lysates, or microsomes can be employed to separate membrane proteins from other subcellular organelles due to their difference in density.108-112 Zhang et al. applied sucrose density
gradient centrifugation to isolate membrane protein fractions from mouse liver, identifying
50% of integral membrane proteins from a total of 175 proteins.112 Washing steps using high
salt and high pH can improve the removal of cytosolic proteins, especially those that are
loosely bound to the cell membrane.113 The combination of sodium carbonate extraction with
sucrose gradient centrifugation has also been used to enrich for membrane proteins. With this
combination, a total of 463 proteins were identified in which 122 (26.3%) were predicted
membrane proteins.110
Triton X-114 and other strong non-ionic detergents may also be used for the
separation of extracted hydrophobic and hydrophilic proteins. The solution is homogenous at
0°C, but separates into an aqueous phase and detergent phase when heated above 20°C with
the separation becoming more apparent at increasing temperatures, and is also affected by the
presence of other surfactants.95 The hydrophilic proteins separate to the aqueous phase and the
hydrophobic membrane proteins are found in the detergent phase.95 This method has been
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shown to be very efficient
glycosylphosphatidylinositol

and has also been used for the separation of

(GPI)-anchored

proteins.115

Thingholm

and

co-workers

investigated the efficiency and reproducibility of combining sodium carbonate extraction with
sucrose centrifugation for the enrichment of membrane proteins tested in the preparation for
phosphorproteomic studies of human mesenchymal stem cell (hMSC) membrane proteins.116
There are also commercially available methods such as the Mem-PERTM Plus Membrane
Protein Extraction Kit (Pierce Biotechnology, Rockford, IL) that use detergents to release
cytosolic proteins into an aqueous phase and solubilize membrane proteins using detergents.
However, it should be noted that although these studies employing two-phase
purification, density sedimentation, or conventional differential centrifugation were successful
in the confirmation of the enrichment of the integral membrane proteins, they have also been
known to be contaminated with significant amounts of cytoplasmic organelles, making it
difficult to compare protein expression profiles between two preparation methods.75,114
1.3.1.2 Cross-linking of Integral Membrane Protein Complexes
Exposed integral membrane proteins can be purified using protein cross-linking
reagents to maintain the membrane protein complexes as close to their native state as possible.
After cell lysis, the non-complexed proteins can be removed by immunoprecipitation using
antibodies directed against the membrane proteins of interest, size-exclusion chromatography,
or through the use of a cross-linker that enables affinity purification.66 Several groups have
employed this technique to get a better understanding of surface protein topology with protein
complexes.117 A variation of this approach was introduced by Freed et al.118 that allowed for
biotinylation and surface protein cross-linking. In turn, the strategy provided a robust means
of affinity purifying the complexes that resulted from the cross-linking.
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Recently,

photocrosslinking strategies have been utilized to improve the purification of membrane
proteins.119 The study by Gubbens and co-workers employed cross-linking mitochondrial
membrane proteins to phospholipids and led to the identification of several membrane
proteins from the sub-sub cellular fraction.119 Their studies indicated that this approach could
be an extremely effective way to further improve the identification of genuine membrane
proteins.
1.3.1.3 Cell-surface Shaving to Improve Identification of Integral Membrane Proteins
The concept of cell-surface shaving for the improvement in identifying and
quantifying proteins exposed on the cell surface has been discussed for quite some time.120,121
The idea is formulated around using a protease in free solution around intact cells. Peptides
that are exposed on the surface are cleaved by the protease into the surrounding solution.
They are then collected and analyzed using tandem mass spectrometry for identification (see
Figure 1.2).66

Figure 1.2 Cell ‘‘shaving.’’ Surface-exposed peptides are released by protease digestion into
the surrounding solution. The peptides are then collected and analyzed by MS/ MS for their
identification (Reproduced from Cordwell, S. J.; Thingholm, T. E. Proteomics 2010, 10, 61166
with permission, Copyright 2013, John Wiley & Sons).
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In theory, this method could prove to be very advantageous. First, it provides
information about the surface topology of the cell (i.e. for those epitopes that are exposed on
the surface, which are capable of interacting with other surface molecules, foreign particles,
etc.). Furthermore, if proven successful, there would be no need for the solubilization of
highly hydrophobic proteins because those peptides exposed on the surface would be soluble
even from integral membrane proteins that are insoluble. Unfortunately, cells have been
unstable during the protease treatment when using this method. In addition, removal of cell
debris is difficult when using centrifugation, and there has been significant contamination of
cytoplasmic proteins after cell lysis. Yet, there has been some success when investigating
bacterial systems (mainly Gram positive containing bacteria due the sturdy cell wall);121,122
nevertheless, there are still a large amount of cytoplasmic proteins remaining on the identified
protein lists, which reduces the confidence in the assignment of those epitopes exposed on the
surface.
There has been work by Speers and co-workers123 on HeLa cells using proteinase-K
and high pH treatment combined with micro-LC-MS/MS performed at high temperatures. The
authors reported a significant improvement in the identification of integral membrane
proteins, with ~87% of those having transmembrane domains. Elortza et al.124 further
modified the strategy and coined the term “shave and conquer” to describe phospholipase D
treatment to remove GPI-anchored proteins from the cell surfaces of both plant and human
cells. While there has been some success with this technique, it should be noted that problems
still exist with cell lysis and that they have yet to be fully realized or overcome.

23

1.3.1.4 Fractionation of Sub-cellular Organelles for Enrichment
The current approach to proteomics is to assess fractions of organelles rather than cell
homogenates by MS. As a result, the complex human proteome can be broken into simpler
components. However, the quality of the data received relies heavily on the purity of the
organelle fraction. There have been reports of more recently developed methods to generate
high purity fractions of organelles that sediment at the same rate as other organelles or
contaminants.127,128
For example, fluorescence-activated organelle sorting (FAOS), in which fluorescently
tagged antibodies interact with highly expressed surface proteins that are specific to the
organelle of interest, has been used to generate highly pure fractions.127 Gauthier et al.
performed the proteomic analysis of the endocrine secretory granules of corticotropes-derived
cells (AtT-20 cells) using FAOS.128 The authors circumvented the density gradient
centrifugation steps. In order to purify the secretory granules, endocrine cells were transfected
with a construct encompassing part of a secretory granule specific protein fused in frame with
green fluorescent protein (GFP). Once sorted, the enriched secretory granules were lysed and
their content was found to be closely related to that derived from other endocrine granules
isolated through conventional density gradient protocols.129 Furthermore, MS analysis of the
ensuing complex protein mixture was performed without resorting to gel electrophoresis,
which, if deemed necessary, could add a further refinement step.
1.3.1.5 Immunoaffinity Techniques for Enriching Integral Membrane Proteins
Affinity enrichment has also been used for the isolation of membrane proteins. In this
case, enrichment was achieved through the use of silica or magnetic beads that have been
coated with specific antibodies, a method that can be applied to both tissue samples and cells
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grown in culture. Several groups have been successful in using immobilized monoclonal
antibodies against known membrane proteins for enrichment.130,131 Moreover, the method is
both an efficient and specific technique for additional purification of previously enriched
fractions of membrane proteins.
In 2004, Chang et al.114 developed a protocol for the isolation of neutrophil plasma
membranes utilizing a plasma membrane marker antibody, anti-CD15, attached to
superparamagnetic beads. Cells were initially disrupted by nitrogen cavitation and then
incubated with anti-CD15 antibody-conjugated superparamagnetic beads. The beads were
then washed to remove unbound cellular debris. These methods were coupled with
immunodetection methods (Western blots) and an adenosine 5′-diphosphate-ribosylation
assay to measure the amount of membrane-associated Giα proteins. Lawson et al.101 used the
same technique in 2006 for the enrichment of membrane proteins from rat liver and two
different hepatic carcinoma cell lines. Zhang and co-workers132 optimized an immunoaffinity
protocol by using secondary antibody super-paramagnetic beads to enrich membrane proteins
from mouse liver and compared the method to sucrose density centrifugation. Their optimized
method showed a threefold increase in the amount of identified membrane proteins, and
contamination of abundant, mitochondrial proteins was decreased. There has been a variation
of this approach using cells that have been coated with antibody-conjugated magnetic beads
with the authors reporting achieving ~98% purity in the isolation of membrane protein
sheets.133
1.3.2

Solubilizing Integral Membrane Proteins
After successful enrichment of the membrane protein fractions, there still remains the

issue of solubilizing the membrane proteins for further downstream analysis. Membrane
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proteins are distributed in the lipid bilayers of cell membrane making them hydrophobic, but
they also have hydrophilic regions that extend into the cytoplasm of the cellular region. They
are very difficult to solubilize in water-based environments, because they easily form
aggregates and precipitates in aqueous media;134 however, water-based environments are vital
for IEF. Therefore, many other detergents, including Triton X-114, octylglucoside, CHAPS,
C8Ø, sulfobetaines (SB 3-10, SB 3-12, etc.), and ASB-14,8,135,136 among others, have been
employed to aid in the solubility of membrane proteins in aqueous solutions.
Unfortunately, none of the detergents that are currently in place are satisfactory for all
the membrane proteins.135,136 For example, C8Ø is good for isolating more abundant and
hydrophobic membrane proteins, but not for a variety of critical membrane-associated
proteins,8 which suffer loses after being processed with C8Ø. Secondly, proteins may
precipitate at or close to their pI during IEF, where their solubility is lowest. 137 Interactions
between proteins with the acrylamide buffering groups resulting in adsorption of proteins in
the immobilized pH gradient (IPG) matrix cause severe quantitative losses of membrane
proteins.
Rabilloud and co-workers138-140 utilized thiourea to alleviate this issue with
hydrophobic membrane proteins. Nonetheless, protein loses still occurred due to thiourea
inhibiting the SDS-protein binding, and, most importantly, increasing the solubility of lipids,
which interfere with the isolation and separation of the membrane proteins in 2DE.141,142
Additionally, there is a limitation on the use of reducing agents. Detergents can interfere with
downstream processing (i.e. mass spectrometry) because they can have negative effects on the
enzymes used for digestion. Some of the main methods for membrane protein solubilization
discussed throughout this section are summarized in Table 1.2.
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Table 1.2 Membrane Protein Solubilization Methods
Membrane
Solubilization
Principle
Sample
Techniques
Origin
Carbonate
extraction and
Avoid
Membrane
solubilization
interference
proteins in D.
using organic
with subsequent radiodurans
solvent free of
MS analysis
strain R1 cells
surfactant
Detergent
solubilization
w/chaotropic
reagents or
strong ionic
detergent
Phase
separation of
extracted
hydrophobic
and hydrophilic
proteins using
detergent

Repeated
freezing and
thawing

Extraction of
detergentresistant
proteins

Triton X-114 is
homogenous at
0°, but forms
detergent phase
at 20°
containing
membrane
proteins and
aqueous phase
with
hydrophilic
proteins
Solubilize
proteins that are
loosely
associated with
the membrane

Rat liver

Results

Drawbacks

Extensive
coverage of the
D. radiodurans
membrane subproteome

Use of
organic
solvents &
high pH
affect
downstream
analysis

Identification of
members of the
annexin family
in the detergentinsoluble
fraction

Method tested
Hydrophilic
the efficiency
proteins were
of solubilizing solely identified
both
in the aqueous
hydrophilic
phase and
and
hydrophobic
hydrophobic
proteins were
proteins in
identified in the
two different detergent phase
phases

Rat liver and
hepatocellular
carcinoma
Morris
hepatoma
7777

Shown to be
reproducible
and reliable

High conc. of
detergents,
laborious

High conc. of
detergents in
membrane
protein
fraction

Repeated
freezing and
thawing of
protein
reduces
stability

Ref.

143

144

104

145

Many reducing agents have been employed for IEF, and each has its own drawbacks.
Dithiothreitol (DTT), dithioerythritol (DTE), and tris(2-carboxyethyl) phosphine (TCEP) are
weakly acidic and are charged at alkaline pH, migrating towards the anode. Consequently,
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there will be a deficiency at the basic end of the IPG strip during IEF and, in turn, will cause
re-oxidation of reduced S-S bonds of the proteins and contribute to the horizontal streak.143
Repeated freezing and thawing is a technique that has been used to solubilize those
proteins only loosely associated with the plasma membrane and not those with many
transmembrane domains.144 Following extraction, various detergents must be used to
solubilize those integral membrane proteins that are highly hydrophobic, but what detergent is
used

is

dependent

upon

the

downstream

separation/fractionation

techniques

employed.104,113,145,146 It is vital that the known biochemistry of the system being investigated
is taken into account. For example, the use of chaotropic reagents such as urea or guanidine
hydrochloride, or strong ionic detergents such as SDS, may not be compatible with some
separation protocols, or may inhibit the optimal functionality of certain proteases like
trypsin.145,147
Many groups have used liver tissue from rats as a model for membrane protein studies.
One study combined sodium cholate and polidocanol to solubilize rat liver membrane proteins
in order to study (Ca2+-Mg2+)-ATPase.146 Studies by Josic and co-workers144,145 have
employed different solubilizing agents and Triton X-100. After the solubilization of the
membrane proteins, they used an ethanol/acetone wash to remove lipids and precipitate the
detergent-resistant proteins. The proteins were then subsequently solubilized with urea and
the zwitterionic detergent CHAPS. Unfortunately, membrane proteins with several
transmembrane domains were not solubilized.148 Prior to separation with SDS-PAGE and LCMS/MS, Clifton et al. utilized EGTA with octyl-glucopyranoside for the extraction of
detergent resistant proteins.149 In a consequent study, the same group used a sequential
extraction method by repeated freezing and thawing as the first step, followed by washes with
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different salt solutions and/or high pH. Thirdly, the integral membrane proteins were
solubilized with different detergents and finally, the proteins that were insoluble in detergent
were extracted with calcium chelation using EDTA or EGTA in combination with
octylglucoside or CHAPS.149
As previously stated, there are still many challenges with solubilization of integral
membrane proteins because several suitable detergents and chaotropes used interfere with the
downstream separations, particularly liquid chromatography (LC). In addition, if mass
spectrometry is to be used (i.e. electrospray ionization, ESI-MS), the use of detergents can
introduce noise into the analytical technique due to the chemicals there within, and thus, must
be removed prior to analysis.153 Although methods exist to achieve detergent removal, they
usually result in loss of analyte and are not necessarily compatible with studies that wish to
examine samples with low yield or sample targets low in abundance.
Detergent removal is typically done by precipitation of the proteins using
trichloroacetic acid (TCA), a combination of chloroform and methanol, or with organic
solvents such as acetone. Furthermore, in addition to the overall loss of proteins from the
sample following precipitation, it is likely possible that hydrophobic proteins of interest are
also lost during this step.101,149 Blonder et al.153 employed the combination of carbonate
extraction and solubilization using organic solvent that was free of surfactants to avoid the
loss of the hydrophobic proteins. They then followed with tryptic digestion prior to MS
analysis. Moreover, thiourea has specifically been shown to improve the solubilization of
membrane proteins.149
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1.3.3 Separating Complex Fractions of Integral Membrane Proteins
After successful purification/enrichment of the membrane proteins and their
solubilization, the sample is still complex and further fractionation is necessary in order to
increase the eventual protein/peptide identification coverage, which is how many proteins are
identified with the subsequent MS analysis. Methods of fractionation are typically focused on
either separation at the peptide or protein level.66 There are various techniques available to
perform protein separation including: two-dimensional electrophoresis utilizing IEF and SDSPAGE; SDS-PAGE coupled to liquid chromatography and tandem MS (LC/MS/MS) known
as “slice and dice;” and methods for peptide separation after proteolytic digestion such as
multidimensional peptide LC coupled to tandem MS and peptide isoelectric focusing (pIEF).
1.3.3.1 Two-dimensional Electrophoresis (2DE) with Isoelectric Focusing (IEF) and
SDS-PAGE for the Separation of Integral Membrane Proteins
For a number of years, the most popular method used for fractionation has been SDSPAGE,155-157 either as the sole method of separation, or in combination with IEF to produce a
2DE technique (i.e. IEF in the first dimension coupled with SDS-PAGE in the second
dimension) that can offer high peak capacities compared to a 1DE approach. While 2DE
remains one of the core separation technologies of proteomic analysis, proteins that are
extremely basic (positively charged), hydrophobic, or of large mass present significant
challenges for 2DE separation due to aggregation, oxidation, precipitation, and the physical
limitations of the 1D immobilized pH gradient (IPG) strip.158 Since the introduction of
commercially available immobilized pH gradient strips, several groups have experimented
with IEF conditions using various detergents alone or in combination,159 thiol oxidants,160 and
alternative detergents.141
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McDonough and co-workers utilized modified equilibrium conditions between the
IPG strip and the second dimension to get better focus and quantification of a positively
charged integral membrane protein and also improved migration into the second dimension.158
Techniques using IEF have enabled fractionation of proteins and peptides to be performed in
solution, and new protocols have been developed using several detergents, thiol oxidation
reagents, and different denaturants in order to make improvements to the isoelectric
focusing.141,159 In order to provide enhanced sensitivity and improved reproducibility for
peptide separations, IEF in IPG strips, free-flow electrophoresis, or in liquid isoelectric
focusing has been used.161,162
Chick et al. used an IPG-pIEF to identify 626 membrane proteins from rat liver,
however, this only represented 42% of the identified proteins suggesting that there is a need
for further investigation into enriched membrane proteomes in order to increase the
identification rate of protein contamination from other sub-cellular fractions.163 Free flow
electrophoresis has been used as a suitable approach for the separation of organelles, peptides,
and proteins164,165 and has been shown to be highly reproducible, with excellent separation
collecting up to 96 fractions.162
There have been variations of the gel-based separation technique reported, such as the
“slice and dice” method in which complex mixtures are separated by SDS-PAGE and the
resulting gel is “sliced” into equal bands throughout the lane. Each band is then “diced” into
smaller pieces and subjected to proteolytic digestion to release peptides that can be identified
using reversed-phase (RP) LC-MS/MS.66 By utilizing this technique, hydrophobic proteins
can be solubilized efficiently. Yet, 2DE employing IEF and SDS-PAGE have significant
limitations at the protein level that minimize their effectiveness for membrane protein
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separation and 2DE usually offers poor resolution of hydrophobic or basic proteins especially
those with > 3 transmembrane domains.
In work published by Xu et al.,166 the authors used IEF with SDS-PAGE to separate
outer membrane proteins from E. coli. With this 2DE technique, they were able to obtain ~50
spots that were representative of membrane proteins. The 2DE gel (IEF/SDS-PAGE) from the
separation is shown in Figure 1.3. The spots that are more darkly stained are most likely
representative of membrane proteins that are more abundant and the faint spots are those of
membrane proteins that are lower in abundance. Several groups have attempted direct analysis
of intact membrane proteins and identification of their covalent modifications. In this
approach, the protein mixtures are first solubilized and then chromatographically resolved.
Intact membrane proteins of up to 61 kDa167-170 have been analyzed directly by LC/MS.

Figure 1.3 A 2DE profile of outer membrane proteins from E. coli employing IEF in the first
dimension and SDS-PAGE in the second dimension (Reproduced from Xu, C.; Lin, X.; Ren,
H.; Zhang, Y.; Wang, S.; Peng, X. Proteomics 2006, 6, 462166 with permission, Copyright
2013, John Wiley & Sons).
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le Coutre and co-workers167 employed high performance liquid chromatography
(HPLC) coupled to electrospray ionization MS (ESI-MS) to separate and identify solubilized
membrane proteins from E. coli. As the authors demonstrated (see Figure 1.4),
chromatography combined with ESI-MS can separate an individual membrane protein from a
crude mixture and measure its molecular mass, which can be used subsequently to identify the
protein with a database search, provided the database sequence is correct and the isolated
protein has not been post-translationally modified.

Figure 1.4 (A) The elution profile of solubilized E. coli membrane proteins with HPLC. (B)
ESI-MS spectrum of the peak indicated in panel A (Reproduced from le Coutre, J.;
Whitelegge, J. P.; Gross, A.; Turk, E.; Wright, E. M.; Kaback, H. R.; Faull, K. F.
Biochemistry 2000, 39, 4237.167 with permission, Copyright 2013, American Chemical
Society).
However, both methods have limited sensitivity making it difficult to detect lower
abundance proteins, and the dynamic range is limited meaning that peptide-focused, liquidbased strategies are more often used.171
1.3.3.2 Separating Integral Membrane Proteins Utilizing Liquid Chromatography
To date, the most common method employed for the separation of integral membrane
proteins or peptides from the proteolytic digestion of integral membrane proteins is high
performance liquid chromatography (HPLC). Because of the complexity of biological
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samples, a multi-dimensional separation approach is required in which various methods are
combined.22,172,173 Strong cation exchange chromatography can be combined with reversedphase liquid chromatography (on- or off-line) for multi-dimensional protein identification
technology (MudPIT), which can be directly coupled to a mass spectrometer for tandem MS
(MS/MS) analysis.22 Wolters et al.22 utilized HPLC with MudPIT analysis to detect and
identify proteins of the S. cerevisiae proteome. Integral membrane proteins are difficult to
identify with 2D-PAGE, mainly due to solubility problems.174 Yet, unlike most other
approaches, in the MudPIT scheme, protein digestion takes place first and thus overcomes
protein solubility in solution or gel. In the analysis of the S. cerevisiae proteome via MudPIT,
131 proteins with three or more predicted transmembrane domains were detected and
identified.22 In addition, a highly efficient separation can be achieved due to the high loading
capacity provided by strong cation exchange combined with the high resolving power of
reversed-phase LC.171,175 This 2D LC strategy is routinely used for the analysis of integral
membrane proteins since hydrophilic peptides from insoluble proteins are adaptable to rapid
analysis.
1.4

Analysis Strategies for Membrane Proteins

1.4.1 Two Main Strategies for Mass Spectrometry Analysis of Proteins
It would be preferable for a proteomic platform to quantitatively analyze the entire
proteome in a high-throughput fashion, and do it with high sensitivity.176 There are two
widely used approaches to protein analysis and identification: Bottom-up and top-down
strategies. In the bottom-up approach, the intact protein mixture is directly subjected to
proteolytic digestion (usually with trypsin) without first separating the proteins. In addition,
proteins in complex mixtures can be separated before enzymatic (or chemical) digestion
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followed by direct peptide mass fingerprinting-based acquisition or further peptide separation
on-line coupled to tandem MS, which is then followed by the separation of the peptides,
typically with liquid chromatography, with the isolated peptides being submitted for tandem
mass analysis.
A variation of the bottom-up approach is called “shotgun proteomics” because it is
typically centered on early digestion of a protein mixture followed by a multidimensional
chromatographic separation of the peptides and then coupled to a mass spectrometer for
peptide mass determination. The essential difference in shotgun proteomics from the
traditional bottom-up technique is that a non-separated protein mixture is digested instead of
an isolated individual protein (see Figure 1.5).

Figure 1.5 Overview of strategies for MS-based protein characterization and identification.
Proteins extracted from biological samples can be analyzed by bottom-up or top-down
methods. An on-line LC–MS strategy can also be used for large-scale protein interrogation
(Reproduced from Han, X.; Aslanian, A.; Yates, J. R., 3rd Current opinion in chemical
biology 2008, 12, 483.177 with permission, Copyright 2013, Elsevier).
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In the top-down approach, proteins in complex mixtures are fractionated and separated
into pure single proteins or less complex protein mixtures, followed by off-line static infusion
of sample into the mass spectrometer for intact protein mass measurement and intact protein
fragmentation.
1.4.1.1 The “Top-Down” Approach
In the “top-down” approach, an individual protein mixture, or an individual protein, is
digested. This digestion generates peptides, which are more uniform and easier to analyze as
opposed to a complex protein sample that contains a mixture of small, large, hydrophobic, and
acidic/basic proteins and these extreme properties tend to yield poor 2D IEF/SDS-PAGE
results4. Top-down MS is becoming a powerful technology for comprehensive analysis of
protein modifications.59,178-188 In contrast to bottom-up MS, top-down MS analyzes intact
proteins without proteolytic digestion as shown in Figure 1.6. This strategy preserves the
labile structural characteristics that are mostly destroyed in bottom-up MS.187 It can
universally detect all the existing modifications, including PTMs (i.e., phosphorylation,
methylation, and acetylation) and sequence variants (i.e., mutants, alternatively spliced
isoforms, and amino acid polymorphisms) concurrently in one spectrum (a “bird's-eye” view)
without a prior knowledge.187

Figure 1.6 Overview of the top-down proteomic strategy (Reproduced from Switzar, L.;
Giera, M.; Niessen, W. M. Journal of proteome research 2013, 12, 1067189 with permission,
Copyright 2013, American Chemical Society).
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Top-down MS first measures the molecular weight of an intact protein and compares it
with the calculated value based on the DNA-predicted protein sequence, which can easily
reveal any changes/modifications in the protein sequence globally (the “top” part). Then, a
specific modified form of interest can be directly isolated in the mass spectrometer (“a gasphase purification”) and subsequently fragmented in the mass spectrometer by tandem MS
(MS/MS), such as collision-induced dissociation (CID) and electron-capture dissociation
(ECD), for highly reliable mapping of the modification sites (the “down” part).187,190 The
incorporation of the novel MS/MS technique, ECD,191 has greatly enhanced the capability of
top-down MS in structural analysis of biomolecules.192 As a non-ergodic fragmentation
method,191 ECD preserves labile PTMs during the fragmentation process; thus, it is
particularly suitable for the localization of labile PTMs.178,180 In terms of an ionization source,
electrospray ionization (ESI) is commonly used for top-down strategies, particularly because
liquid chromatography (LC), used in the separation of the peptides, couples naturally to ESI
due to the ability of continuous sample infusion into the ESI source.193 However, this
continuous infusion of sample can overwhelm the mass spectrometer and cause a more
complex peptide mass spectra to be generated. The top-down approach has the benefit of
giving closer to full sequence coverage.194 Top-down approaches have been used to better
understand the link between the observed changes and biological states of proteins.
These links usually become clearer when studying the regulation of a protein’s
function/activity achieved through changes in abundance, PTMs, balances in protein isoforms
(different forms of the same protein that can arise from the same gene by alternative splicing
or single nucleotide polymorphisms), cleavage of the proteins, and relocalization. In many
instances, different isoforms are present and can lead to different activities or functions. It
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should be noted that this approach requires high-resolution instrumentation such as FT-ICR
MS, electron capture dissociation or electron transfer dissociation capabilities and reports
have suggested that even quadrupole time-of-flight (Q-TOF) instrumentation can be modified
to successfully undertake top-down approaches.195
High-resolution instrumentation is needed because of the need to resolve the high
molecular weights of intact proteins and protein mixtures with high complexity. The topdown strategy has been successful in identifying post-translational modifications in individual
proteins, including myosin-binding protein C,180 and histones.196 The sequencing of
polymorphisms has also been done using this technique.198 Typically, intact proteins need to
be extracted from cell/tissue lysate, solubilized, and separated/purified before MS analysis.
Protein samples then need to be introduced to a mass spectrometer in buffer conditions
compatible with MS analysis.
The buffers employed to extract/solubilize proteins usually involve a high salt
concentration, with the addition of detergents, such as SDS, Triton X-100, etc. to increase the
solubility of the protein. These salts and detergents interfere with MS detection of proteins
because they are present in large excess relative to proteins and have much higher ionization
efficiency, which will, therefore, suppress protein signals. Standard procedures for detergent
removal typically involve precipitation and resolubilization of proteins in detergent-free
buffers, which may result in sample loss because some portion of protein may become
insoluble in detergent-free buffers. Recently, there are efforts allocated in designing MScompatible acid labile detergents with the hope of replacing these traditional detergents.198,199
Alternatively, proteins can also be selectively solubilized based on their inherent chemical
properties, such as biospecificity, hydrophobicity, and charge without the use of a
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detergent.200 Moreover, these techniques can also be used to fractionate a specific subproteome before chromatographic separation.
Gel-based separation is widely used in bottom-up proteomics because trypsin-digested
peptides can be effectively retrieved from gels.201,202 However, it is technically challenging to
extract the intact proteins from gel matrices with a high recovery rate.203 Thus, gel-based
separation is not applicable in top-down MS. Solution-based isoelectric focusing, coupled
with a multiplex tube gel electrophoresis separation device, referred to as gel-eluted liquid
fraction entrapment electrophoresis,204 has been developed for intact protein separation based
on their MWs and applied to proteins (10–250 kDa) with a high resolution and a high
recovery rate.183,201,205 Nevertheless, the surfactant SDS is still present in the sample so the
proteins need to be precipitated in organic solvent and resolubilized in MS-compatible
buffers. LC is ideally suited for proteomics because it can be conveniently interfaced with
MS.206-208 The major LC techniques utilized for intact protein separation include affinity
chromatography, ion-exchange chromatography, size-exclusion chromatography, and RP
chromatography.48 Affinity chromatography has been one of the most effective and specific
protein purification methods.50 For example, immunoaffinity methods have been used to
effectively

purify

cardiac

troponin

I

(cTnI)

from

animal

and

human

myocardium.178,185,186,209,210
Nonetheless, most of the affinity methods have been performed off-line, requiring an
additional separation/desalting procedure using RPLC. Ion-exchange chromatography and
SCX chromatography have also been used for intact protein separation.206,211-213 In addition,
these separation techniques are used to perform the first-dimension separation, followed by
RP chromatography in the second dimension. RP chromatography enhances the separation
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from the previous step and performs desalting as the last sample preparation step before MS
analysis.212,213 The 2-dimensional LC approach has the advantage of preconcentrating and
desalting the species of interest simultaneously, yielding a higher peak capacity and better
separation and, if connected on-line, minimizing sample loss. In contrast to the wellestablished bottom-up proteomics, the top-down proteomics is still in its early developmental
stage and has yet to fully overcome its technical challenges in sample preparation, instrument
sensitivity/detection limit, and throughput/automation.187,214-216
However, new technological developments are needed to advance top-down
proteomics for the analysis of complex samples of cell/tissue lysate and biological fluid.
Although the top-down approach is powerful in protein modification analysis, it is primarily
performed with direct infusion of a single protein or simple protein mixture (separated offline), therefore, the analytical throughput and efficiency for large-scale proteome analysis is
still a major challenge. To address these limitations, increasing efforts have been made to
improve the front-end separation of complex protein mixtures and automated database
searching informatics.
1.4.1.2 The “Bottom-Up” Approach
The vast majority of proteomic studies are performed using the ‘bottom-up” approach.
In this particular workflow (see Figure 1.7), after separation, intact proteins are cleaved using
proteases such as Lysine C or enzymes such as trypsin, proteinase-K, or pepsin. Trypsin is
most commonly used due to the fact that it is highly specific when cleaving the C-terminal
side of lysine and arginine residues except when a proline is positioned directly on the Cterminal side of the cleavage site.66 Furthermore, trypsin digestion for most proteins creates a
series of peptides in a mass range that is compatible with nearly all MS instruments. However,
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although trypsin is the ideal choice for a protease in most of these analyses, other enzymes
have also been used as alternatives for digestion or used in parallel with one another to
increase the overall proteome coverage.218 Proteins can also be cleaved utilizing enzyme-free
approaches or by combinations of non-enzymatic hydrolysis.

Figure 1.7 Overview of the bottom-up proteomic strategy (Reproduced from Switzar, L.;
Giera, M.; Niessen, W. M. Journal of proteome research 2013, 12, 1067189 with permission,
Copyright 2013, American Chemical Society)
Bottom-up strategies are the standard for large-scale or high-throughput analysis of
highly complex samples. There are usually two workflows associated with the bottom-up
approach: “sort-then-break” and “break-then-sort.”219 The latter workflow involves protein
digestion being conducted first without any prefractionation/separation step and then, the
peptides are separated by multidimensional chromatography followed by tandem MS. In the
“sort-then-break” approach, off-line protein fractionation and separation is performed first
before protein digestion, followed by direct peptide analysis.
When bottom-up analysis is performed on a mixture of proteins it is called “shotgun”
proteomics, a term coined by the Yates lab21,22 because it is analogous to shotgun genomic
sequencing.

Shotgun proteomics provides an indirect measurement of proteins through

peptides derived from proteolytic digestion of intact proteins. In a typical shotgun proteomics
experiment, the peptide mixture is fractionated and subjected to LC-MS/MS analysis. Peptide
identification is achieved by comparing the tandem MS spectra derived from peptide
fragmentation with theoretical tandem MS spectra generated from searching a database of
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protein spectra. Protein interface is accomplished by assigning peptide sequences to proteins.
Because peptides can be either uniquely assigned to a single protein or shared by more than
one protein, the identified proteins may be further scored and grouped based on their peptides.
Bottom-up strategies are suitable for automation, and high sample throughput can be
achieved.220-222 These procedures typically identify a very limited number of peptides per
protein, but still enough to identify the gene from which the protein was encoded. They work
well in the study of microorganisms where the assumption that one gene codes for only one
protein. However, when higher eukaryotes are investigated, processes including alternative
splicing, RNA editing and post-translational modification can lead to several different protein
species from a single gene. Peptide-based identification strategies enable the identification of
the genes from which these proteins are derived. The bottom-up approaches generally do not
provide information on the entire protein sequence, and similarly suffer from the fact that
peptides from many possible forms of the parent gene products (arising from partial
degradation and various covalent modifications) are generally indistinguishable in the absence
of additional information (e.g., the MW of the parent protein).
Multidimensional protein identification technology (MudPIT) is an automated bottomup approach in which the complexity problem is addressed at the peptide level.22,221
Following enzymatic digestion of a total protein mixture, peptides are separated on a biphasic
liquid chromatography column using a strong-cation exchange support as the initial phase,
and subsequently reversed-phase material. The peptides are then delivered online to a tandem
mass spectrometer, and MS/MS spectra are automatically detected for as many peptides as
possible and those spectra used to search protein sequence databases. With this
LC/LC/MS/MS procedure, a high-separation of peptides is achieved. The complex
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deconvolution takes place mainly in the chromatography step, but the ability of the mass
spectrometer to handle several peptides at a time also contributes to the multiple
dimensions.223
Two generally applicable bottom-up approaches for protein identification include one
based upon mass measurements for a set of peptide digestion products from the parent protein
and the other based on MS fragmentation (MS/MS) of one or more of these peptides. The first
approach is referred to as peptide mass fingerprinting. A set of peptide fragments unique to
each protein is created and their masses used as a ‘‘fingerprint’’ to identify the original
protein. The peptide mass fingerprinting approach has been broadly applied with conventional
MS instrumentation, but its throughput is limited because it requires prior isolation of a single
protein (or a simple mixture). The second approach to protein identification is based on the
information from dissociation (e.g., using collisional activation or some other energy
deposition process) of one or more polypeptides that have typically been isolated by the first
stage of the MS analysis.224-225 Furthermore, the entire bottom-up process can be laborious,
time consuming, and limited to adopting automated processes.
1.5

Advantages of Using Microfluidics for Proteomic Analysis
To minimize the disadvantages associated with bench-top strategies (i.e. time

consumption, sample loss, automation, sample volume, etc.), researchers have been and are
continuing to explore the use of microchips for proteomic analysis. There are several
advantages toward the use of microfluidic platforms for proteomic analysis. Some of the key
advantages of microfluidics are the miniaturization and integration of multiple process
operations in a single device enabling (a) distinct processing steps without sample transfer, (b)
shorter analysis times afforded by decreasing length scales without loss of efficiency and
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reducing analyte diffusion, (c) handling of nanoliter volumes, (d) high-throughput processing,
(e) a high degree of parallelization, and (f) automation of processing steps.230
Devices like these offer the potential of enabling highly efficient, reproducible, and
standardized proteomic workflows coupled with low sample consumption. Furthermore,
process automation can diminish the need for highly trained analytical personnel, which is a
vital attribute in clinical settings. Moreover, limiting manual input reduces the risk of
contaminations, which has a major impact on the reliability of proteome analyses.231 In a 2011
critical review, Liu and Fan discussed the attractiveness of thermoplastic microfluidic devices
for both DNA and protein studies including immunoassays and protein separations.232 This is
especially beneficial when the sample contains low abundant proteins such as integral
membrane proteins. A high surface-to-volume ratio is afforded when miniaturized platforms
are used, which is preferable in the case of protein extraction where the analyte-wall
interaction is required especially for extraction onto a solid support. The mass transport is also
improved for microfluidics due to smaller diffusional dimensions, which is advantageous for
protein digestion or extraction.
1.5.1 Survey of Reported Microfluidic Platforms for Protein Analysis
Several microchip-based proteomic strategies have been demonstrated in the past
decade, especially for integrating multiple processing steps onto a single platform for
proteomic analysis. Summaries of microfluidic systems that have been used for the analysis of
proteins prior to mass spectrometry analysis are listed in Table 1.3 and described within this
section.
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Table 1.3 Microfluidic Systems for Protein Analysis with processing devices combined prior
to MS analysis
Devices or Units
Combined

Chip
Material

Sample Analyzed

Efficiency/Comments

Ref.

Porous silica preconcentration unit and
µ-CGE separation

Glass

Mixture of up to 7
purified proteins

Pre-concentration
factors of ~600 fold

230

Proteolytic reactor and
IMAC affinity unit for
peptide enrichment

Glass

Model proteins
were analyzed
individually

Capture bias on
IMAC; system
required further
optimization due to
non-specific binding

Polystyrene beads for
SPE desalting and a CE
unit with ESI-interface

PDMS

Six-peptide
mixtures dissolved
in physiological salt
solution

SPE enrichment
column and a reversed
phase separation
channel with a
nanoelectrospray
emitter

Glass

Protein digests
spiked into rat
plasma samples

LOD is in the
femtomole range

231

232

234
LOD of 1–5 fmol.

For example, Li et al.227 identified proteins from membrane-bound protein extracts of
Haemophilus influenzae by separation of the proteome fraction first using 1D SDS-PAGE,
then digesting the excised protein spots, and finally introducing the peptides into an integrated
microchip consisting of capillary electrophoresis (CE) and nanoelectrospray. The use of
surface coatings and a gold-coated nanoelectrospray tip allowed the microchip performance to
be similar to a conventional nanoelectrospray CE in terms of LOD and the resolution per
meter, yet faster due to the ease of creating shorter capillaries.
The application of the device enabled the identification of peptides in tryptic digests of
glycoproteins and further demonstrated that chip-based electrospray devices can be used with
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quadrupole time-of-flight mass spectrometry. The authors reported a concentration LOD of
3.2-43.5 nM for different peptides and migration time and peak area reproducibility (i.e.,
RSD) of 3.1% and 6-13%, respectively. Musiyimi and co-workers228 developed a poly(methyl
methacrylate), PMMA, CE chip that was directly coupled to a rotating ball for a MALDI-TOF
MS analysis of protein digests. Mellors and Ramsey229 demonstrated electrospray MS directly
from the corner of a glass chip without a nozzle (external tip) after CE. The CE-MS analysis
of peptides and proteins using this device resulted in efficiencies of over 2 x105 theoretical
plates (or 106 plates/m).
In the work performed by Foote and co-workers,230 a microfabricated device with the
ability to electrophoretically concentrate fluorescently labeled proteins prior to separation was
developed (see Figure 1.8). The proteins were concentrated using a porous silica membrane
between adjacent microchannels that allowed for the passage of buffer ions, but excluded
larger migrating molecules. The concentrated proteins were then injected into a separation
column for electrophoretic analysis. Pre-concentration factors of ~600-fold were achieved
using this on-chip format, which was followed by a SDS µ-CGE separation of the proteins.
The channels were filled with CE-SDS protein run buffer that was purchased from BioRad
and allowed a current of ~1.2 µA when a voltage of 1 kV was applied between
preconcentration reservoir 1 and the sample reservoir. Individual microchips were used for up
to >200 preconcentration cycles using an applied voltage of 1 kV and an average
preconcentration time of ~1 min.
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Figure 1.8 (A) Schematic of microchip layout used for peptide preconcentration. (B)
Microscopic image of preconcentrator-injector channels. (C) Schematic cross section through
injector and preconcentrator channels (Reproduced from Foote, R. S.; Khandurina, J.;
Jacobson, S. C.; Ramsey, J. M. Anal Chem. Preconcentration of Proteins on Microfluidic
Devices Using Porous Silica Membranes. 2005, 77, 57.230 with permission, Copyright 2013,
American Chemical Society).
Yue et al.231 described a glass microfluidic system for proteomics that included
proteolysis directly coupled to affinity selection (see Figure 1.9). Their initial results using
standard phosphopeptide fragments from β-casein in peptide mixtures showed selective
capture of the phosphorylated fragments using immobilized metal affinity chromatography
(IMAC) beads packed into a microchannel. The results showed selective capture of only
phosphopeptide fragments, but digestion of protein was incomplete as indicated from multiple
peaks in the CE separations. Application to digestion and capture of a serum fraction showed
capture of material; however, non-specific binding was evident.
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Figure 1.9 Diagram of an integrated trypsin digestion and affinity capture process along with
a picture of the actual microdevice (Reproduced from Yue, G. E.; Roper, M. G.; Balchunas,
C.; Pulsipher, A.; Coon, J. J.; Shabanowitz, J.; Hunt, D. F.; Landers, J. P.; Ferrance, J. P.
Analytica chimica acta, Protein digestion and phosphopeptide enrichment on a glass
microchip. 2006, 564, 116.231 with permission from Elsevier, Copyright 2013).
An integrated poly(dimethylsiloxane) (PDMS) microchip for SPE and CE followed by
ESI/TOF MS has been developed and evaluated by Dahlin and co-workers.232 The microchip
(see Figure 1.10) was fabricated in a novel one-step procedure where PDMS was cast over
steel wires in a mold. Once the wires were removed, they defined 50 µm cylindrical channels.
Fused-silica capillaries were then successfully inserted into the structure in a tight fit
connection. The inner walls of the inserted fused-silica capillaries and the PDMS microchip
channels were modified with PolyE-323 (a positively charged polymer) that is used to reduce
protein and peptide adsorption on capillary walls during electrophoresis. In this approach, the
chip was fabricated in a two-level cross design. The channel at the lower level was packed
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with 5 µm hyper-cross-linked polystyrene beads acting as a SPE medium used for desalting.
The upper level channel acted as a CE channel and ended in an integrated emitter tip coated
with conducting graphite powder to facilitate the electrical contact for ESI.

Figure 1.10 (A) Schematic of a PDMS microchip device. Channel A: sample inlet; Channel
B: CE; Channel C: waste channel. (B) Schematic showing the instrumental setup and the
connection of the microchip to the ESI/TOF MS (Reproduced from Dahlin, A. P.; Bergstrom,
S. K.; Andren, P. E.; Markides, K. E.; Bergquist, J. Anal Chem. Poly(dimethylsiloxane)Based Microchip for Two-Dimensional Solid-phase Extraction-Capillary Electrophoresis with
an Integrated Electrospray Emitter Tip. 2005, 77, 5356.232 with permission, Copyright 2013,
American Chemical Society).
To evaluate the microchip, six-peptide mixtures were dissolved in physiological salt
solution, injected, desalted, separated, and sprayed into a MS for analysis with a limit-ofdetection in the femtomolar range. The applied CE voltage was varied from -6 to -16 kV with
an increment of -2 kV for every injection, giving an electric field of -193 to -516 V/cm. An
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integrated microfabricated system composed of a proteolytic reactor and chromatographic
column with direct interface to ESI-MS was reported by Carlier et al.233 The system was
fabricated from SU-8 and used to perform protein digestion, sample purification, salt removal,
and chromatography followed by MS analysis. The chromatographic end of the chip was
terminated with a nano-ESI interface. The digestion module was composed of trypsin
covalently attached to a monolithic polymer, which was also used to prepare a hydrophobic
stationary phase for the desalting or separation of peptides prior to MS analysis
In a similar effort to combine preconcentration with electrophoretic separations,
Fortier et al.234 investigated the analytical performances of a fabricated microfluidic device,
which included an enrichment column, a reversed phase separation channel, and a
nanoelectrospray emitter embedded together in polyimide layers. This configuration
minimized transfer lines and connections and reduced post-column peak broadening and dead
volume. The compact microchip was interfaced to both ion trap and TOF MS, and its
analytical potentials were evaluated in the context of proteomic applications. Sensitivity
measurements were performed on a dilution series of protein digests spiked into rat plasma
samples and provided a detection limit of 1–5 fmol.
Huft et al.235 fabricated a column geometry that allowed both robust and low-pressure
packing of liquid chromatography columns in PDMS devices (see Figure 1.11). They
combined the use of high-performance chromatography and valve-based microfluidics. The
packing was achieved in minutes and enabled the integration of multiple parallel columns on
a single device with high yield and without defects. The approach works by using microvalve
control to reconfigure the columns for operation in either the packing or separation mode. The
authors utilized pulse tests to show that the columns fabricated in this manner can achieve
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high efficiency and reproducibility. They also reported plate heights (for the separation of
dye-labeled ssDNA) that were comparable to conventional high-performance capillary
columns and plate numbers that exceeded 1,000,000 plates.

Figure 1.11 Micrographs of solid-phase chromatography columns fabricated in PDMS. (a)
before packing of the columns, (b) front of one column after packing, (c) back of same
column from b with resin inlet closed, (d) bypass channels along a section of unpacked
column, (e) section in panel d after packing, (f) resin inlet from c. (Reproduced from Huft, J.,
Haynes, C. A., and Hansen, C. L. Anal Chem 2013, 85, 1797.235 with permission, Copyright
2013, American Chemical Society).
Gottschlich236 and Liu237 both reported lab-on-chip techniques for separating and
detecting protein mixtures. Gottschlich and co-workers integrated a microreactor, injector and
electrophoretic separator and a second reactor for derivatization on a monolithic substrate
followed by fluorescence detection. Liu integrated capillary electrophoresis, postcolumn
labeling and fluorescence detection on a microfabricated system. Wang and et al.239 described
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a microfluidic device that integrated an electrospray ionization source for MS with a protein
digestion bed, a capillary electrophoresis channel, and an injector on a monolithic substrate.
The protein digestion bed had trypsin immobilized onto microbeads to permit faster digestion
and to eliminate autodigestion products that might hinder sample characterization.
1.5.2.1 Digital Microfluidics for Proteomic Analysis
Microfluidic devices that can handle droplets can also perform a variety of functions
(i.e. sorting, storage, and splitting) and can be integrated to MS or CE instrumentation.240,241
Digital microfluidics (DMF) is characterized by the manipulation of discrete droplets on
hydrophobic, insulated electrode arrays that have no channels. When successive potentials are
applied to the electrodes, droplet manipulations such as merging, mixing, splitting, and
dispensing from reservoirs are facilitated.242 Because droplets are individually addressable
and have individual boundaries, they can act as discrete microreactors. A DMF method was
developed for the extraction and purification of protein from a complex biological sample by
precipitation, rinsing, and resolubilization, with protein recoveries of roughly 80%.243
Applications involving MS can also be used with DMF, which has increased its popularity in
recent years. In-line coupling with DMF is a likely fit because both techniques require liquid
samples and compatible volumes. Jebrail and co-workers reported the first in-line interface for
DMF and nanoESI-MS.244 The device consisted of a DMF platform and a microchannel
nanoESI emitter that was used for the quantification of amino acids from samples of dried
blood spots.
Another way to integrate (in-line) DMF and MS is to use a specialized ionization
technique. Surface acoustic wave nebulization (SAWN) exploits the acceleration of acoustic
waves that have propagated on the surface of a piezoelectric substrate and produces an aerosol
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that contains solvated ions from a liquid droplet on the surface.245 Dennison et al. coupled
SAWN to MS for top-down protein fragmentation studies.246 Luk and Wheeler reported an
integrated DMF device (see Figure 1.12) for multistep proteomic processing.247

Figure 1.12 A sequence of images depicting the proteomic sample workup of the protein
sample going through reduction, alkylation, and digestion on the DMF device. (a,b) Droplets
containing insulin and TCEP merged are dispensed from reservoirs, merged and mixed. (c) A
droplet of iodoacetamide being dispensed and merged with the sample droplet and mixed.
After incubation (d) the sample droplet is merged with a droplet of trypsin for digestion and
(e) final incubation. (Reproduced from Luk, V. N. and Wheeler, A. R. Anal Chem 2009, 15,
4524.247 with permission, Copyright 2013, American Chemical Society).
The device performed sample reduction, alkylation, and enzymatic digestion on a
single platform and interfaced with MALDI-MS to qualitatively confirm the protein products
from the reaction steps. This device is an excellent example of integrating multiple processing
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steps in proteomics on a single platform for analysis. Luk and Wheeler have also used DMF
to fabricate hydrogel microreactors for proteolytic digestion (see Figure 1.13).248

Figure 1.13 Series of images from a movie and a schematic displaying the hydrogel
proteolytic enzymes microreactors performing digestion in a 2-mm-diameter gel disc on a
DMF device. (Reproduced and adapted from Luk, V. N.; Fiddes, L. K.; Luk, V. M.;
Kumacheva, E.; Wheeler, A. R. Digital Microfluidic Hydrogel Microreactors for proteomics.
Proteomics 2012, 12, 1310.248 with permission, Copyright 2013, American Chemical
Society).
The authors employed cylindrical agarose discs with immobilized trypsin or pepsin
and integrated them into DMF devices. The 1 mg/mL BSA or lysozyme protein samples were
sequentially reduced, alkylated, and digested with all sample and reagent handling controlled
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by droplet operation. The MALDI-MS analysis of the products showed that by performing
digestion in this manner, they were able to obtain higher sequence coverage.
Digital microfluidics is not a cure-all for all MS applications, and there are still some
challenges and limitations that need to be addressed before DMF becomes a widespread
technique. Biofouling, which is a negative side effect of using high surface-to-volume ratios
due to the increased rate of adsorption of analytes from solution to the solid surface, is
problematic for DMF and can lead to cross-contamination. However, the drawbacks of
biofouling have lead to significant improvements such as the use of oils to encapsulate
droplets,249,250 the use of nanostructured super-hydrophobic surfaces or amphiphilic additives
to limit adsorption,251,252 and films that are removable to prevent cross-contamination between
steps. In spite of these challenges, DMF is still an emerging powerful tool for upstream
sample processing in proteomic analysis. The ‘hands-off’ approach augments the ability to
fully automate sample processing steps and analysis on a single platform, which makes DMF
extremely attractive.
1.6

More Efforts Toward On-chip Proteomic Processing
The uses of spotted array-based tools have also garnered attention for proteomic

analysis.253 In array-based methods, small spots of proteins are immobilized onto siliconbased substrates (usually glass). The array can then be used to screen complex protein
mixtures for particular binding affinities or other interactions. These arrays potentially address
several concerns associated with the 2DE-MS (IEF/SDS-PAGE): the arrays can be used at
little cost, provide consistently reliable and rapid results and are simple to use. Haab and
colleagues254 utilized printed protein arrays to measure protein–protein interactions based on a
fluorescence assay. Spotted arrays can also be used to probe protein–small molecule
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interactions. Immobilized proteins are patterned onto a microscope slide using high-precision
contact printing to deliver small quantities of protein to an aldehyde-coated glass surface.255
Using this system, spot densities of >1600 spots cm−2 can be achieved with spot diameters of
150–200 μm. This technology has been applied to the identification of protein kinase
substrates and for screening protein–protein interactions.
Surface-enhanced affinity capture, a promising version of surface-enhanced laser and
ionization (SELDI) technology,256 uses probe surfaces to extract or structurally modify a
particular protein. After the addition of a matrix solution to enhance laser energy transfer and
sample ionization, samples are analyzed using TOF-MS. Advantages of this approach include
a reduced amount of sample preparation before MS and the ability to capture trace amounts of
proteins directly from biological fluids.
Although these devices hold tremendous promise to address some of the limitations
facing approaches for proteome analysis, they too have their own limits (i.e. fabrication,
material compatibility, etc.). Much of the work mentioned here thus far deals with the analysis
of known protein mixtures or peptides and not complex biological samples that contain
membrane proteins.
1.7

Concluding Remarks
It should be noted that the majority of the aforementioned microfluidic systems

analyzed peptides, model proteins, nucleic acids, or purified protein samples. Therefore, there
is still a need for a proteomic platform that can analyze complex biological samples such as
those containing integral membrane proteins or whole cell lysates. As previously stated,
membrane proteins offer an abundance of possibilities for biomarker discovery, drug
development, and treatment of various diseases such as cancer.
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The need to understand the biological mechanisms involved in cancer and infectious
and inflammatory diseases at the clinical levels implies not only comprehensive protein
identification but also expression profiling of proteins across healthy and disease patient
samples. In this context, the challenge of proteomics lies in the complexity of protein
mixtures, the number of samples, and the reproducibility of analysis. Kotz and co-workers257
developed a microfluidic device to isolate neutrophils directly from whole blood in order to
process proteins for proteomic (mass spectrometry) studies (see Figure 1.14).

Figure 1.14 Microfluidic device used for clinical genomic and proteomic studies. (a)
microfluidic chip design and (b) schematic of the surface functionalization of antibodies to the
device. (Reprinted and adapted from Kotz, K. T.; Xiao, W.; Miller-Graziano, C.; Qian, W. J.;
Russom, A.; Warner, E. A.; Moldawer, L. L.; De, A.; Bankey, P. E.; Petritis, B. O.; Camp, D.
G., 2nd; Rosenbach, A. E.; Goverman, J.; Fagan, S. P.; Brownstein, B. H.; Irimia, D.; Xu, W.;
Wilhelmy, J.; Mindrinos, M. N.; Smith, R. D.; Davis, R. W.; Tompkins, R. G.; Toner, M. Nat
Med 2010, 16, 1042.257 with permission, Copyright 2013).
The authors demonstrated the scalability of the device as well as its application in a
clinical setting. The microfluidic device was able to capture highly enriched (>95%)
neutrophils directly from whole blood in ~5 min and in sufficient quantity and purity for mass
spectrometry-based proteomic analysis. The proteomic samples were of high enough quality
to discriminate between small differences in neutrophil activation states. Furthermore, the
authors implemented the utility of the device in a clinical program and observed the changes
in gene expression of neutrophils that are highly regulated after traumatic injury.
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To date, there is still a need for a microfluidic system that can perform a complete
proteomic analysis of a complex protein sample, especially those containing membrane
proteins. When considering an integrated system such as those listed in the sections above, it
is very important that the processes there within are compatible one another. It is critical that
each step can operate independently, but there also cannot be interference between steps. For
example, reagents used for extracting or isolating proteins in a sample must be compatible
with subsequent separation and mass analysis steps. In addition, when investigating the use of
a microfluidic system, it may be beneficial to take a step-by-step approach to ensure that the
downstream processes are not negatively affected by those upstream. Improvements still need
to be made in the area of protein enrichment and purification, which is a critical aspect of the
work because as much material as possible is needed for the separation and the further
downstream processes of protein digestion and subsequent peptide mass analysis since there
is no procedure in place to amplify protein such as PCR for DNA. Much of the work
mentioned previously involves off-chip protein enrichment strategies, which could result in
loss of sample when moving on to subsequent analysis (i.e. separation, MS analysis, etc.).
1.8

Research Objective
The objective of this work was to design, fabricate, and characterize the operation of a

fully integrated fluidic system that will serve as a foundation for a novel method to analyze
proteins from complex biological samples based upon a top-down proteomic strategy.
However, before integration is done, we must optimize each entity separately. Because
enrichment is so critical in the case of low abundant proteins (i.e. integral membrane
proteins), a module for the enrichment and purification of integral membrane proteins will be
fabricated and will employ affinity techniques and microposts to extract membrane proteins
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from whole cell lysate. This platform will be particularly useful for extracting only integral
membrane proteins of interest through the use of a bioaffinity reactor based on the avidinbiotin interaction. The use of this platform is two-fold as it will extract the integral membrane
proteins and also purify the membrane protein fraction by excluding cytosolic proteins and
nucleic acid material.
The next step is the 2-dimensional CE separation of intact integral membrane proteins
with μ-capillary gel electrophoresis (μ-CGE) in the first dimension coupled with micellar
electrokinetic chromatography (MEKC) in the second dimension. This module is based upon
previous work performed in our group.258,259 The separation in the first dimension will be
based on the molecular weights of the individual proteins and the second dimension will
separate the proteins based upon their hydrophobicity and interaction with SDS micelles. We
are taking a top-down approach because we want to separate the proteins intact and then do
further analysis with MS. The two modules will be integrated, a module for digestion added,
and coupled with MS based upon work previously done by Musyimi and Lee. 228,260 Once
completed, the fluidic system will offer researchers a fully integrated microfluidic platform
for the complete analysis of integral membrane proteins from complex biological samples. A
system of this nature will afford future opportunities for biomarker discovery, drug
development, and diagnostics.
1.9

References

(1)

de Hoog, C. L.; Mann, M. Annual review of genomics and human genetics 2004, 5,
267.

(2)

Wilkins, M. R.; Pasquali, C.; Appel, R. D.; Ou, K.; Golaz, O.; Sanchez, J. C.; Yan, J.
X.; Gooley, A. A.; Hughes, G.; Humphery-Smith, I.; Williams, K. L.; Hochstrasser, D.
F. Biotechnology (N Y) 1996, 14, 61.

59

(3)

Schramm, A.; Apostolov, O.; Sitek, B.; Pfeiffer, K.; Stuhler, K.; Meyer, H. E.; Havers,
W.; Eggert, A. Klinische Padiatrie 2003, 215, 293.

(4)

Kussmann, M.; Affolter, M.; Fay, L. B. Combinatorial chemistry & high throughput
screening 2005, 8, 679.

(5)

Srinivas, P. R.; Verma, M.; Zhao, Y.; Srivastava, S. Clinical chemistry 2002, 48,
1160.

(6)

Hanash, S. M.; Pitteri, S. J.; Faca, V. M. Nature 2008, 452, 571.

(7)

Santoni, V., Malloy, M. and Rabilloud, T. Electrophoresis 2000, 21, 1054.

(8)

Santoni, V.; Kieffer, S.; Desclaux, D.; Masson, F.; Rabilloud, T. Electrophoresis
2000, 21, 3329.

(9)

Garrels, J. I. The Journal of biological chemistry 1989, 264, 5269.

(10)

Garrels, J. I.; Franza, B. R., Jr. The Journal of biological chemistry 1989, 264, 5283.

(11)

Garrels, J. I.; Franza, B. R., Jr. The Journal of biological chemistry 1989, 264, 5299.

(12)

Fountoulakis, M.; Takacs, M. F.; Berndt, P.; Langen, H.; Takacs, B. Electrophoresis
1999, 20, 2181.

(13)

Fountoulakis, M.; Takacs, M. F.; Takacs, B. Journal of chromatography. A 1999, 833,
157.

(14)

Gygi, S. P., Rist, B., Gerber, S.A., Turecek, F., Gelb, M.H. and Aebersold, R. Nature
Biotechnology 1999, 17, 994.

(15)

Corthals, G. L.; Wasinger, V. C.; Hochstrasser, D. F.; Sanchez, J. C. Electrophoresis
2000, 21, 1104.

(16)

Oh-Ishi, M.; Satoh, M.; Maeda, T. Electrophoresis 2000, 21, 1653.

(17)

Ferro, M.; Salvi, D.; Riviere-Rolland, H.; Vermat, T.; Seigneurin-Berny, D.;
Grunwald, D.; Garin, J.; Joyard, J.; Rolland, N. Proc Natl Acad Sci U S A 2002, 99,
11487.

(18)

Galeva, N.; Altermann, M. Proteomics 2002, 2, 713.

(19)

Sintegral membrane proteinson, R. J.; Connolly, L. M.; Eddes, J. S.; Pereira, J. J.;
Moritz, R. L.; Reid, G. E. Electrophoresis 2000, 21, 1707.

60

(20)

Link, A. J.; Eng, J.; Schieltz, D. M.; Carmack, E.; Mize, G. J.; Morris, D. R.; Garvik,
B. M.; Yates, J. R., 3rd Nat Biotechnol 1999, 17, 676.

(21)

Washburn, M. P.; Wolters, D.; Yates, J. R., 3rd Nat Biotechnol 2001, 19, 242.

(22)

Wolters, D. A.; Washburn, M. P.; Yates, J. R., 3rd Anal Chem 2001, 73, 5683.

(23)

Rose, K.; Bougueleret, L.; Baussant, T.; Bohm, G.; Botti, P.; Colinge, J.; Cusin, I.;
Gaertner, H.; Gleizes, A.; Heller, M.; Jimenez, S.; Johnson, A.; Kussmann, M.;
Menin, L.; Menzel, C.; Ranno, F.; Rodriguez-Tome, P.; Rogers, J.; Saudrais, C.;
Villain, M.; Wetmore, D.; Bairoch, A.; Hochstrasser, D. Proteomics 2004, 4, 2125.

(24)

Lander, E. S. et al. Nature 2001, 409, 860.

(25)

Venter, J. C. et al. Science 2001, 291, 1304.

(26)

Lion, N.; Rohner, T. C.; Dayon, L.; Arnaud, I. L.; Damoc, E.; Youhnovski, N.; Wu, Z.
Y.; Roussel, C.; Josserand, J.; Jensen, H.; Rossier, J. S.; Przybylski, M.; Girault, H. H.
Electrophoresis 2003, 24, 3533.

(27)

Seddon, A. M.; Curnow, P.; Booth, P. J. Biochimica et biophysica acta 2004, 1666,
105.

(28)

Morre, D. In Molecular Techniques and Approaches in Developmental Biology;
Chrispeels, M. J., Ed.; John Wiley: New York, NY, 1973, p 1.

(29)

Morre, D. J.; Morre, D. M. BioTechniques 1989, 7, 946.

(30)

Lenstra, J. A.; Bloemendal, H. European journal of biochemistry / FEBS 1983, 135,
413.

(31)

Anderson, N. L.; Anderson, N. G. Molecular & cellular proteomics : MCP 2002, 1,
845.

(32)

Collins, F. S.; Lander, E. S.; Rogers, J.; Waterston, R. H.; Int Human Genome
Sequencing, C. Nature 2004, 431, 931.

(33)

Froehlich, T.; Arnold, G. J. Journal of Neural Transmission 2006, 113.

(34)

Lay, J. O.; Borgmann, S.; Liyanage, R.; Wilkins, C. L. Trac-Trends Anal. Chem.
2006, 25, 1046.

(35)

Ahmed, N.; Rice, G. E. Journal of chromatography. B, Analytical technologies in the
biomedical and life sciences 2005, 815, 39.

61

(36)

Wang, H.; Hanash, S. Journal of chromatography. B, Analytical technologies in the
biomedical and life sciences 2003, 787, 11.

(37)

Tang, J.; Gao, M.; Deng, C.; Zhang, X. Journal of chromatography. B, Analytical
technologies in the biomedical and life sciences 2008, 866, 123.

(38)

Issaq, H. J.; Chan, K. C.; Janini, G. M.; Conrads, T. P.; Veenstra, T. D. Journal of
chromatography. B, Analytical technologies in the biomedical and life sciences 2005,
817, 35.

(39)

Shi, Y.; Xiang, R.; Horvath, C.; Wilkins, J. A. Journal of chromatography. A 2004,
1053, 27.

(40)

Fujii, K.; Nakano, T.; Hike, H.; Usui, F.; Bando, Y.; Tojo, H.; Nishimura, T. Journal
of chromatography. A 2004, 1057, 107.

(41)

Vitali, B.; Wasinger, V.; Brigidi, P.; Guilhaus, M. Proteomics 2005, 5, 1859.

(42)

Coombes, K. R.; Morris, J. S.; Hu, J.; Edmonson, S. R.; Baggerly, K. A. Nat
Biotechnol 2005, 23, 291.

(43)

Ransohoff, D. F. Nature reviews. Cancer 2005, 5, 142.

(44)

Aebersold, R.; Mann, M. Nature 2003, 422, 198.

(45)

Stevens, T. J.; Arkin, I. T. Proteins 2000, 39, 417.

(46)

Wu, C. C. a. Y., J.R. Nature Biotechnology 2003, 21, 262.

(47)

Domon, B.; Aebersold, R. Science 2006, 312, 212.

(48)

Geer, L. Y.; Markey, S. P.; Kowalak, J. A.; Wagner, L.; Xu, M.; Maynard, D. M.;
Yang, X.; Shi, W.; Bryant, S. H. Journal of proteome research 2004, 3, 958.

(49)

Sadygov, R. G.; Yates, J. R., 3rd Anal Chem 2003, 75, 3792.

(50)

Fenyo, D.; Beavis, R. C. Anal Chem 2003, 75, 768.

(51)

Yates, J. R., 3rd; Morgan, S. F.; Gatlin, C. L.; Griffin, P. R.; Eng, J. K. Anal Chem
1998, 70, 3557.

(52)

Craig, R.; Cortens, J. C.; Fenyo, D.; Beavis, R. C. Journal of proteome research 2006,
5, 1843.

(53)

Frewen, B. E.; Merrihew, G. E.; Wu, C. C.; Noble, W. S.; MacCoss, M. J. Anal Chem
2006, 78, 5678.

62

(54)

Stein, S. E.; Scott, D. R. J. Am. Soc. Mass Spectrom. 1994, 5, 859.

(55)

Mann, M.; Wilm, M. Anal Chem 1994, 66, 4390.

(56)

Tabb, D. L.; Saraf, A.; Yates, J. R., 3rd Anal Chem 2003, 75, 6415.

(57)

Tanner, S.; Shu, H.; Frank, A.; Wang, L. C.; Zandi, E.; Mumby, M.; Pevzner, P. A.;
Bafna, V. Anal Chem 2005, 77, 4626.

(58)

Meng, F.; Forbes, A. J.; Miller, L. M.; Kelleher, N. L. Mass spectrometry reviews
2005, 24, 126.

(59)

Han, X.; Jin, M.; Breuker, K.; McLafferty, F. W. Science 2006, 314, 109.

(60)

Chait, B. T. Science 2006, 314, 65.

(61)

Kuster, B.; Schirle, M.; Mallick, P.; Aebersold, R. Nature reviews. Molecular cell
biology 2005, 6, 577.

(62)

Mallick, P.; Schirle, M.; Chen, S. S.; Flory, M. R.; Lee, H.; Martin, D.; Ranish, J.;
Raught, B.; Schmitt, R.; Werner, T.; Kuster, B.; Aebersold, R. Nat Biotechnol 2007,
25, 125.

(63)

Huber Lukas, A., Pfaller, K. and Vietor, I. Circulation Research 2003, 92, 962.

(64)

Josic, D. a. C., J.G. Proteomics 2007, 7, 3010.

(65)

Yan, W.; Aebersold, R.; Raines, E. W. Journal of Proteomics 2009, 72, 4.

(66)

Cordwell, S. J.; Thingholm, T. E. Proteomics 2010, 10, 611.

(67)

Lodish, H. Molecular Cell Biology; 5th ed., 2003.

(68)

Kikuchi, M., Hatano, N., Yokota, S., Shimozawa, N., Imanaka, T. and Taniguchi, H.
Journal of Biological Chemistry 2004, 279, 421.

(69)

Vuong, G. L., Weiss, S.M., Kammer, W., Priemer, M., Vingron, M., Nordheim, A.
and Cahill, M.A. Electrophoresis 2000, 21, 2594.

(70)

Chen, W. N.; Yu, L. R.; Strittmatter, E. F.; Thrall, B. D.; Camp, D. G., 2nd; Smith, R.
D. Proteomics 2003, 3, 1647.

(71)

Jang, J. H.; Hanash, S. Proteomics 2003, 3, 1947.

(72)

Sabarth, N.; Lamer, S.; Zimny-Arndt, U.; Jungblut, P. R.; Meyer, T. F.; Bumann, D.
The Journal of biological chemistry 2002, 277, 27896.

63

(73)

Shin, B. K.; Wang, H.; Yim, A. M.; Le Naour, F.; Brichory, F.; Jang, J. H.; Zhao, R.;
Puravs, E.; Tra, J.; Michael, C. W.; Misek, D. E.; Hanash, S. M. The Journal of
biological chemistry 2003, 278, 7607.

(74)

Tang, X.; Yi, W.; Munske, G. R.; Adhikari, D. P.; Zakharova, N. L.; Bruce, J. E.
Journal of proteome research 2007, 6, 724.

(75)

Zhang, W.; Zhou, G.; Zhao, Y.; White, M. A.; Zhao, Y. Electrophoresis 2003, 24,
2855.

(76)

Zhao, Y.; Zhang, W.; Kho, Y.; Zhao, Y. Anal Chem 2004, 76, 1817.

(77)

Josic, D.; Clifton, J. G.; Kovac, S.; Hixson, D. C. Current opinion in molecular
therapeutics 2008, 10, 116.

(78)

Polanski, M., Anderson, M. D. Biomarker Insights 2006, 2, 1.

(79)

Josic, D.; Clifton, J. G. Proteomics 2007, 7, 3010.

(80)

Bouzianas, D. G. Expert Rev Anti-Infe 2007, 5, 665.

(81)

Viswanathan, K. a. F., K. Expert Review of Proteomics 2007, 4, 815.

(82)

Wahl, A., Weidanz, J., Hildeband, W. Expert Review of Proteomics 2006, 3, 641.

(83)

Mellgren, R. L.; Zhang, W. L.; Miyake, K.; McNeil, P. L. Journal of Biological
Chemistry 2007, 282, 2567.

(84)

Balestrieri, M. L.; Giovane, A.; Mancini, F. P.; Napoli, C. Current medicinal
chemistry 2008, 15, 555.

(85)

Lewczuk, P.; Wiltfang, J. Proteomics 2008, 8, 1292.

(86)

Bermudez-Crespo, J.; Lopez, J. L. Proteomics. Clinical applications 2007, 1, 983.

(87)

Rucevic, M.; Hixson, D.; Josic, D. Electrophoresis 2011, 32, 1549.

(88)

Lai, Z. W.; Steer, D. L.; Smith, A. I. Current opinion in molecular therapeutics 2009,
11, 623.

(89)

Landry, Y.; Gies, J. P. Fund Clin Pharmacol 2008, 22, 1.

(90)

Griffin, N. M.; Schnitzer, J. E. Molecular & cellular proteomics : MCP 2011, 10,
R110 000935.

(91)

Blonder, J.; Chan, K. C.; Issaq, H. J.; Veenstra, T. D. Nat Protoc 2006, 1, 2784.

64

(92)

He, J.; Liu, Y.; He, S.; Wang, Q.; Pu, H.; Tong, Y.; Ji, J. Proteomics. Clinical
applications 2007, 1, 231.

(93)

Gutstein, H. B.; Morris, J. S.; Annangudi, S. P.; Sweedler, J. V. Mass spectrometry
reviews 2008, 27, 316.

(94)

Robinson, J. M.; Ackerman, W. E. t.; Tewari, A. K.; Kniss, D. A.; Vandre, D. D.
Analytical biochemistry 2009, 387, 87.

(95)

Bordier, C. The Journal of biological chemistry 1981, 256, 1604.

(96)

Taylor, R. S.; Wu, C. C.; Hays, L. G.; Eng, J. K.; Yates, J. R., 3rd; Howell, K. E.
Electrophoresis 2000, 21, 3441.

(97)

Stasyk, T.; Huber, L. A. Proteomics 2004, 4, 3704.

(98)

Gloriam, D. E.; Foord, S. M.; Blaney, F. E.; Garland, S. L. Journal of medicinal
chemistry 2009, 52, 4429.

(99)

Lindberg, S.; Banas, A.; Stymne, S. Plant physiology and biochemistry : PPB /
Societe francaise de physiologie vegetale 2005, 43, 261.

(100) Josic, D.; Brown, M. K.; Huang, F.; Callanan, H.; Rucevic, M.; Nicoletti, A.; Clifton,
J.; Hixson, D. C. Electrophoresis 2005, 26, 2809.
(101) Lawson, E. L.; Clifton, J. G.; Huang, F.; Li, X.; Hixson, D. C.; Josic, D.
Electrophoresis 2006, 27, 2747.
(102) Righetti, P. G.; Castagna, A.; Antonioli, P.; Boschetti, E. Electrophoresis 2005, 26,
297.
(103) Shin, J. H.; Krapfenbauer, K.; Lubec, G. Electrophoresis 2006, 27, 2799.
(104) Roy, I.; Mondal, K.; Gupta, M. N. Journal of chromatography. B, Analytical
technologies in the biomedical and life sciences 2007, 849, 32.
(105) Cao, R.; Li, X.; Liu, Z.; Peng, X.; Hu, W.; Wang, X.; Chen, P.; Xie, J.; Liang, S.
Journal of proteome research 2006, 5, 634.
(106) Srivastava, R.; Pisareva, T.; Norling, B. Proteomics 2005, 5, 4905.
(107) Schindler, J.; Lewandrowski, U.; Sickmann, A.; Friauf, E.; Nothwang, H. G.
Molecular & cellular proteomics : MCP 2006, 5, 390.

65

(108) Adam, P. J.; Boyd, R.; Tyson, K. L.; Fletcher, G. C.; Stamps, A.; Hudson, L.; Poyser,
H. R.; Redpath, N.; Griffiths, M.; Steers, G.; Harris, A. L.; Patel, S.; Berry, J.; Loader,
J. A.; Townsend, R. R.; Daviet, L.; Legrain, P.; Parekh, R.; Terrett, J. A. The Journal
of biological chemistry 2003, 278, 6482.
(109) Blonder, J.; Terunuma, A.; Conrads, T. P.; Chan, K. C.; Yee, C.; Lucas, D. A.;
Schaefer, C. F.; Yu, L. R.; Issaq, H. J.; Veenstra, T. D.; Vogel, J. C. The Journal of
investigative dermatology 2004, 123, 691.
(110) Foster, L. J.; Zeemann, P. A.; Li, C.; Mann, M.; Jensen, O. N.; Kassem, M. Stem Cells
2005, 23, 1367.
(111) Navarre, C.; Degand, H.; Bennett, K. L.; Crawford, J. S.; Mortz, E.; Boutry, M.
Proteomics 2002, 2, 1706.
(112) Zhang, L.; Xie, J.; Wang, X.; Liu, X.; Tang, X.; Cao, R.; Hu, W.; Nie, S.; Fan, C.;
Liang, S. Proteomics 2005, 5, 4510.
(113) Fujiki, Y.; Hubbard, A. L.; Fowler, S.; Lazarow, P. B. The Journal of cell biology
1982, 93, 97.
(114) Chang, P. S.; Absood, A.; Linderman, J. J.; Omann, G. M. Analytical biochemistry
2004, 325, 175.
(115) Elortza, F.; Nuhse, T. S.; Foster, L. J.; Stensballe, A.; Peck, S. C.; Jensen, O. N.
Molecular & cellular proteomics : MCP 2003, 2, 1261.
(116) Thingholm, T. E.; Larsen, M. R.; Ingrell, C. R.; Kassem, M.; Jensen, O. N. Journal of
proteome research 2008, 7, 3304.
(117) Weerasekera, R.; She, Y. M.; Markham, K. A.; Bai, Y.; Opalka, N.; Orlicky, S.;
Sicheri, F.; Kislinger, T.; Schmitt-Ulms, G. Proteomics 2007, 7, 3835.
(118) Freed, J. K.; Smith, J. R.; Li, P.; Greene, A. S. Proteomics 2007, 7, 2371.
(119) Gubbens, J.; Ruijter, E.; de Fays, L. E.; Damen, J. M.; de Kruijff, B.; Slijper, M.;
Rijkers, D. T.; Liskamp, R. M.; de Kroon, A. I. Chemistry & biology 2009, 16, 3.
(120) Solis, N.; Larsen, M. R.; Cordwell, S. J. Proteomics 2010, 10, 2037.
(121) Tjalsma, H.; Lambooy, L.; Hermans, P. W.; Swinkels, D. W. Proteomics 2008, 8,
1415.
(122) Rodriguez-Ortega, M. J.; Norais, N.; Bensi, G.; Liberatori, S.; Capo, S.; Mora, M.;
Scarselli, M.; Doro, F.; Ferrari, G.; Garaguso, I.; Maggi, T.; Neumann, A.; Covre, A.;
Telford, J. L.; Grandi, G. Nat Biotechnol 2006, 24, 191.

66

(123) Speers, A. E.; Blackler, A. R.; Wu, C. C. Anal Chem 2007, 79, 4613.
(124) Elortza, F.; Mohammed, S.; Bunkenborg, J.; Foster, L. J.; Nuhse, T. S.; Brodbeck, U.;
Peck, S. C.; Jensen, O. N. Journal of proteome research 2006, 5, 935.
(125) Mutch, S. A.; Kensel-Hammes, P.; Gadd, J. C.; Fujimoto, B. S.; Allen, R. W.; Schiro,
P. G.; Lorenz, R. M.; Kuyper, C. L.; Kuo, J. S.; Bajjalieh, S. M. et al. Journal of
Neuroscience 2010, 31, 1461.
(126) Mutch, S. A.; Kensel-Hammes, P.; Gadd, J. C.; Fujimoto, B. S.; Schiro, P. G;
Bajjalieh, S. M.; Chium D. T. Nature Protocols 2001, 6, 1953.
(127) Gauthier, D. J. and Lazure, C. Expert Reviews in Proteomics 2008, 5, 603.
(128) Gauthier, D. J.; Sobota, J. A.; Ferraro, F.; Mains, R. E.; Lazure, C. Proteomics 2008,
8, 3848.
(129) Brunner, Y.; Coute, Y.; Iezzi, M.; Foti, M.; Fukuda, M.; Hochstrasser, D. F.;
Wollheim, C. B. Mol Cell Proteomics 2007, 6, 1007.
(130) Meikle, P. J.; Ng, K. F.; Johnson, E.; Hoogenraad, N. J.; Stone, B. A. The Journal of
biological chemistry 1991, 266, 22569.
(131) Van Hoof, D.; Dormeyer, W.; Braam, S. R.; Passier, R.; Monshouwer-Kloots, J.;
Ward-van Oostwaard, D.; Heck, A. J.; Krijgsveld, J.; Mummery, C. L. Journal of
proteome research 2010, 9, 1610.
(132) Zhang, L.; Wang, X.; Peng, X.; Wei, Y.; Cao, R.; Liu, Z.; Xiong, J.; Ying, X.; Chen,
P.; Liang, S. Journal of proteome research 2007, 6, 34.
(133) Watarai, H.; Hinohara, A.; Nagafune, J.; Nakayama, T.; Taniguchi, M.; Yamaguchi,
Y. Proteomics 2005, 5, 4001.
(134) Chevallet, M.; Santoni, V.; Poinas, A.; Rouquie, D.; Fuchs, A.; Kieffer, S.; Rossignol,
M.; Lunardi, J.; Garin, J.; Rabilloud, T. Electrophoresis 1998, 19, 1901.
(135) Babu, G. J.; Wheeler, D.; Alzate, O.; Periasamy, M. Analytical biochemistry 2004,
325, 121.
(136) Santoni, V.; Rabilloud, T.; Doumas, P.; Rouquie, D.; Mansion, M.; Kieffer, S.; Garin,
J.; Rossignol, M. Electrophoresis 1999, 20, 705.
(137) Esteve-Romero, J.; Simo-Alfonso, E.; Bossi, A.; Bresciani, F.; Righetti, P. G.
Electrophoresis 1996, 17, 704.
(138) Rabilloud, T.; Adessi, C.; Giraudel, A.; Lunardi, J. Electrophoresis 1997, 18, 307.

67

(139) Molloy, M. P.; Herbert, B. R.; Walsh, B. J.; Tyler, M. I.; Traini, M.; Sanchez, J. C.;
Hochstrasser, D. F.; Williams, K. L.; Gooley, A. A. Electrophoresis 1998, 19, 837.
(140) Rabilloud, T. Electrophoresis 1996, 17, 813.
(141) Musante, L.; Candiano, G.; Ghiggeri, G. M. Journal of chromatography. B,
Biomedical sciences and applications 1998, 705, 351.
(142) Wang, S. B., Hu, Q., Sommerfeld, M., Chen, F. Journal of Applied Phycology 2003,
15, 485.
(143) Thingholm, T. E.; Larsen, M. R. Methods Mol Biol 2009, 527, 57.
(144) Thingholm, T. E.; Jorgensen, T. J.; Jensen, O. N.; Larsen, M. R. Nat Protoc 2006, 1,
1929.
(145) Nguyen, V.; Cao, L.; Lin, J. T.; Hung, N.; Ritz, A.; Yu, K.; Jianu, R.; Ulin, S. P.;
Raphael, B. J.; Laidlaw, D. H.; Brossay, L.; Salomon, A. R. Molecular & cellular
proteomics : MCP 2009, 8, 2418.
(146) Hoving, S.; Gerrits, B.; Voshol, H.; Muller, D.; Roberts, R. C.; van Oostrum, J.
Proteomics 2002, 2, 127.
(147) Clifton, J. G.; Li, X.; Reutter, W.; Hixson, D. C.; Josic, D. Journal of
chromatography. B, Analytical technologies in the biomedical and life sciences 2007,
849, 293.
(148) Josic, D.; Zeilinger, K. Methods Enzymol 1996, 271, 113.
(149) Lin, S. H.; Fain, J. N. The Journal of biological chemistry 1984, 259, 3016.
(150) Josic, D.; Clifton, J. G. Proteomics 2007, 7, 3010.
(151) Nouwens, A. S.; Cordwell, S. J.; Larsen, M. R.; Molloy, M. P.; Gillings, M.; Willcox,
M. D.; Walsh, B. J. Electrophoresis 2000, 21, 3797.
(152) Clifton, J. G.; Brown, M. K.; Huang, F.; Li, X.; Reutter, W.; Hofmann, W.; Hixson, D.
C.; Josic, D. Journal of chromatography. A 2006, 1123, 205.
(153) Blonder, J.; Goshe, M. B.; Moore, R. J.; Pasa-Tolic, L.; Masselon, C. D.; Lipton, M.
S.; Smith, R. D. Journal of proteome research 2002, 1, 351.
(154) Rabilloud, T. Electrophoresis 1998, 19, 758.
(155) Anderson, N. G.; Anderson, N. L. Analytical biochemistry 1978, 85, 331.

68

(156) Anderson, N. L.; Anderson, N. G. Electrophoresis 1991, 12, 883.
(157) O'Farrell, P. H. The Journal of biological chemistry 1975, 250, 4007.
(158) McDonough, J.; Marban, E. Proteomics 2005, 5, 2892.
(159) Luche, S.; Santoni, V.; Rabilloud, T. Proteomics 2003, 3, 249.
(160) Olsson, I.; Larsson, K.; Palmgren, R.; Bjellqvist, B. Proteomics 2002, 2, 1630.
(161) Chick, J. M.; Haynes, P. A.; Bjellqvist, B.; Baker, M. S. Journal of proteome research
2008, 7, 4974.
(162) Li, R. X.; Zhou, H.; Li, S. J.; Sheng, Q. H.; Xia, Q. C.; Zeng, R. Journal of proteome
research 2005, 4, 1256.
(163) Chick, J. M.; Haynes, P. A.; Molloy, M. P.; Bjellqvist, B.; Baker, M. S.; Len, A. C.
Journal of proteome research 2008, 7, 1036.
(164) Hartwig, S.; Feckler, C.; Lehr, S.; Wallbrecht, K.; Wolgast, H.; Muller-Wieland, D.;
Kotzka, J. Proteomics 2009, 9, 3209.
(165) Islinger, M.; Weber, G. Methods Mol Biol 2008, 432, 199.
(166) Xu, C.; Lin, X.; Ren, H.; Zhang, Y.; Wang, S.; Peng, X. Proteomics 2006, 6, 462.
(167) le Coutre, J.; Whitelegge, J. P.; Gross, A.; Turk, E.; Wright, E. M.; Kaback, H. R.;
Faull, K. F. Biochemistry 2000, 39, 4237.
(168) Whitelegge, J. P.; Zhang, H.; Aguilera, R.; Taylor, R. M.; Cramer, W. A. Molecular &
cellular proteomics : MCP 2002, 1, 816.
(169) Gomez, S. M.; Nishio, J. N.; Faull, K. F.; Whitelegge, J. P. Molecular & cellular
proteomics : MCP 2002, 1, 46.
(170) Cadene, M.; Chait, B. T. Anal Chem 2000, 72, 5655.
(171) Ning, Z. B.; Li, Q. R.; Dai, J.; Li, R. X.; Shieh, C. H.; Zeng, R. Journal of proteome
research 2008, 7, 4525.
(172) Machtejevas, E.; John, H.; Wagner, K.; Standker, L.; Marko-Varga, G.; Forssmann,
W. G.; Bischoff, R.; Unger, K. K. Journal of chromatography. B, Analytical
technologies in the biomedical and life sciences 2004, 803, 121.
(173) Peng, J.; Elias, J. E.; Thoreen, C. C.; Licklider, L. J.; Gygi, S. P. Journal of proteome
research 2003, 2, 43.

69

(174) Santoni, V.; Molloy, M.; Rabilloud, T. Electrophoresis 2000, 21, 1054.
(175) Barnea, E.; Sorkin, R.; Ziv, T.; Beer, I.; Admon, A. Proteomics 2005, 5, 3367.
(176) Haynes, P. A.; Yates, J. R., 3rd Yeast 2000, 17, 81.
(177) Han, X.; Aslanian, A.; Yates, J. R., 3rd Current opinion in chemical biology 2008, 12,
483.
(178) Ayaz-Guner, S.; Zhang, J.; Li, L.; Walker, J. W.; Ge, Y. Biochemistry 2009, 48, 8161.
(179) Ge, Y.; Lawhorn, B. G.; ElNaggar, M.; Strauss, E.; Park, J. H.; Begley, T. P.;
McLafferty, F. W. J Am Chem Soc 2002, 124, 672.
(180) Ge, Y.; Rybakova, I. N.; Xu, Q.; Moss, R. L. Proc Natl Acad Sci U S A 2009, 106,
12658.
(181) Zabrouskov, V.; Ge, Y.; Schwartz, J.; Walker, J. W. Molecular & cellular proteomics
: MCP 2008, 7, 1838.
(182) Zhang, J.; Dong, X.; Hacker, T. A.; Ge, Y. J Am Soc Mass Spectrom 2010, 21, 940.
(183) Zabrouskov, V.; Han, X.; Welker, E.; Zhai, H.; Lin, C.; van Wijk, K. J.; Scheraga, H.
A.; McLafferty, F. W. Biochemistry 2006, 45, 987.
(184) Kelleher, N. L.; Lin, H. Y.; Valaskovic, G. A.; Aaserud, D. J.; Fridriksson, E. K.;
McLafferty, F. W. J. Am. Chem. Soc. 1999, 121, 806.
(185) Solis, R. S.; Ge, Y.; Walker, J. W. J Muscle Res Cell M 2008, 29, 203.
(186) Xu, F. M.; Xu, Q. G.; Dong, X. T.; Guy, M.; Guner, H.; Hacker, T. A.; Ge, Y.
International journal of mass spectrometry 2011, 305, 95.
(187) Siuti, N.; Kelleher, N. L. Nature methods 2007, 4, 817.
(188) Ryan, C. M.; Souda, P.; Bassilian, S.; Ujwal, R.; Zhang, J.; Abramson, J.; Ping, P.;
Durazo, A.; Bowie, J. U.; Hasan, S. S.; Baniulis, D.; Cramer, W. A.; Faull, K. F.;
Whitelegge, J. P. Molecular & cellular proteomics : MCP 2010, 9, 791.
(189) Switzar, L.; Giera, M.; Niessen, W. M. Journal of proteome research 2013, 12, 1067.
(190) McLafferty, F. W.; Breuker, K.; Jin, M.; Han, X.; Infusini, G.; Jiang, H.; Kong, X.;
Begley, T. P. The FEBS journal 2007, 274, 6256.
(191) Zubarev, R. A.; Horn, D. M.; Fridriksson, E. K.; Kelleher, N. L.; Kruger, N. A.;
Lewis, M. A.; Carpenter, B. K.; McLafferty, F. W. Anal Chem 2000, 72, 563.

70

(192) Cooper, H. J.; Hakansson, K.; Marshall, A. G. Mass spectrometry reviews 2005, 24,
201.
(193) Emmett, M. R.; Caprioli, R. M. J. Am. Soc. Mass Spectrom. 1994, 5, 605.
(194) Whitelegge, J.; Halgand, F.; Souda, P.; Zabrouskov, V. Expert Rev Proteomics 2006,
3, 585.
(195) Armirotti, A.; Benatti, U.; Damonte, G. Rapid communications in mass spectrometry :
RCM 2009, 23, 661.
(196) Pesavento, J. J.; Bullock, C. R.; LeDuc, R. D.; Mizzen, C. A.; Kelleher, N. L. The
Journal of biological chemistry 2008, 283, 14927.
(197) Whitelegge, J. P.; Zabrouskov, V.; Halgand, F.; Souda, P.; Bassilian, S.; Yan, W.;
Wolinsky, L.; Loo, J. A.; Wong, D. T.; Faull, K. F. International journal of mass
spectrometry 2007, 268, 190.
(198) Meng, F. Y.; Cargile, B. J.; Patrie, S. M.; Johnson, J. R.; McLoughlin, S. M.; Kelleher,
N. L. Analytical Chemistry 2002, 74, 2923.
(199) Chen, E. I.; McClatchy, D.; Park, S. K.; Yates, J. R. Analytical Chemistry 2008, 80,
8694.
(200) Arrell, D. K.; Neverova, I.; Van Eyk, J. E. Circulation Research 2001, 88, 763.
(201) Kellie, J. F.; Tran, J. C.; Lee, J. E.; Ahlf, D. R.; Thomas, H. M.; Ntai, I.; Catherman,
A. D.; Durbin, K. R.; Zamdborg, L.; Vellaichamy, A.; Thomas, P. M.; Kelleher, N. L.
Molecular bioSystems 2010, 6, 1532.
(202) Armirotti, A.; Damonte, G. Proteomics 2010, 10, 3566.
(203) Fridriksson, E. K.; Baird, B.; McLafferty, F. W. J. Am. Soc. Mass Spectrom. 1999, 10,
453.
(204) Tran, J. C.; Doucette, A. A. Analytical Chemistry 2008, 80, 1568.
(205) Vellaichamy, A.; Tran, J. C.; Catherman, A. D.; Lee, J. E.; Kellie, J. F.; Sweet, S. M.
M.; Zamdborg, L.; Thomas, P. M.; Ahlf, D. R.; Durbin, K. R.; Valaskovic, G. A.;
Kelleher, N. L. Analytical Chemistry 2010, 82, 1234.
(206) Neverova, I.; Van Eyk, J. E. J Chromatogr B 2005, 815, 51.
(207) Yates, J. R.; Ruse, C. I.; Nakorchevsky, A. Annual Review of Biomedical Engineering
2009, 11, 49.

71

(208) Qian, W. J.; Jacobs, J. M.; Liu, T.; Camp, D. G., 2nd; Smith, R. D. Molecular &
cellular proteomics : MCP 2006, 5, 1727.
(209) Messer, A. E.; Jacques, A. M.; Marston, S. B. J Mol Cell Cardiol 2007, 42, 247.
(210) Zong, C.; Young, G. W.; Wang, Y.; Lu, H.; Deng, N.; Drews, O.; Ping, P. Proteomics
2008, 8, 5025.
(211) Gundry, R. L.; Fu, Q.; Jelinek, C. A.; Van Eyk, J. E.; Cotter, R. J. Proteomics.
Clinical applications 2007, 1, 73.
(212) Sintegral membrane proteinson, D. C.; Ahn, S.; Pasa-Tolic, L.; Bogdanov, B.; Mottaz,
H. M.; Vilkov, A. N.; Anderson, G. A.; Lipton, M. S.; Smith, R. D. Electrophoresis
2006, 27, 2722.
(213) Sharma, S.; Sintegral membrane proteinson, D. C.; Tolic, N.; Jaitly, N.; Mayampurath,
A. M.; Smith, R. D.; Pasa-Tolic, L. Journal of proteome research 2007, 6, 602.
(214) Garcia, B. A. J Am Soc Mass Spectrom 2010, 21, 193.
(215) Armirotti, A.; Damonte, G. Proteomics 2010, 10, 3566.
(216) Kelleher, N. L. Anal Chem 2004, 76, 197A.
(217) Kellie, J. F.; Tran, J. C.; Lee, J. E.; Ahlf, D. R.; Thomas, H. M.; Ntai, I.; Catherman,
A. D.; Durbin, K. R.; Zamdborg, L.; Vellaichamy, A.; Thomas, P. M.; Kelleher, N. L.
Molecular bioSystems 2010, 6, 1532.
(218) Chen, R.; Jiang, X.; Sun, D.; Han, G.; Wang, F.; Ye, M.; Wang, L.; Zou, H. Journal of
proteome research 2009, 8, 651.
(219) Zhang, Y.; Fonslow, B. R.; Shan, B.; Baek, M. C.; Yates, J. R., 3rd Chemical reviews
2013, 113, 2343.
(220) Guerrera, I. C.; Kleiner, O. Bioscience reports 2005, 25, 71.
(221) Link, A. J. Trends in biotechnology 2002, 20, S8.
(222) Godovac-Zimmermann, J.; Kleiner, O.; Brown, L. R.; Drukier, A. K. Proteomics
2005, 5, 699.
(223) Lin, D., Alpert, A. J., and Yates, J. R. Am Genom. Proteomic Technol. 2001, 1, 38.
(224) Yates, J. R., 3rd; McCormack, A. L.; Eng, J. Anal Chem 1996, 68, 534A.

72

(225) McCormack, A. L.; Schieltz, D. M.; Goode, B.; Yang, S.; Barnes, G.; Drubin, D.;
Yates, J. R., 3rd Anal Chem 1997, 69, 767.
(226) Lee, J.; Soper, S. A.; Murray, K. K. Journal of mass spectrometry : JMS 2009, 44,
579.
(227) Li, J.; Kelly, J. F.; Chernushevich, I.; Harrison, D. J.; Thibault, P. Anal Chem 2000,
72, 599.
(228) Musyimi, H. K.; Guy, J.; Narcisse, D. A.; Soper, S. A.; Murray, K. K. Electrophoresis
2005, 26, 4703.
(229) Mellors, J. S.; Gorbounov, V.; Ramsey, R. S.; Ramsey, J. M. Anal Chem 2008, 80,
6881.
(230) Foote, R. S.; Khandurina, J.; Jacobson, S. C.; Ramsey, J. M. Analytical Chemistry
2005, 77, 57.
(231) Yue, G. E.; Roper, M. G.; Balchunas, C.; Pulsipher, A.; Coon, J. J.; Shabanowitz, J.;
Hunt, D. F.; Landers, J. P.; Ferrance, J. P. Analytica Chimica Acta 2006, 564, 116.
(232) Dahlin, A. P.; Bergstroem, S. K.; Andren, P. E.; Markides, K. E.; Bergquist, J.
Analytical Chemistry 2005, 77, 5356.
(233) Carlier, J.; Arscott, S.; Thomy, V.; Camart, J. C.; Cren-Olive, C.; Le Gac, S. Journal
of chromatography. A 2005, 1071, 213.
(234) Fortier, M.-H.; Bonneil, E.; Goodley, P.; Thibault, P. Analytical Chemistry 2005, 77,
1631.
(235) Huft, J.; Haynes, C. A.; Hansen, C. L. Anal Chem 2013, 85, 1797.
(236) Gottschlich, N.; Culbertson, C. T.; McKnight, T. E.; Jacobson, S. C.; Ramsey, J. M.
Journal of chromatography. B, Biomedical sciences and applications 2000, 745, 243.
(237) Liu, Y.; Foote, R. S.; Jacobson, S. C.; Ramsey, R. S.; Ramsey, J. M. Anal Chem 2000,
72, 4608.
(238) Wang, C.; Oleschuk, R.; Ouchen, F.; Li, J.; Thibault, P.; Harrison, D. J. Rapid
communications in mass spectrometry : RCM 2000, 14, 1377.
(239) Lorenz, R. M. and Chiu, D. T. Acc Chem Res 2008, 42, 649.
(240) Pei, J.; Li, Q. and Kennedy, R. T. J Am Soc Mass Spectrom 2010, 21, 1107.
(241) Kirby, A. E. and Wheeler, A. R. Anal Chem 2013, 85, 6178

73

(242) Jebrail, M.J. and Wheeler, A. R. Anal Chem 2009, 81, 330.
(243) Jebrail, M. J.; Yang, H.; Mudrik, J. M.; Lafreniere, N. M.; Mcroberts, c.; Al-Dirbashi,
O. Y.; Fisher, L.; Chakraborty, P. and Wheeler, A. R. Lab Chip 2011, 11, 3218.
(244) Ho, j.; Tan, M. K.; Go, D. B.; Yeo, L. Y.; Friend, J. R. and Chang, H. C. Anal Chem
2011, 83, 3260.
(245) Dennison, A.; Edgar, J.; Winters, D.; Yoon, s. H.; Huang, Y.; Li, Y.; Walton, A.;
Mackay, L.; Goodlett, D. R. and Landridge-Smith, P. Development and Application of
Surface Acoustic Wave Nebulization with Digital Microfluidics for Top-Down Protein
Fragmentation. Presented at 60th ASMS Conference on Mass Spectrometry and
Applied Topics, Vancouver, Canada, 2012, TOC pm 3:30.
(246) Luk, V. N. and Wheeler, A. R. Anal Chem 2009, 81, 4524.
(247) Luk, V. N.; Fiddes, L. K.; Luk, V. M.; Kumacheva, E. and Wheeler, A. R. Proteomics,
2012, 12, 1310.
(248) Aijian, A. P.; Chatterjee, D. and Garrell, R. L. Lab Chip 2012, 12, 2552.
(249) Srinivasan, V.; Pamula, V.; Paik, P. and Fair, R. Protein Stamping for MALDI Mass
Spectrometry Using and Electrowetting-based Microfluidic Platform. In Proceedings
of SPIE-The International Society for Optical Engineering 5591; International Society
for Optics and Photonics: Bellingham, WA; 2004; pp 26-32.
(250) Lapierre, F.; Piret, G.; Drobecq, H.; Melnyk, O. Coffinier, Y.; Thomy, V. and
Boukerroub, R. Lab Chip 2011, 11, 1620.
(251) Luk, V. N.; Mo, G. C. H. and Wheeler, A. R. Langmuir 2008, 24, 6382.
(252) Yang, H.; Luk, V. N. ;Abdelgawd, M.; Barbulovic-Nad, I. and Wheeler, A. R. Anal
Chem 2009, 81, 1061.
(253) Dorsam, R. T.; Gutkind, J. S. Nature reviews. Cancer 2007, 7, 79.
(254) Haab, B. B.; Dunham, M. J.; Brown, P. O. Genome biology 2001, 2,
RESEARCH0004.
(255) MacBeath, G.; Schreiber, S. L. Science 2000, 289, 1760
(256) Merchant, M., Weinberger, S. R., Electrophoresis 2000, 21, 1164.

74

(257) Kotz, K. T.; Xiao, W.; Miller-Graziano, C.; Qian, W. J.; Russom, A.; Warner, E. A.;
Moldawer, L. L.; De, A.; Bankey, P. E.; Petritis, B. O.; Camp, D. G., 2nd; Rosenbach,
A. E.; Goverman, J.; Fagan, S. P.; Brownstein, B. H.; Irimia, D.; Xu, W.; Wilhelmy,
J.; Mindrinos, M. N.; Smith, R. D.; Davis, R. W.; Tompkins, R. G.; Toner, M. Nat
Med, 2010, 16, 1042.
(258) Osiri, J. K.; Shadpour, H.; Park, S.; Snowden, B. C.; Chen, Z. Y.; Soper, S. A.
Electrophoresis 2008, 29, 4984.
(259) Shadpour, H.; Soper, S. A. Anal Chem 2006, 78, 3519.
(260) Lee, J.; Musyimi, H. K.; Soper, S. A.; Murray, K. K. J Am Soc Mass Spectrom 2008,
19, 964.

75

2

Solid-phase Extraction/Purification of Membrane Proteins from MCF-7 Breast
Cancer Cells Using a UV-modified PMMA Microfluidic Bioaffinity µSPE Device

2.1

Introduction
Membrane proteins play key roles in both the pathology and physiology of biological

cells including: regulating the trafficking of ions and solutes in and out of the cell, cell-to-cell
interactions, and responses to stimuli through surface receptors.1 Some specific modifications
to membrane proteins have been linked to different pathologic states such as, cancer,
neurological disorders, and diabetes.2 Because of these roles, membrane proteins have
received attention as possible targets for the development of new therapeutics.
Membrane proteins represent ~1/3 of proteins that are encoded by the human
genome.3,4 Yet, only a small fraction of the cell surface proteome has been characterized1,5
due to the difficulty in the handling of membrane proteins making their study challenging.
Because of the interest in discovering and validating disease-specific protein signatures of
diagnostic value or finding new drug targets discovery of personalized therapeutics, studies
aimed at the identification, characterization, and quantification of membrane proteins has
increased over the past few years. Most notably, several biopharmaceuticals (mainly
antibodies) that target membrane proteins are already being used and studied for the treatment
of tumors and lymphomas as well as some autoimmune diseases.6
It has been difficult to analyze membrane proteins due to their low abundance,
especially compared to the cytosolic proteins, their lower frequency of tryptic cleavage sites
in the transmembrane domain,6 and the heterogeneity of membrane proteins.7,8 Therefore, a
number of different approaches have been developed to address these issues. Methods that
have been utilized for the isolation of membrane proteins specifically have exploited such
analytical methods as ultracentrifugation,9,10 affinity selection of modified or non-modified
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membrane proteins (antibody- or lectin-based approaches),11,12 or two-phase partitioning13,14
and extraction.15,16 Unfortunately, these methods have failed to produce highly pure isolates
of the membrane proteins due in part to the large contamination from the cytosolic fraction.
More recently, improved techniques for the enrichment of membrane proteins, both in vivo
and in vitro, have been reported.17 These include the chemical capture of glycosylated
membrane proteins,18 silica beads with the appropriate membrane protein-specific
coatings,19,20 or cell surface biotinylation followed by solid-phase affinity extraction using
surface immobilized avidin.21-23
The empirical formula of biotin was determined by du Vigneaud and co-workers24 in
1941 and the structure was established by the same group in 1942.25,26 The Merck Research
Laboratories confirmed the structure via total synthesis of racemic biotin.27 In 1966, x-ray
crystallographic analysis established the absolute configuration of natural (+)-biotin as shown
in Figure 2.1.28 The biotin-binding proteins avidin (from the egg white of birds, reptiles, and
amphibians) and streptavidin (from the bacterium Streptomyces avidinii) have been employed
for the selection of biotinylated targets due to the complex’s high affinity (Ka = 1015 M-1).29

Figure 2.1 Absolute configuration of natural (+)-biotin.
Avidin (pI=10-10.5) has a mass of 67-68 kDa and is formed from four 128 amino
acid-subunits with each subunit containing an epitope for biotin (see Figure 2.2) with all
binding sites being stable over a wide pH and temperature range. Furthermore, avidin
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maintains its high affinity to biotin in spite of the broad range of chemical modifications it can
undergo making it useful for the purification of biotinylated molecules from complex sample
matrices. Streptavidin (mass = 53 kD) has a lower pI (pI = 6.8-7.5) than avidin and is nonglycosylated allowing a lower degree of nonspecific binding to it compared to avidin.

Figure 2.2 Biotin–avidin Interaction: Biotin (green, red, and blue spheres) fits inside a pocket
formed by a subunit of avidin protein (blue ribbon). (Reproduced from Weber, P. C.;
Ohlendorf, D. H.; Wendoloski, J. J.; Salemme, F. R. Science 1989, 243, 85.30 with
permission, Copyright 2013, AAAS).
Streptavidin contains a bacterial recognition sequence called the RYD motif
(tripeptide Arg-Tyr-Asp) that is similar to the mammalian RGD motif (tripeptide Arg-GlyAsp) that mediates cell attachment. This RYD motif can bind to cell surface receptors causing
high background signals in certain samples. There is a deglycosylated avidin known as
NeutrAvidin which has a lower mass (60 kDa) compared to avidin but retains the high biotinbinding affinity. The deglycosylation of NeutrAvidin lowers the pI (pI = 6.3) and reduces the
lectin binding to undetectable levels. In addition, lysine residues remain available and the
NeutrAvidin can be derivatized or conjugated to a variety of targets at high loads.
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NeutrAvidin also lacks the RYD sequence that streptavidin has so there is no risk of
nonspecific binding. These advantages make NeutrAvidin attractive as the protein to use for
biotin-binding assays.7,31-35 Table 2.1 summarizes the differences between the various biotinbinding proteins.
Table 2.1 Summary of Biotin-binding Proteins
Avidin

Streptavidin

NeutrAvidin

Molecular Weight

67-68 kD

53 kD

60 kD

Biotin Binding Sites

4

4

4

Isoelectric Point (pI)

10-10.5

6.8-7.5

6.3

Affinity for Biotin
(Kd)

~10-15 M

~10-14-10-15 M

~10-15 M

Non-specific
Binding

Low

High

Lowest

There are three essential components necessary for a reagent to be used for
biotinylation: (i) a reactive moiety for the covalent attachment of biotin to a functional group
on the chemical target(s). The most commonly used reactive moieties are esters, such as Nhydroxysuccinimide (NHS), that can undergo a nucleophilic substitution reaction with
primary amines (e.g. ε-amino group in exposed lysine residues present in proteins or
peptides). (ii) The biotin moiety itself, which is used for the subsequent interaction of the
biotinylated targets with the affinity-based reagent (avidin, streptavidin, or NeutrAvidin). The
valeric acid side chain of biotin is important for the avidin association, but the carboxylic acid
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group can also present on biotin can be derivatized to incorporate other reactive groups.
Utilizing the biotin/avidin association can allow for the use of strong detergents during the
purification/extraction steps without loss of material.36 (iii) A chemical spacer of adequate
length to allow for efficient capture of the biotinylated targets with a solid phase in which
avidin is covalently attached. The spacer, which is poised between the biotin molecule and the
target, can improve biotin accessibility to its association partner by minimizing steric effects
induced by the solid surface. The spacer may also contain a functional moiety that can be
cleaved chemically or physically to aid in target release after extraction and purification of
targets.
In the past decade, several groups have used biotin/avidin affinity interactions to
purify membrane proteins. In 2007, Tang and co-workers33 used three hydrophobic cellpermeable chemical probes, which were designed and synthesized in-house on a modular
scaffold for profiling the membrane proteome of S. oneidensis. Zhao et al.35 employed
biotin/streptavidin to enrich plasma membrane protein fractions. The authors employed a
hypotonic buffer and homogenization to lyse biotinylated cells from a human lung carcinoma
cell line. After lysis, streptavidin-coated magnetic beads were added to the lysate suspension
(see Figure 2.3). The beads were collected using a magnetic plate with the resulting fraction
designated as the plasma membrane fraction. The plasma membrane fraction was washed with
1 mL of 1 M KCl (high-salt wash), 0.1 M Na2CO3, pH 11.5 (high-pH wash), and finally with
a hypotonic buffer. The method resulted in a 400-fold enrichment of plasma membrane
proteins relative to the endoplasmic reticulum, which was a major contaminant in the plasma
membrane fraction, and also dramatically reduced contamination from other cellular
organelles.
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Figure 2.3 Overview of the assay utilized by Zhao et al. to enrich plasma membrane proteins
from human lung carcinoma cells (Reproduced from Zhao, Y.; Zhang, W.; Kho, Y.; Zhao, Y.
Anal Chem 2004, 76, 1817.35 with permission, Copyright 2013 American Chemical Society).
In this work, we present a novel method for the affinity enrichment of membrane
proteins specifically using a microfluidic device for solid-phase extraction (SPE), which was
made via hot embossing using a polymer substrate, in this case poly(methylmethacrylate),
PMMA (µSPE device). The extraction bed contained micropillars that were covalently
decorated with NeutrAvidin using EDC/NHS coupling chemistry between the NeutrAvidin
molecules and the activated polymer surface; UV-activation (254 nm) of the polymer surface.
Based on modification procedures of thermoplastics previously outlined in our group,37 the
PMMA enrichment devices were exposed to UV light to generate surface-confined carboxylic
acids followed by thermal assembly of the device. Neutravidin could subsequently be
covalently strapped to the activated surface and used to select biotinylated proteins following
cell lysis.
This device was used for the solid-phase extraction and purification of membrane
proteins from a whole cell lysate. The micropillars were used to increase the available surface
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area to improve the dynamic range of the assay. As an example of the utility of the µSPE
device, MCF-7 breast cancer cells and the extraction of the membrane proteins was evaluated.
Intact MCF-7 cells were biotinylated using a reagent that contained a spacer moiety that could
be cleaved to quantitatively release the enriched membrane fraction.
Poly(methyl methacrylate), PMMA, was selected as the µSPE device substrate
because of its ease of surface modification using UV light (254 nm), its biocompatibility, and
the high surface density of functional groups it generates following UV activation. The µSPE
device surfaces, including the micropillars, were decorated with NeutrAvidin via EDC/NHS
coupling chemistry. We covalently attached biotin to extracellular primary amine groups of
membrane proteins with the biotin providing an anchoring group for the affinity enrichment
of these biotinylated proteins. The proteins were modified with sulfo-NHS-SS-biotin
containing a disulfide-cleavable linker possessing a 24.3 Å spacer to reduce any steric effects.
Washes with high salt and high pH solutions were used to remove interfering cytosolic
species. Then, the bound membrane proteins could be released from the µSPE device by
flooding the bed with a solution of 1,4-dithiothreitol (DTT) in a solubilization buffer. A
Bradford assay was used to aid in the evaluation of membrane protein recovery and Western
Blotting was performed to evaluate the presence of potential interferences from cytosolic
proteins.
2.2

Materials and Methods

2.2.1 Fabrication of PMMA µSPE for Membrane Protein Enrichment
Fabrication of the microfluidic device involved three major steps: (1) Mold insert
fabrication using a micro-milling machine (Kern MMP, Kern Micro- and Feinwerktechnik,
Murnau-Westried, Germany); (2) hot embossing of the microfluidic structures (HEX02,
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JenOptik Mikrotechnik, Jena, Germany) into 3 mm thick PMMA substrates (Goodfellow,
United Kingdom); and (3) post-processing of the microfluidic device including drilling of
sample reservoirs, UV modification of the immobilization beds and cover plate assembly. The
embossed device consisted of six, 24 mm long and 1.4 mm wide channels with microposts
serving as the extraction bed. The post dimensions were 100 μm (height) x 100 μm (diameter)
with a 50 μm spacing and a total of 3,600 microposts per bed. Each affinity bed had a total
surface area of 110 mm2. Solution reservoirs were created by drilling 1 mm holes into the 3
mm thick PMMA wafers.
Thin PMMA sheets, 0.25 mm thick, were used to enclose the µSPE device by thermal
fusion bonding. Prior to enclosure, the PMMA substrate was cleaned using isopropyl alcohol
followed by sonication in ddH2O, then dried in an oven at 70ºC for 30 min. The PMMA
substrate and cover plate were sandwiched between two borosilicate glass plates (McMaster,
Atlanta, GA, USA) and clamped together prior to insertion into a convection oven. The
thermal fusion bonding of the PMMA assembly was done at 100ºC for 20 min.
2.2.2 Design and Operation of the µSPE Device
A variety of methods have been reported to introduce solid extraction phases into
microfluidic devices, such as derivatization of microchannel walls with molecular reagents
that bear the desired affinity agent, the use of polymeric membranes as sorbents, or the
incorporation of magnetic or silica beads.38 The first demonstration of SPE in a microfluidic
format was performed by introducing silica beads into a microchannel and was used for the
analysis of amino acids and peptides.39 We have previously demonstrated a simple and
effective method for creating high surface area extraction beds, which incorporate microposts
embossed into a fluidic channel. This dramatically simplifies the fabrication process by
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eliminating the need for loading silica beads into small channels or the formation of
monoliths.40

Figure 2.4 (A) Illustration of the topographical layout of the PMMA µSPE device showing
the three beds with microposts used for the affinity capture of membrane proteins. (B&D)
SEM images of the capture bed and a high magnification SEM (E) of the microposts. (C) A
photo of the finished PMMA µSPE device.
A schematic of the fluidic chip is shown in Figure 2.4A. Also shown are SEMs of the
microposts poised within the affinity bed (B, D, & E), and a picture of the assembled device
(C). Operation of the device involved 3 steps: (i) The sample was loaded into a syringe with
the syringe connected via polyetheretherketone (PEEK) tubing (IDEX, Oak Harbor, WA)
possessing a length of 9 cm (177 μm ID) to the input and output reservoirs of the µSPE device
(see Figure 2.4C); (ii) the sample was dispensed into the reservoirs by loading wit a syringe
pump (Harvard Apparatus, Holliston, MA); and (iii) the effluent was collected in
microcentrifuge tubes. The affinity bed was washed with buffer solutions by manual loading.
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The washing steps were critical in order to remove residual amounts of cellular debris that
could potentially interfere with downstream analysis of the membrane proteins.
2.2.3 Surface Modification of the PMMA µSPE Device
The functional scaffold for NeutrAvidin attachment to the PMMA surface was built
using a photochemical method (see Scheme 1). In this method, the affinity beds and cover
plate were irradiated with a UV light source (22 mW/cm2; 254 nm) for 15 min using a low
pressure Hg lamp (GLF-42, Jelight Company Inc., Irvine, CA). After thermal fusion bonding
of the cover slip to the device, the channel was filled with a buffered solution of 0.05 M 2-(Nmorpholino) ethanesulfonic acid (MES, pH 5.0) containing 60 mg/mL of 1-ethyly-3-(3dimethylaminopropyl)carbodiimide (EDC) and 6 mg/mL of N-hydroxysuccinimide (NHS).
The solution was allowed to react with the surface at room temperature for 30 min to obtain a
succinimidyl ester intermediate.
Scheme 1 shows the photochemical modification of the surface of the µSPE device
and the subsequent immobilization of NeutrAvidin via the EDC/NHS coupling reaction.
Scheme 1 also describes the surface chemistry for the EDC/NHS coupling and the
intermediates that are formed along with the amide bond that is used to immobilize
NeutrAvidin to the pendant PMMA surface-confined carboxylic acids that are formed
following UV activation. Figure 2.5 shows images of pristine PMMA, UV-modified PMMA,
and the PMMA surface with immobilized NeutrAvidin that were taken using brightfield and
fluorescence microscopy (for fluorescence microscopy, the excitation wavelength was 488
nm).

85

Scheme 1 Reaction processes and intermediates formed on the PMMA surface during the
EDC/NHS coupling reaction and NeutrAvidin immobilization. 1. Carboxylic acid; 2. EDC; 3.
O-Acylisourea active intermediate; 4. NHS; 5. NHS-Ester intermediate; 6. Primary Aminecontaining molecule (i.e. NeutrAvidin); 7. NHS; 8. Amide bond formation.

After the EDC/NHS reaction had incubated with the activated affinity bed surface for
30 min, the surface was rinsed with 1x PBS (pH 8.0) to remove excess EDC/NHS. Next, a
100 μL aliquot of 8 μM NeutrAvidin (in PBS, pH 8.0) was introduced into the extraction bed
using manual loading with a syringe. The reaction was allowed to proceed overnight at 4ºC,
after which the affinity bed was rinsed with 1x PBS (pH 8.0) to remove any unbound
NeutrAvidin.
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Figure 2.5. Images of the affinity surface: A) Before UV modification (10x, brightfield); B)
after UV modification (10x, brightfield); C) after NeutrAvidin immobilization (20x,
brightfield); and D) after NeutrAvidin immobilization (20x, fluorescence at 488 nm). All
images had an exposure time of 300 ms.
Using a calculation from Lahiri and co-workers,41 we were able to determine the
theoretical estimate of the maximal amount of immobilization for NeutrAvidin corresponding
to the maximum number of molecules of NeutrAvidin (0.9)(1014/πr2) per square millimeter
that can be close packed in a hexagonal arrangement. We assume that the NeutrAvidin
molecules are hard spheres with a radius of 2.6 nm. From the calculation, we found that 6.85
pmol/cm2 was the theoretical maximum density of NeutrAvidin that could be immobilized
given the total surface area of the bed (1.1 cm2).
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2.2.4 Mem-PER™ Plus Membrane Protein Extraction Reagent Kit
In order to provide a direct comparison of the µSPE device and the associated assay to
a currently available method for membrane protein extraction, a protein extraction kit
available through Pierce Biotechnology (Rockford, IL) was utilized to extract membrane
proteins from MCF-7 cells. The kit was used for the enrichment of integral membrane
proteins and membrane-associated proteins from cultured mammalian cells or tissue and
employs a detergent-based extraction protocol, which eliminates the use of phase separation
based solely on hydrophobicity. The cells were permeabilized with a detergent to allow
release of soluble cytosolic proteins from the membrane proteins. A second detergent was
then used to solubilize the membrane proteins.
Approximately 5 × 106 cells were harvested from the culture dish and were
centrifuged at 300× g for 5 min. Then, the pellet was washed with 3 mL of a cell wash
solution and the resultant solution centrifuged at 300× g for 5 min. The supernatant was
removed and discarded and the cell pellet was resuspended in 1.5 mL of Cell Wash Solution
and transferred to a centrifuge tube and centrifuged at 300× g for 5 min with the supernatant
discarded. Next, 750 μL of Permeabilization Buffer was added to the cell pellet and briefly
vortexed to obtain a homogeneous solution. The pellet was then incubated at 4ºC for 10 min
with constant mixing. After incubation, the cells were centrifuged at 16,000× g for 15 min
with the supernatant discarded, which contained the cytosolic proteins. Once the cytosolic
proteins were removed, 500 μL of the Solubilization Buffer was added to the remaining cell
pellet and the cells were resuspended. The cell pellet was then incubated at 4ºC for 30 min
with constant mixing. Lastly, centrifugation was done at 16,000x g for 15 min at 4ºC. The
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remaining supernatant contained the solubilized membrane and membrane-associated
proteins.
2.2.5 Sample Preparation
2.2.5.1 Cell Biotinylation and Lysis
The biotinylation of the membrane proteins was performed on the intact MCF-7cells
using a membrane impermeable reagent. As a result, only membrane proteins should be
biotinylated, reducing the contamination of cytosolic proteins and other cellular material. The
MCF-7 cells, an invasive breast ductal carcinoma, were utilized as a model in these studies.
The biotinylation reagent Sulfo-NHS-SS-Biotin (molecular weight of 606.69 g/mol),
Sulfosuccinimidyl-2-(biotinamido)-ethyl-1,3'-

dithiopropionate,

(Pierce

Biotechnology,

Rockford, IL) is membrane impenetrable and also contains a disulfide-cleavable linker
possessing a 24.3 Å spacer to reduce any steric effects caused by the NeutrAvidin support and
the biotinylated membrane proteins.

Figure 2.6 Structure of NHS-SS-Biotin with the 24.3 Å spacer.
The MCF-7 adherent cells were first washed with ice-cold 1x PBS (pH 8.0) three
times to remove any amine contaminants and culture media from the cells. The cells were
then suspended at a concentration of 5 x 106 cells/mL in 1x PBS (pH 8.0). Immediately before
use, a 10 mM solution of Sulfo-NHS-SS-Biotin was prepared by adding 164 μL of ultrapure
water to 1 mg of the biotinylation reagent. Approximately 80 μL of the biotinylation reagent
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was added per milliliter of reaction volume (volume added = 160 μL). The reaction was
incubated at room temperature for 30 min with constant mixing. After incubation, the cells
were washed with 1 mg/mL of lysine (pH 8.0) to quench the reaction by coupling to any nonreacted biotinylation reagent and then washed two times with ice-cold 1x PBS (pH 8.0) to
remove any remaining contaminants. The cells were then centrifuged at 300× g for 10 min
(4ºC) to obtain a pellet. A fluorescence image (taken at 488 nm) of intact and biotinylated
MCF-7 cells is shown in Figure 2.7.

20x, 20 µm

20x, 20 µm

Figure 2.7 Fluorescence images taken at 488 nm (200 ms exposure time) of biotinylated
MCF-7 cells that have been stained with FITC- conjugated avidin to show that the cells were
biotinylated.
After washing, a 4% CHAPS buffer, 7M urea, 2M thiourea, 30 mM Tris and 5 mM
magnesium acetate (pH 8.5) were added to the pellet to lyse the cells. Dialysis was performed
overnight with two buffer changes of 4% CHAPS (4ºC) to further remove excess biotin.
Biotin incorporation was estimated using HABA, 2-(4’-hydroxyazobenzene)-2-carboxylic
acid. The method is based on the ability of HABA to bind to avidin to form a complex with a
maximum absorption at 500 nm. A sample containing biotinylated targets is added to the
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HABA-avidin solution and because of biotin’s higher affinity for avidin, it displaces HABA
and the absorption at 500 nm decreases proportionately.42 The absorbance of the HABAavidin solution is measured before and after adding the biotinylated sample with the change in
absorbance related to the amount of biotin present in the sample. Based on the absorbance
measurements from the cells that were biotinylated, it was determined that there were
between 2-3 biotin molecules per protein molecule.
2.2.5.2 Western Blotting Analysis
We determined the concentrations of both the membrane proteins and cytosolic
proteins from the extraction procedure using a Bradford assay which used 8.2 μg of each
protein fraction (membrane, cytosolic, and total lysate). Gel runs for the blotting assay
employed the BioRad Mini-PROTEAN System (BioRad, Hercules, CA, USA). The procedure
we followed is summarized below.
A 3x Laemmli sample buffer (6% SDS, 30% glycerol, 187.5 mM Tris, 15% βmercaptoethanol, 0.006% bromophenol blue) with a 5 mL total volume was added to each
protein fraction in order to prepare them for gel electrophoresis. The fractions were heated at
95°C for 5 min, cooled on ice and briefly vortexed before being placed on the gel. A 4-15%
BioRad precast gel was used along with a PageRuler Prestained Protein Ladder (Pierce
Biotechnology, Rockford, IL, USA) that had a molecular weight range of 10-250 kDa. The
running buffer (Tris/Glycine/SDS) was used to rinse the wells of the gel and the gel was
placed in the gel box along with the running buffer. Five μL of the PageRuler was added to
the well and 50 μL of each protein sample was added to the remaining wells. The gel was run
for ~35 min at 200 V until the dye front could no longer be seen.
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While the gel was running, a PVDF membrane was prepared by incubating in
methanol for 30 s, rinsed briefly in ddH2O and then incubated in ice-cold transfer buffer (20%
methanol, 10x Western Transfer Buffer, ddH2O) for 5 min. The gel was removed from the
cassette case and placed on the PVDF membrane and both were sandwiched together with a
transfer cassette. The PVDF/gel was placed back into the gel box along with the transfer
buffer and run again for 70 min at 250 mA. When the run was completed, the membrane was
removed from the cassette and rinsed briefly with a Tris-buffered saline and Tween-20 buffer
(0.1% TBST, Tris-buffered saline, Tween-20, ddH2O). The membrane was blocked in 5%
milk (dry milk, 0.1% TBST) for 1 h. The membrane was then incubated overnight at 4°C with
the primary antibody (Anti-beta-actin antibody) in 5% dry milk and 0.1% TBST.
After incubation, the antibody solution was decanted from the membrane. The
membrane was washed 5 times for 5 min with the 0.1% TBST buffer and blocked for 5 min in
5% milk. The membrane was incubated for 1 h at room temperature with the secondary
antibody in 5% milk. The stock secondary antibody solution was diluted 1:5000 with a milk
solution (1 μL anti-actin secondary antibody + 5 mL 5% milk). The membrane was washed
again with 0.1% TBST (5 times, 5 min) and once for 5 min with 1x Tris-buffered saline
(TBS).
Enhanced chemiluminescence (ECL) was employed for detection of the resultant
bands. The method works by detecting horseradish peroxidase (HRP) tethered to the
secondary antibody forming an enzyme complex. The complex catalyzes the conversion of
the chemiluminescent substrate into a sensitized reagent in the vicinity of the antibody, which
on further oxidation by hydrogen peroxide produces a triplet (excited) carbonyl that emits
light when it decays to the singlet carbonyl. ECL allows detection of minute quantities of a
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biomolecule; proteins can be detected down to femtomole quantities. Once the ECL solution
was prepared, the membrane was placed side up on a piece of plastic wrap and 2.5 mL of the
ECL solution was pipetted over the membrane and incubated for 5 min making sure that no
part of the membrane dried out. The membrane was removed from the ECL solution and
excess solution was carefully blotted away. The membrane was placed in a plastic sleeve and
lightly taped in place. The blot was exposed to film in a darkroom for 30 s and visualized.
2.3

Results and Discussion

2.3.1 Solid-phase Extraction/Purification of Biotinylated MCF-7 Cell Surface
Membrane Proteins with Microfluidic Bioaffinity µSPE Device
Previously reported methods for purifying membrane proteins from complex samples
have combined the isolation of membrane proteins with specific protein tagging strategies to
minimize cross-contamination. For example, antibodies directed against certain membrane
proteins were immobilized onto magnetic beads and used for the purification of specific
membrane proteins. Unfortunately, this method was limited to proteins for which a specific
antibody was available.43 Protein radioactive labeling has also been employed in different
protein studies,44 and quantitative analysis of proteins by MS was often performed with
isotope-coded affinity tags.45 In 2002, Sabarth et al. used the hydrophilic reagent, S-NHS-LCbiotin (sulfosuccinimidyl-6-(biotinamido)hexanoate), to biotinylate surface proteins of E. coli
with enrichment via avidin-affinity chromatography.31 As previously mentioned, commercial
kits for the extraction of membrane proteins with the use of detergents exist, however, they
can potentially possess a high degree of cytosolic contamination that can complicate
identification of the membrane proteins due to the relatively higher abundance of the cytosolic
components.
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The steps employed in our µSPE device and assay of membrane proteins from whole
cell lysates are shown in Scheme 2. In the first step, modification of the PMMA surface
followed by immobilization of NeutrAvidin is undertaken. Once the surface has been
decorated with NeutrAvidin, the affinity bed is ready for infusion of the biotinylated proteins.

Scheme 2 Overview of the on-chip extraction/purification assay for membrane proteins from
cell lysates. Prior to cell lysis, the intact cells were biotinylated.
For the present set of experiments, the cell lysate was infused into the affinity bed at a
flow rate of 5.0 μL/min to allow sufficient time for the biotinylated proteins to interact with
the surface-confined NeutrAvidin. The surface was then rinsed with a high salt/high pH wash
to remove any loosely-bound cytosolic proteins. Following the wash, 300 mM DTT (in 4%
CHAPS) was infused continuously for 2 h through the µSPE bed. The surface was finally
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rinsed with 1x PBS (pH 8.0) and the effluent containing the released membrane proteins
collected for further analysis. The cell lysate originating from 5 x 106 MCF-7 biotinylated
cells in 4% CHAPS buffer was infused through the affinity bed of the µSPE device. To
determine if the biotinylated proteins had indeed been captured by the surface-immobilized
NeutrAvidin, we employed avidin labeled with FITC to visualize the affinity surface after
infusion of the cell lysate through the device. The FITC-labeled avidin could bind to any
available sites remaining on the biotinylated proteins that were not complexed to the surfaceconfined NeutrAvidin molecules. Figure 2.8 shows fluorescence images of membrane
proteins captured on the surface of the bioaffinity device after flooding the bed with FITClabeled avidin.

Figure 2.8 Images A and B showing captured membrane proteins on the UV/NeutrAvidinmodified PMMA capture surface. All images were done at a 300 ms exposure time with
fluorescence done at 488 nm with FITC-labeled avidin

Figure 2.8A & B show the immobilized membrane proteins at two different
magnifications. As shown in Figure 2.8, fluorescence did appear within the affinity beds that
were infused with the MCF-7 lysate. However, the resultant fluorescence appeared to be
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globular and patchy on the surface of the micropillars. This data suggested that the membrane
proteins were not well solubilized using only the 4% CHAPS buffer system before infusion
into the affinity bed as well as possibly being partially associated with the cell membrane.
Thus, it appears that the 4% CHAPS buffer was not sufficient for both cell lysis and
solubilization.
To further aid with the solubilization process, a proprietary solubilization buffer
(Pierce Biotechnology, Rockford, IL) was added to the cell lysate after biotinylation and lysis
with 4% CHAPS. The addition of this solubilization buffer proved helpful in solubilizing the
membrane protein fraction. The results of this new solubilization procedure are shown in
Figure 2.9. As shown in the fluorescence image, the resulting fluorescence was more
homogeneous around the surface of the pillars containing NeutrAvidin instead of “patchylike,” and globular as noted in Figure 2.8.
A
Flow

B
Flow

10x, 100 µm

C
Flow

20x, 50 µm

40x, 25 µm

Figure 2.9 Images of the UV/NeutrAvidin-modified PMMA capture surface after the addition
of solubilization buffer to the MCF-7 cell lysate. Images A, B, and C were taken at 10x, 20x,
and 40x magnification, respectively and all images were done at a 300 ms exposure time.
Fluorescence was done at 488 nm with FITC-labeled avidin.
This result indicated that this lysis and solubilization procedure was much more
effective than the case of using 4% CHAPS only. Also, as can be seen from these images, the
fluorescence was visible from all of the pillars in the microscope field-of-view with all sides
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of the pillar showing fluorescence. Therefore, we are operating with a load of protein
(originating from 5 x 106 MCF-7 cells) that saturates the affinity surface.

Figure 2.10 Fluorescence at 488 nm (300 ms exposure time) of the μ-SPE surface after
NeutrAvidin immobilization and flooding the bed with avidin-FITC to check for non-specific
adsorption of the FITC-labeled avidin on the surface.
To make sure that the resulting fluorescence shown in Figure 2.9 did not result from
non-specific adsorption of the fluorescently labeled avidin to the PMMA micropillars, we
subjected the NeutrAvidin-immobilized affinity bed to a solution containing the FITC-labeled
avidin without the bed being subjected to the biotinylated proteins. No fluorescence from the
FITC-labeled avidin was observed (see Figure 2.10) indicating that there was no non-specific
adsorption.
2.3.2 Release of Captured Biotinylated Membrane Proteins from the µSPE Surface
After affinity selection of the biotinylated membrane proteins by the µSPE device, a
300 mM solution of DTT (in 4% CHAPS) was continuously infused into the SPE bed at a
flow rate of 5.0 μL/min for 2 h to release the selected membrane proteins by reducing the
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disulfide bond carried in the Sulfo-NHS-biotin reagent. Infusion was done in the dark to
prevent photobleaching of the FITC on the surface. A total of 100 μL of a rinsing effluent (1x
PBS, pH 8.0) was infused. The chip was then imaged at a 20x magnification using a
fluorescence microscope with excitation at 488 nm and a 300 ms exposure time. The resulting
image is shown in Figure 2.11. As shown, there was no visible fluorescence from the µSPE
surfaces suggesting that the biotinylated membrane proteins were in fact released from the
surface.

Figure 2.11 Fluorescence image of the μ-SPE surface when excited at 488 nm (300 ms
exposure time) following DTT release of the biotinylated membrane proteins.
We further verified that the selected proteins were indeed released from the affinity
bed by measuring the fluorescence of the resulting effluent that was collected during the DTT
infusion/rinse. Figure 2.12 shows a calibration plot of the fluorescence signal that was
generated by the avidin-FITC (in DTT).
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Figure 2.12 Calibration curve of varying concentrations of avidin-FITC.
The fluorescence signal from the effluent not only indicated that there were membrane
proteins released from the µSPE bed. A sample of biotinylated MCF-7 membrane proteins
that had been labeled with avidin-FITC was also measured in a fluorimeter so that we could
determine the initial amount of membrane protein material being used. The concentration of
biotinylated protein in a 1 mL sample was found to be 1.71 ± 0.25 pmol. We ran MCF-7
whole cell lysate (5 x 106 cells) volumes of 500, 100, 50, 10, 5, and 1 µL, respectively through
the µSPE bed. Recovery of biotinylated protein was calculated by examining the mass of the
protein sample before and after purification on the µSPE device. For a 0.374 ± 0.03 pmol
sample of biotinylated membrane protein input, a capture efficiency of biotinylated membrane
proteins was estimated to be 34.92 ± 3.27%, while it increased to 83 ± 2.14% when the
membrane protein concentration was set below 0.019 ± 0.00051 pmol (Figure 2.13).
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Figure 2.13 The recovery of biotinylated MCF-7 membrane proteins loaded onto the µSPE
device using the extraction/purification assay. The total concentration (pmol) before and after
µSPE purification was estimated from fluorescence data, which only measured proteins that
were biotinylated. Error bars in the graph represent standard deviations from three replicate
runs.
The lower recoveries that are observed with higher concentrations of biotinylated
protein suggest that the amount of protein that was introduced exceeded the load capacity of
the µSPE capture bed (i.e. available NeutrAvidin sites). The protein saturation point of 1.71
pmol calculated from Figure 2.13 corresponds well with the theoretical surface density of 6.85
pmol/cm2.
2.3.3 Western Blotting Analysis to Evaluate the Purity of Extracted MCF-7 Membrane
Proteins
To determine the purity of the µSPE fractions free from cytosolic contamination,
Western blotting was performed using actin as a marker for cytosolic contamination because
it is highly abundant in the cytosol. Western blotting using EpCAM (epithelial cell adhesion
molecule) was also used to check for the presence of membrane proteins in µSPE effluent
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because it is a membrane protein highly expressed in MCF-7 cells (~200,000-300,000 per
cell).46,47
The results for the actin Western blot of the protein fractions extracted using the
detergent-based technique are shown in Figure 2.14. The Western blot clearly showed the
presence of actin with intense bands in the total cell lysate (T) and the cytosolic (C) fractions.
In addition, there was also an actin band in the lane where the membrane protein band was,
suggesting contamination by cytosolic proteins using the detergent-based isolation technique.
This indicated that the detergent-based method is not efficient in removing highly abundant
cytosolic proteins from the membrane fraction.
The same Western blot analysis was also carried out after processing the MCF-7 cell
lysate (biotinylated) on the µSPE chip to check the purity of the membrane protein fraction. In
this case, 25 ng of DTT-released biotinylated membrane protein was loaded onto the gel.
Figure 2.14 B & C shows the blots of a biotinylated membrane protein sample that was eluted
from the µSPE device. There is clear evidence of the actin band for the total lysate prior to
processing using the µSPE device. Lane M of the actin Western blot consisted of the sample
that was run through the µSPE affinity bed, subjected to DTT release with the effluent
collected following release. In this case, no actin band was evident indicating that the
µSPE/DTT release effluent was free from cytosolic contamination.
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A

B

C

Figure 2.14 (A) Actin Western blot of MCF-7 protein fractions that were extracted using a
detergent-based extraction method (Section 2.2.4). The total lysate (T), membrane protein
fraction (M), and the cytosolic protein fraction (C) were all analyzed. The blot shows that
there is cytosolic protein contamination in the membrane protein fraction (presence of actin).
(B) Actin Western blot of the µSPE extracted membrane proteins (M) and total cell lysate (T)
(before on-chip analysis) and (C) EpCAM blot of total cell lysate and µSPE extracted
membrane protein sample. The band indicates the presence of actin in the sample. The
EpCAM blot confirms that there are membrane proteins present in the effluent from the SPE
bed.
We also ran an EpCAM Western blot to make sure that we did in fact have membrane
proteins present in the µSPE/DTT release effluent. The blot confirmed the presence of
EpCAM in the lane where the µSPE/DTT release effluent was loaded indicating that we were
able to detect biotinylated membrane proteins using this Western blot procedure.
2.3.4 Computational Modeling to Understand the Effects of the Chip Geometry on
Protein Capture
The µSPE bed consisted of a series of staggered microposts onto which NeutrAvidin
was immobilized to serve as the material for enrichment and purification of the biotinylated
membrane proteins introduced into the device via hydrodynamic flow. Within this section, we
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were interested in understanding how the µSPE bed’s geometry, in terms of micropost shape
and spacing, affects the capture efficiency of proteins. These studies were carried out using
computational fluid dynamics (CFD) conducted with COMSOL Multiphysics 4.3a as well as
mathematical derivations using the principles of diffusion.
2.3.4.1 CFD Modeling of Velocity Fields, Protein Flux, and Protein Capture in Several
µSPE Bed Configurations
For the CFD simulations, three model geometries composed of staggered rows of
micropillars were tested: (I) Circular posts with radii of 50 µm and center-to-center spacing of
150 µm; (II) circular posts with radii of 10.0 µm and center-to-center spacing of 40.0 µm; and
(III) diamond posts with side length of 20.0 µm (fileted by 5 µm to reflect the fabrication
limits of micro-milling) and center-to-center spacing of 40.0 µm. Geometries I and III were
used to understand scaling effects (post size and post spacing), and geometry II was used to
understand the effects of post shape (circular versus diamond). Note that in all of these model
geometries, the number of posts was restricted to only a few staggered rows (relative to the
hundreds occupying a physical µSPE bed) to ensure numerical tractability of the
computations.
Using these geometries, we conducted fluid dynamic simulations of steady-state (time
independent) laminar flow through the µSPE beds. For this, COMSOL solves the NavierStokes equations to provide velocity fields. For comparison, all µSPE beds were designed
within COMSOL to have the same fluidic inlet with the fluid (modeled with the properties of
water) entering the beds assigned a linear velocity of 0.83 mm s-1 to reflect a physical
volumetric flow rate of 1 µL min-1. After solving for the steady-state velocity fields, the timedependent transport of a dilute protein (herein utilizing BSA as a model protein with a
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diffusion coefficient48 of 60 µm2 s-1 and without adjusting for the effects of biotinylation) was
calculated.
We first simulated the steady-state (time independent) laminar flow profiles of water
traveling through the µSPE beds. The CFD solutions for geometries I-III are shown in Figure
2.15. It is clear that for all geometries, flow around the posts positioned nearest the bed walls
is slightly reduced compared to the bulk flow likely resulting from viscous drag along the
walls, an artifact of the Poiseuille flow, and the no-slip condition.

Figure 2.15 Velocity profiles of SPE bed geometries 1-III. Flow fields are scaled in both size
and magnitude. Solid, white arrows indicate the direction of flow.
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It was also evident that the flow’s linear velocity is more homogenous throughout the
µSPE beds for geometries II and III, an important point considering flow rate directly
translates to protein mass flux. Thus, the beds with smaller posts may provide more uniform
flow in addition to a higher surface area. Using these steady-state velocity fields, we
conducted time-dependent simulations for the transport of a dilute protein (BSA) solution.
These models were simulated for 17.5-25 s with a maximum time step of 0.01 s.
Additionally, the BSA protein was permitted to react with the microposts through
biotin-avidin binding. The reaction of a biotinylated protein (B) with immobilized avidin (A)
is governed by:
𝐴+𝐵↔𝐴𝐵

(1)

where AB is the avidin-biotin-protein complex, i.e., the captured protein. The rate of this
encounter is balanced by the following equation:49
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The rate constants in Eq. (2) have been quantitated by surface plasmon resonance
imaging, where kon and koff were found to be 8.7 ± 0.3 · 104 M-1 s-1 and 7.2 ± 0.5 · 10-2 s-1,
respectively. These parameters reflect the entropic considerations of surface reactions; they
favor the reactant state more than free solution kinetics.50 Furthermore, we approximated the
maximum surface density of extracted biotinylated membrane protein, [B]max, as 6.85 pmol
cm-2. This is a one to one ratio with a theoretical monolayer of NeutrAvidin proteins and
appropriately neglects the multivalency of avidin proteins due to steric effects between
membrane proteins, which are of similar size to NeutrAvidin molecules.51
These constants and the rate expression in Eq. (2) were used in conjunction with the
velocity fields and time-dependent protein transport to provide the time-lapse images in
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Figure 2.16A-D. Line plots of the surface density of captured protein are also shown in
Figure 2.16. This data indicates that for geometry I, less protein is initially captured on the
rear surface area of the large, circular posts. However, this phenomenon is reduced after
several seconds and the coverage of captured protein becomes more homogenous as it is for
the other geometries. This is likely due to the reaction kinetics shown in Eq. (2).

Figure 2.16 Time-dependent (with the first set of images arbitrarily assigned as 0 s) protein
concentration profiles (A, rainbow scale), and surface densities of captured protein (B-D, grey
scale along post borders) for SPE bed geometries III and I. Line plots of surface densities are
presented for all three geometries against the spatial y-coordinate (illustrated in 0 s images).
Only protein flowing in laminar flow streams passing directly over the post surface
has the potential to be affinity captured. Initially, protein in these flow streams may be
depleted by the front of the posts before they reach the rear surface area of the post. But, over
time the higher surface density of affinity captured protein on the front of the posts disfavors
protein capture by Eq. (2), leaving more protein for capture on the rear of the posts. This
would likely not be visible on the smaller posts in geometry II and III. However, they too

106

exhibited reduced reaction kinetics at longer times in the line plots in Figure 2.16. Because
biotinylated protein were infused over the course of an hour, it is not likely that heterogeneous
protein immobilization on the posts of geometry I would be experimentally observable nor
were they (see Figure 2.9) or bear any consequence on the µSPE bed’s performance for
capturing biotinylated proteins from the whole cell lysate.
2.3.4.2 Diffusion Model for Approximating the Effects of Post Geometry on the Effective
Bed Length
Due to computational limits, COMSOL was incapable of modeling an entire µSPE
bed, but it is wise to assess how protein diffusion propagates throughout the µSPE bed’s
entire length (L = 24 mm). In general, diffusion of a protein is governed by Fick’s 2nd law,
where the probability (P) of occupying the axial position (x) at time (t) is dictated by its
diffusion coefficient (D):

(3)
An analytic solution to this differential equation is:
(

)

(-

)

(4)

√

where P(x,t) is a Gaussian packet with standard deviation (

√

√

̅ ), where ̅ is

the protein’s average velocity throughout the µSPE bed. The probability packet P(x,t) spreads
in time, indicating that a protein molecule is more likely to occupy axial positions farther
from its initial position.
However, the protein does not travel linearly through the bed, instead it will travel
around the posts and effectively travel a distance of

, where C is a geometric

correction factor intimately tied to the post shape. For circular posts, the protein will travel
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about a half perimeter of the circle yielding

; for diamond posts, the protein

√

travels about a triangle, yielding

; these assignments can be shown to be

independent of the post size and are geometrically illustrated in Figure 2.17. Consequently,
the effective path length of proteins in an SPE bed with circular posts is roughly twice that of
one with diamond posts permitting twice the time for diffusion to increase the probability that
proteins interact with the posts.

Figure 2.17 Schematic illustration of the path correction factor (C) for both circular and
diamond posts. The probability of protein-post interaction (Pi) for geometries I and III, both
with (solid black, where
) the path
√ ) and without (solid grey, where
correction factor applied to the µSPE bed’s length.
If we consider a worst case scenario, where a protein has the initial position exactly
centered (

) between two posts with spacing

(boundary conditions of

), we

can approximate that after the protein has passed through the µSPE bed, the probability that it
has diffused to and interacted with the posts ( ) is given by integration of the following
equation:
(

̅)

∫|

|

(
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̅)

(5)

The standard statistical method (shown in Figure 2.18) to perform this integration uses
z-scores associated with the Gaussian packet, where ( )
area of the Gaussian packet from (

and

( )

is the normalized

to ( ). Thus, Eq. (5) can be simplified to:
̅)

-[

(

)

-

(

-

)

]

(6)

Figure 2.18 Schematic for extracting the probability of a protein interacting with SPE bed
posts (Pi) from the Gaussian probability packets in the analytic solution of Fick’s 2nd law.
Equation (6) can then be solved with a standard Excel spreadsheet by calculating
√

̅ then solving for (

) and

using the NORMSDIST function in a

standard Excel worksheet. In Figure 2.18, we show the solutions for geometries I and III.
Here, we used the average velocities through the µSPE beds I and III that were obtained via
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the simulation results in Figure 2.15 and scaled these velocities proportionally for higher flow
rates. Also, we tested both geometries for the effect of applying the path correction factors.
Note that this model approximates the protein’s velocity as ̅ irrespective of its axial position
x, thereby ignoring Poiseuelle flow and under approximating diffusion effects.
In all cases, higher flow rates restrict protein diffusion and increase the probability that
proteins will never contact the microposts and thus, not be recovered. Regardless of the path
correction factor, geometry III outperforms geometry I in this model, predominately because
the smaller spacing between posts in geometry III necessitates the protein to diffuse a shorter
distance to contact a post. If the path correction factor is not applied, geometry I has a 20%
higher probability of capturing the protein flowing at 0.1 µL min,-1 and even with the path
correction factor, which slightly enhances the performance of geometry I with respect to
elongated protein path length for increased axial diffusion, geometry III remains optimal due
to the small interpost spacing. In future developments of the µSPE geometry, circular posts
with post spacing on the order of 10 µm (likened to geometry II) may enable increased
throughput without detracting from the assay’s efficiency.
2.4

Conclusion
A polymer microfluidic chip was designed, fabricated, and evaluated for the solid-

phase extraction and purification of membrane proteins from a cell lysate generated from
MCF-7 cells that were subjected to a biotinylation step prior to lysis. The µSPE assay was
shown to produce significantly lower levels of cytosolic protein contamination compared to a
commercially-available detergent method, which is based on liquid-liquid extraction.
Furthermore, the surface activation protocol via UV-exposure was simple in execution and the
production of bed containing polymer micropillars formed via hot embossing did not require
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extensive post-fabrication steps to create the selection bed, such as the addition of
functionalized beads or the formation of chemically modified polymer or monolithic supports.
We were able to recover ~83% of the biotinylated protein fraction using 100 µm diameter
circular posts that were spaced by 50 µm. The total load of protein for this bed geometry was
determined to be 6.85 pmol cm-2. While the total load is modest, this can be increased by
reducing the post diameter and spacing.
The results secured using this novel µSPE device and assay for the extraction and
purification of membrane proteins will provide a very attractive platform for future studies
requiring the analysis of these proteins to determine potential therapeutic targets or selection
agents for various cell types due to the higher purity fractions isolated and the ability to
process small numbers of cells with high enrichment factors. For example, when the µSPE
device is integrated to devices for multidimensional electrophoresis, solid-phase proteolytic
digestion and mass spectrometry, top-down proteomic analysis of membrane proteins from
rare cells can be undertaken, such as circulating tumor cells.
2.5
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3

Microchip Two-dimensional Membrane Protein Expression Profiling Using
Laser-Induced Fluorescence

3.1

Introduction

A common method for protein analysis involves the use of two-dimensional electrophoresis
that commonly employs an isoelectric focusing (IEF) dimension, which separates the proteins
based upon differences in their isoelectric point (pI) using immobilized pH gradient strips
(IPG), followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
which sorts proteins through differences in their molecular weights (Figure 3.1). To determine
the identity of the various proteins comprising these 2D maps, the spots can be subjected to
high resolution MS/MS analysis (top-down proteomics) or digested via proteolytic enzymes
followed by MS analysis (bottom-up proteomics).27 Complex biological samples, such as
blood serum and cell lysates, hold great promise for clinical diagnostics. The wide range of
protein components that can potentially exist in complex biological samples makes it difficult
to analyze these types of materials using one-dimensional (1D) separations due to the limited
peak capacity provided by these separation platforms.
As noted by Giddings,2 the combination of two different separation techniques can
provide a significantly higher peak capacity, P, than the individual 1D mechanisms as long as
the dimensions compromising the multi-dimensional separation are orthogonal, which means
that the selected dimensions possess different, but compatible, separation mechanisms.
Furthermore, the subsequent dimension in any multi-dimensional separation should not
destroy the resolution achieved by the previous one. If the separation mechanisms of the
multi-dimensional separation are orthogonal, the product of the peak capacity contained
within the individual separation dimensions gives the number of resolved components.3
Although IEF/SDS-PAGE continues to be the main separation method for many proteomic
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studies, there are still drawbacks associated with utilizing the technique. IEF/SDS-PAGE is a
time-consuming and laborious process involving extensive gel pouring and pH gradient
formation as well as long operational times (>24 h) to generate the required 2D map.
Moreover, after the separation, protein bands require staining for visualization and subsequent
band excision from the gel for follow-up identification purposes, which can result in sample
loss.4,5 In addition, membrane proteins tend to be excluded when using IEF/SDS-PAGE due
to their poor solubility in the buffering system utilized,6,7 and the staining and visualization
techniques associated with IEF/SDS-PAGE often do not detect proteins that are typically low
in abundance due to limitations in the mass detection limits.8

Figure 3.1 Workflow of traditional 2D IEF/SDS-PAGE and a schematic of the two separation
mechanisms.
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Because of the drawbacks of 2D IEF/SDS-PAGE, researchers focused their efforts
toward the use of capillary-based 2D separations using various combinations of
electrophoresis or chromatography methods. Examples of these types of 2D platforms include
capillary

sieving

electrophoresis

coupled

to

micellar

electrokinetic

capillary

chromatography,9-11 nano-reverse phase liquid chromatography coupled to strong cation
exchange chromatography,12 and size-exclusion liquid chromatography coupled to reverse
phase liquid chromatography13 have all been used for the analysis of proteins by researchers.
While capillary-based multi-dimensional separation reports have shown success in
eliminating tedious tasks such as gel pouring and reducing the development time of
electrophoresis, the increasing demands on proteomic studies have compelled the need to
further reduce development times, process smaller sample volumes, generate higher
throughput by performing multiple separations in parallel, and integrate front-end processing
to the 2D separation. Therefore, the techniques encompassing microchip capillary
electrophoresis (µ-CE) have been considered as attractive alternatives to their traditional
capillary counterparts.
3.1.1 2D Separations on Microfluidic Chips
Microchip 2D separations offer automation capabilities and rapid separations with
high resolving power as opposed to the conventional slab gel techniques (IEF/SDS-PAGE).
They can also provide viable interfaces between the separation dimensions to minimize
unswept volumes between separation dimensions preserving plate numbers. The separation
efficiencies are high in µ-CE due to effective heat dissipation, the ability to use higher electric
field strengths, minimal sample consumption due to smaller footprints, and faster times
because of shorter column lengths. Li et al.14 integrated IEF with parallel sodium dodecyl
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sulfate micro-capillary gel electrophoresis (SDS µ-CGE) for a comprehensive 2D separation
of five model proteins and generated a peak capacity of ~1,700 in 10 min. Chen et al.15
described a microfabricated 2D IEF/SDS-PAGE system that separated three model proteins a
little under 2 min.; however, the peak capacity was not reported. Yang and collaborators16
reported a 2D IEF/SDS-PAGE separation of whole cell E. coli protein lysate with an
estimated peak capacity of 2,880 that was obtained within 12 min.
All of the abovementioned examples of microchip 2D employed IEF in the first
dimension. Regrettably, IEF requires an equilibration step before the focusing step,16 which in
turn increases the overall development times of the entire 2D separation. Additionally, IEF is
not compatible with highly hydrophobic proteins (membrane proteins) as they are not
compatible with the aqueous buffers required for IEF. To avoid some of the issues associated
with using IEF, alternative techniques such as CZE or micellar electrokinetic chromatography
(MEKC) have been employed.
Ramsey and co-workers17 separated peptides with a 2D microchip system that
combined open-channel electrochromatography (OCEC) with CZE in which they reported a
peak capacity of 150 that was obtained in 13 min. The same group also utilized glass
microfluidic devices to perform 2D separations of bovine serum albumin tryptic digest.18 A
MEKC separation was performed in 19.6 cm-long serpentine channel with the peptides
rapidly sampled into a 1.3 cm long second dimension channel where they were separated by
CE. Figure 3.2 shows the device employed for the separations. The turns in the serpentine
channels were asymmetrically tapered to minimize geometrical contributions to band
broadening and they provided ample channel length for high-efficiency chromatographic
separations.
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Figure 3.2 Image of the microchip used by Ramsey et al. Injections were made at valve 1
(V1) for the first dimension MEKC separation and at valve 2 (V2) for the second dimension
CE separation. Detection of the sample was done at 1 cm downstream from V2 at point D
using laser-induced fluorescence. The reservoirs are labeled sample (S), buffer 1 (B1), sample
waste 1 (SW1), buffer 2 (B2), sample waste 2 (SW2), and waste (W). (Reproduced from
Ramsey, J. D.; Jacobson, S. C.; Culbertson, C. T.; Ramsey, J. M. Anal Chem 2003, 75,
3758.18 with permission, Copyright 2013, American Chemical Society).
The electric field strengths were 200 V/cm for MEKC and 2,400 V/cm for CE. A peak
capacity of 4,200 (110 in the first dimension and 38 in the second dimension) was reported for
the 2D separation of bovine serum albumin tryptic digest with an analysis time of less than 15
min.
The use of microemulsions in microemulsion electrokinetic chromatography
(MEEKC) has also emerged as an attractive alternative to MEKC. It was first introduced by
Watarai et al.19 in 1991 for the separation of fluorescent aromatic compounds and has been
widely applied for the separation of various analytes including proteins.20-23 The separation
medium in MEEKC is a microemulsion, which is a transparent solution consisting of an oil
(i.e., n-heptane), a surfactant (i.e., SDS), a co-surfactant (i.e., n-butanol), and water. The
structure of oil in a water emulsion is similar to that of micelles in MEKC except the
microemulsion has an oil droplet as a core.23
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Figure 3.3 (A) Depiction of micelle formation in aqueous buffer and its utilization in the
second dimensional phase have a microchip 2D SDS µ-CGE and MEKC protein separation.
(B) Depiction of microemulsion formation in aqueous buffer and its utilization in the second
dimensional phase of a microchip 2D SDS µ-CGE and MEEKC protein separation. a =
anionic proteins acquire their charge in two ways: (1) because the pH conditions for the
separation is above their pKa and (2) because SDS imparts a negative charge on the proteins
during sample prep and during the first dimension separation. (Reproduced from Osiri, J. K.;
Shadpour, H.; Soper, S. A. Anal Bioanal Chem 2010, 398, 489 with permission, Copyright
2013, Springer Science and Business Media).
Figure 3.3 depicts the formation of micelles in aqueous buffer, its employment in the
second dimensional phase of 2D SDS µ-CGE and MEKC protein separation, and how
microemulsions are formed. The SDS micelles form in buffer above the SDS cmc, critical
micellar concentration (0.24% w/v). The aggregate number for SDS is about 62 molecules
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forming a core diameter of ~17Å. In a reverse polarity mode (detection is anodic), SDS
micelles migrate towards the anode due to their ionized sulfate group, which is negatively
charged, whereas the direction of EOF is towards the cathode. Separation in the MEKC is
based on the differences in the partition coefficient of proteins within the micelles and the
aqueous phase and according to the mass-to-charge ratio of proteins when they are in the
aqueous medium.
More hydrophobic domains within a protein result in stronger hydrophobic character
and the more hydrophobic proteins have a tendency to interact more with the micellar core.
On the other hand, anionic proteins experience columbic repulsion and may not interact with
the micelles. This is especially true when their hydrophobic domains are masked by SDS (see
rods that are gold only or gold/blue without any black color). These proteins are separated
based on their electrophoretic mobility in the aqueous medium with the proteins possessing
the highest charge-to-mass ratio migrating the fastest.
Overall, the migration of proteins is in the order of 1-6 with protein 1 migrating the
fastest and protein 6 migrating the slowest. In MEEKC, SDS surfactants impart a net negative
charge to the oil emulsions, and the co-surfactant (n-butanol) reduces the surface tension
between the oil and the aqueous phase, which results in a miscible oil/water system. The
hydrophobic core diameter for the microemulsion is ~100Å.
3.1.2 Previously Reported Work Employing SDS µ-CGE with MEKC for 2D
Separations
The Soper research group has reported 2D microchip separations using SDS µ-CGE
with both MEKC and MEEKC. In 2006, Shadpour and Soper described two-dimensional
electrophoretic separations of proteins in a PMMA-based microchip. SDS µ-CGE (SDS 14200 sieving matrix with 12 mM Tris-HCl, 0.1% w/v (3.5 mM) SDS, pH 8.5, containing
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0.05% MHEC, methyl hydroxyl ethyl cellulose) and MEKC (12 mM Tris-HCl, 0.4 % w/v (14
mM) SDS, pH 8.5, containing 0.05% MHEC) were used as the separation modes in the first
and second dimension of the electrophoresis, respectively. The use of MHEC aids in the
suppression of the electroosmotic flow (EOF) while preserving the selectivity of the
separation. The electrophoretic separations were carried out at ambient temperature in reverse
mode (detection end anodic).

Figure 3.4 Photograph of the PMMA µ-capillary electrophoresis chip used for the 2D
separations. The channel width in all cases was 15 µm with a channel depth of ~30 µm. The
solution reservoirs were; (A) sample reservoir; (B) sample waste reservoir; (C) SDS µ-CGE
buffer reservoir; (D) SDS µ-CGE buffer waste reservoir; (E) MEKC or MEEKC buffer
reservoir; (F) MEKC or MEEKC buffer waste reservoir. d1 represents the LIF detection
position for the 2D separations. (Reproduced from Shadpour, H.; Soper, S. A. Anal Chem
2006, 78, 3519.24 with permission, Copyright 2013, American Chemical Society).
The PMMA microchip (Figure 3.4) incorporated a 30-mm SDS µ-CGE and a 10-mm
MEKC dimension length and electrokinetic injection and separation were used with field
strengths of up to 400 V/cm. Platinum wires were used to apply high voltages to the
reservoirs. For the SDS µ-CGE dimension, the injection and effective separation lengths were
each 10 mm. The total separation channel length for a complete 2D separation was 20 mm
(i.e., 10 mm for both the 1st and 2nd dimensions). The 30 nM protein mixture consisted of 10
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Alexa Fluor 633 conjugated proteins (wheat germ agglutinin (WG), actin (AC), ovalbumin
(OV), protein A (PA), streptavidin (ST), bovine serum albumin (BSA), Helix pomatia (HPA),
transferrin (TR), concanavalin A (CO), and lectin peanut agglutinin (PNA), ranging in size
from 38 to 110 kDa, detected using laser-induced fluorescence with excitation/emission at
633/652 nm. They reported plate numbers (N) of 4.8 x 104 and 1.2 x 104 in the SDS µ-CGE
and MEKC separation dimensions, respectively, for the proteins corresponding to plate
heights (H) of 0.62 and 0.87 µm.
Both the SDS µ -CGE (1D separation) and MEKC (1D separation) are shown in
Figure 3.5. The electropherograms suggest that the proteins that are closer in MW comigrate
and are not resolved from one another indicating the need for a 2D separation that can provide
improved resolution. The time to start the second dimension (MEKC) depends on the
migration time (MT) of the smallest protein or co-migrated proteins in the SDS µ-CGE
dimension. The migration time can be estimated by using Eq 1. for the smallest component
(lowest MW) in any given mixture. For this work, the estimated MT was ~71 s for WG,
which was the smallest protein (38,000 Da) in the mixture. Therefore, the first MEKC cycle
was set to start at 70 s.

log (MW) = 1.59 x 10-2MT + 3.45

(1)

The MEKC cycles were performed by proper switching of the high voltage applied to
points E and F (see Figure 3.4). The word “cycle” refers to a complete MEKC electrophoretic
run that was used for the second dimension.
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A

B

Figure 3.5 (A) SDS µ-CGE analysis (1D separation of a 30 nM protein mixture using the
PMMA microchip. (B) The MEKC separation (1D) of a 30 nM protein mixture using the
PMMA microchip. (Reproduced from Shadpour, H.; Soper, S. A. Anal Chem 2006, 78,
3519.24 with permission, Copyright 2013, American Chemical Society).
Based on all proteins eluting from the MEKC channel within a 10 s separation
window, the MEKC cycles were then fixed at 10 s. For different protein mixtures, longer
separation windows could be selected at the expense of longer 2D development times. The
linear output of the detector from 2D analysis and three-dimensional images of the 2D µ-CE
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separation are shown in Figure 3.6. It can be seen that the 2D analysis was able to resolve all
10 proteins in the mixture, including those species that could not be separated using individual
1D separations under similar experimental conditions.

Figure 3.6 2D µ-CE separation of a 30 nM protein mixture in the PMMA microchip. (A)
Linear output of the LIF 632.8 nm detector system from the 2D analysis of the protein sample
(B) A three-dimensional image of the data shown in A with the cycle number plotted versus
the MEKC migration time. (Reproduced from Shadpour, H.; Soper, S. A. Anal Chem 2006,
78, 3519.24 with permission, Copyright 2013, American Chemical Society).
For some time, most of the µ-CE examples were focused on demonstrating proof-ofconcept of the multidimensional separation using model systems, which can limit the number
of components analyzed with the constituents present in similar concentrations, both of which
do not represent “true” biological samples. Therefore, Osiri and co-workers25 also reported
2D profiling of fetal calf serum (FCS) proteins within 30 min using SDS µ-CGE in the first
dimension and µ-MEKC in the second dimension. The FCS proteins were covalently labeled
with a thiol-reactive AlexaFluor 633 dye prior to the µ-CE 2D separation and detected using
laser-induced fluorescence (LIF). The sample was electrokinetically injected into the
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separation channel at 200 V/cm with the 2D SDS µ-CGE × MEKC separations in the first and
second dimensions performed at 300 V/cm and 400 V/cm respectively.
A

B

Figure 3.7 SDS µ-CGE/µ-MEKC 2D separation of a FCS protein mixture. The 2D SDS µCGE × MEKC were performed at 300 V/cm and 400 V/cm, respectively. (A) 2D image of the
microchip FCS map. (B) 3D landscape of the FCS proteins. Reproduced from Osiri, J. K.;
Shadpour, H.; Park, S.; Snowden, B. C.; Chen, Z. Y.; Soper, S. A. Electrophoresis 2008, 29,
4984.25 with permission, Copyright 2013, John Wiley & Sons).
The SDS µ-CGE was performed utilizing an effective length, the length used for the
separation, Leff = 60 mm while the µ-MEKC separation employed Leff = 50 mm. The results
of the 2D separation are shown in Figure 3.7. The authors reported a peak capacity for the 2D
separation of 2,600 (±149).
Separations on microfluidic platforms have garnered much appeal for the analysis of
complex biological samples because they can easily lend themselves to performance
characteristics that rival their macroscale counterparts using a much shorter operational time,
but still generating much improved data production rates. In addition, these formats, due to
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their small footprint and lithographic fabrication techniques, will permit the development of
multi-channel formats that can significantly improve the production rate of data. In the
aforementioned report, our lab has demonstrated the ability to generate peak capacities of
2,600 (±149) for a biological serum sample using an 11 cm effective separation length in both
dimensions. Although the peak capacity is well below the number of protein components
typically found in a serum proteome, it is still attractive for the analysis of a complex sample
such as serum. In addition, the isolation of sub-populations of protein types, such as
membrane proteins, is also appealing for this peak capacity and the analysis of a sample of
cell lysate.
Therefore, in this work, we report the use of a polymer-based microchip for 2D
profiling of the membrane protein fraction of MCF-7 cell lysates with sufficient peak
capacities using SDS µ-CGE in the first dimension and µ-MEKC in the second dimension.
The readout strategy relied upon the employment of laser-induced fluorescence (LIF), which
was accomplished by covalently labeling the MCF-7 membrane proteins with an aminereactive DyLight NHS Ester 550 dye prior to the µ-CE 2D separation. The SDS µ-CGE was
performed using Leff = 30 mm while the µ-MEKC separation utilized Leff = 40 mm. We then
compared our µ-CE separation results with results reported in literature on the conventional
2D IEF/SDS-PAGE of MCF-7 cell lysate.
3.2

Materials and Methods

3.2.1 Microchip Fabrication
PMMA was selected as the µ-CE substrate because of its suitable physiochemical
properties for this application, such as minimal non-specific adsorption artifacts and low
levels of autofluorescence, improving the detection limits for ultra-sensitive fluorescence
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detection. Microchips were made according to procedures described previously. In brief,
microstructures were micromilled into a brass plate (0.25” thick alloy 353 engravers brass,
McMaster-Carr, Atlanta, GA, USA) using a Kern MMP 2522 micromilling machine (KERN
Mikro-und Feinwerktechnik GmbH & Co., Germany).
Once fabricated, the mold master produced PMMA replicates using hot-embossing.
Hot-embossing required heating the molding tool to 155°C and pressed into the PMMA plate
with a pressure of 1,100 psi for 4 min using a PHI Precision Press (PHI-Tulip, City of
Industry, CA, USA). Following embossing, the PMMA substrate was cooled to room
temperature and removed from the molding die. The embossed PMMA substrate was cleaned
with 50% isopropanol in ultrapure water. Finally, a PMMA cover plate (0.250 mm) was
thermal fusion bonded to the substrate by heating in a temperature programmable furnace to
107°C, slightly above the Tg of PMMA. Figure 3.8A shows the topographical layout of the
microdevice used for this work. All channels were 50 µm deep and 50 µm wide. Buffer,
sample, or waste reservoirs are shown in Figure 3.8A, in which letters A to F are
representative of the 1.5 mm diameter solution reservoirs on the PMMA microchip.
3.2.2 Laser-induced Fluorescence (LIF) Detection, Power Supply and Data Analysis
Fluorescence detection was accomplished using an in-house constructed LIF system.
A schematic diagram of this detection system is shown in Figure 3.8B. The excitation source
consisted of a laser diode with a lasing wavelength of 532 nm (LBS-532-TD-5, Laserglow
Technologies, Toronto, ON, Canada). The diode laser light was filtered using a laser line filter
(LLF1, CWL = 532 nm, XL08, Omega Optical, Brattleboro, VT, USA).
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Figure 3.8 (A) Schematic of the 2D microchip electrophoresis device used for these studies.
The channels were 50 µm deep and 50 µm wide in all cases. The 1st and 2nd dimension
channels were 4 cm (filled with gel media) and 5 cm (filled with MEKC buffer), respectively,
in terms of their total column lengths. The effective column lengths for the 1st and 2nd
dimensions were 3 cm and 4 cm, respectively. (B) Diagram of the in-house constructed LIF
system used for the µ-CE separation. The system was configured in an epi-illumination
format and was equipped with a 40x microscope objective (NA = 0.65) used to focus the laser
excitation radiation into the micro-separation channel and collect the resulting fluorescence as
well (epi-illumination). An x-y-z micro-translational was used to position the chip above the
objective. A 532 nm diode laser served as the excitation source.
A dichroic mirror (XF2018, Omega Optical) reflected the 532 nm and the laser light
beam was directed into a focusing objective using a second dichroic mirror (XF2055, Omega
Optical). The excitation beam was focused utilizing a 40x microscope objective (Nikon,
Natick, MA, USA) into the separation channel of the microchip, which was situated on an x,
y, z micro-translational stage (Newport, Irvine, CA, USA). The fluorescence emission
resulting from the DyLight 550 labeled membrane proteins was collected by the same
objective and transmitted through the dichroic, reflected onto another dichroic mirror
(DMLP605, Thorlabs, Newton, NJ, USA) and finally filtered through a filter stack containing
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a long pass filter (CWL = 550 nm, 3RD550LP, Omega Optical) and a band pass filter (CWL
= 570 nm, XB99, Omega Optical).
The resulting photons were transduced employing a single photon avalanche diode
(SPAD; SPCM 200B, PicoQuant, Berlin, Germany). Programmed high-voltage was applied to
the reservoirs of the microchip with six independently controlled power supplies (EMCO,
Sutter Creek, CA, USA). Electrical contact between the solution in the fluid reservoirs and the
high-voltage leads was achieved utilizing platinum wires (Scientific Instrument Services,
Ringoes, NJ, USA). The LIF signals were acquired on a personal computer equipped with an
I/O interface board (CB-68LP, National Instruments, Austin, TX, USA) and a pulse converter
(TB-01, IBH, Glasgow, UK). The software for data acquisition and control of the power
supply was created using LabView. The LabView program interface is shown in Figure 3.9.
Dye-labeled protein samples were first electrokinetically injected into the injection cross (AB, Figure 3.8A) by applying a positive potential at waste reservoir (B) while grounding the
sample reservoir (A). Data were collected continuously from the start of the initial SDS µCGE after the injection step. SDS µ-CGE was initiated by applying a positive potential at the
waste reservoir (D) and grounding reservoir C.
In this particular case, proteins were sampled into the second dimension from the
onset of the first dimension; therefore, proteins were allowed to separate in the second
dimension after a 3 s electrophoretic run in the first dimension by applying a positive potential
to reservoir E while grounding D. This 3 s separation in the first dimension transferred
proteins into the second dimension for further separation. LIF was monitored on E-F at 40
mm (d, see Figure 3.8A) from the intersection of C-D and E-F (see Figure 3.8A).

130

Figure 3.9 Computer screen-shot of the LabView program used to control the power supply
that applies voltage to the reservoirs during the electrophoretic separations of the MCF-7
membrane proteins. The total separation time and the time to start the sampling into the
second dimension is also set using this program.
Raw 2D electropherograms were converted to 2D images and then to threedimensional (3D) landscape representations (see Results and Discussion) by taking the LIF
signals from successive runs for each MEKC cycle and plotting the electropherogram at the
corresponding cycle on the SDS µ-CGE axis. This procedure was performed using OriginLab
software (Northampton, MA, USA) and ImageJ software (National Institutes of Health,
Bethesda, MD).
3.2.3 Fluorescence Labeling of the MCF-7 Membrane Protein Fraction
Prior to fluorescence labeling and separation, the MCF-7 membrane proteins were
extracted as described previously in Section 2.2.4 using the Mem-PER™ Plus Membrane
Protein Extraction Reagent Kit available through Pierce Biotechnology (Rockford, IL). The
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membrane proteins were covalently labeled with DyLight 550 (excitation/emission = 562/576
nm), an amine-reactive dye (Pierce Biotechnology, Rockford, IL, USA) following the
manufacturer’s guidelines. Briefly, after extraction, the membrane proteins were reacted with
the DyLight 550 in an approximate 1:10 molar ratio for 1 h. The excess dye was removed
using a Zeba Spin column (Pierce Biotechnology, Rockford, IL, USA). The amine reactive
dye contained N-hydroxysuccinimide (NHS) esters that reacted with primary amines on the
membrane proteins, forming a stable, covalent amide bond. The DyLight 550-conjugated
proteins of the membrane protein fraction were then diluted in the µ-CE run buffer in a 1:5
volume ratio (membrane protein sample: run buffer) along with 2-mercaptoethanol and heated
to 95°C for 5 min. Prior to use in the microchip, all solutions were filtered with a 0.2 µm
Nylon-66 membrane syringe filter (Cole-Parmer Instrument Co., Vernon Hills, IL, USA)
except for membrane protein solutions, which were centrifuged (~6,000 rpm, 5 min) to
remove any particulates.
3.2.4 2D Electrophoretic Separations with 2D SDS-PAGE/MEKC Microfluidic Device
Before the electrophoretic separation, a solution of 2 mg/mL of methyl hydroxyethyl
cellulose (MHEC) (Fluka BioChemika, Switzerland) was dissolved in 1X PBS (pH = 7.2,
Sigma-Aldrich, St. Louis, MO, USA) and flushed through the fluidic channels through
reservoir A (see Figure 3.8A) while applying vacuum to reservoir F. This process aids in the
suppression of the electroosmotic flow (EOF). The EOF in PMMA channels with buffer
containing MHEC (0.05% w/v) as a dynamic coating agent has been measured to be ~1.20 ±
0.07 x 10-5 cm2/Vs.243 It should also be noted that no sieving properties are provided by
buffers containing methylcellulose derivatives (e.g., MHEC) when the concentration is below
0.1%.311 All electrophoretic separations were carried out at ambient temperature in reverse
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mode (detection end anodic) for both SDS µ-CGE and the MEKC dimensions. Prior to the µCE 2D separation, the first dimension channel (see Figure 3.8A) was filled with a sieving
matrix, which consisted of SDS 14-200 linear polyacrylamide gel (Beckman Coulter Inc.,
Fullerton, CA, USA) containing 0.05% w/v MHEC. The gel filling was monitored using
brightfield microscopy to make sure the gel was filled exactly at the intersection of the 1 st and
2nd dimensions. The second dimension channel was then filled with the MEKC buffer, which
consisted of 12 mM Tris-HCl, 0.4% w/v SDS, and 0.05% w/v MHEC (pH = 8.5).
For the injection/separation scheme, shown in Figure 3.10, 2D separations were
performed in channels A-B, C-D, and E-F serving as injection, 1st dimension SDS µ-CGE and
2nd dimension MEKC channels, respectively, and setting the detection point at d (see Figure
3.8A). After the gel and run buffers were pressure filled into the channels, reservoir A was
emptied and subsequently filled with 2 µL of the dye-labeled membrane protein sample. The
sample was injected into the sampling channel (see A-B channel, Figure 3.8A) at 200 V/cm.
The injection was initiated by grounding the voltage to the sample reservoir (A, Figure 3.8A)
and applying +0.30 kV to the waste reservoir (B, Figure 3.8A) to fill the cross channel (points
C-F were floated during the injection).
Following injection, a high positive voltage was switched to point D and point C was
grounded (Figure 3.8A). Then, pull back voltages (~10% of applied voltage to point D) were
applied to the sample and waste reservoirs (A and B, see Figure 3.8A). The electric fields (E)
employed for the SDS µ-CGE and the MEKC separations were 350 V/cm and 400 V/cm,
respectively.
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Figure 3.10 The injection/separation scheme depicting the formation of the protein plug when
voltages are applied during injection and separation, respectively.
Table 3.1 represents the high-voltage protocol adopted for the 2D separation. As
shown in this Table, the injection and run steps were the same as discussed previously. The
SDS µ-CGE separation was carried out at 350 V/cm using Leff = 30 mm (see C-D channel,
Figure 3.8A). The 2nd dimension MEKC separations were programmed to begin after a 30
min electrophoretic run time in the 1st dimension (SDS µ-CGE). Each 2nd dimension MEKC
cycle consisted of a 250 s run cycle (MEKC development time) and operated at a field
strength of 400 V/cm, which was found to be sufficient time to assure that all of the
components injected into the 2nd dimension reached the LIF detection zone (Leff = 40 mm).
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Table 3.1. High-voltage protocol for 2D separations using the PMMA microchip. Letters A –
F refer to reservoirs on the 2D platform as shown in Figure 3.7A. 1G: Grounded, F: Floating.
Step
Injection
SDS µ-CGE
Second
MEKC cycle
First to second
sample
transfer

A
G
+ 0.14

Applied voltages (kV)1
B
C
D
+ 0.30
F
F
+ 0.14
G
+ 1.40

E
F
F

F
F
F

+ 0.14

+ 0.14

F

F

G

+ 2.00

+ 0.14

+ 0.14

G

+ 1.40

F

F

Sample eluting from the 1st dimension was injected into the 2nd dimension after a 3 s
run period in the 1st dimension. During the MEKC cycle, the applied field in the 1st dimension
was stopped, parking the components in the 1st dimension during the 2nd dimension run.
3.2.5 2D Slab Gel Separation of MCF-7 Proteins Using IEF/SDS-PAGE
The results of the traditional 2D gel electrophoresis from the work of Pionneau and
co-workers27,28 was used as a comparison of traditional 2DE gel separations of MCF-7
proteins utilizing IEF with SDS-PAGE. IPG strips from pH 5 to 8 were used in the first
dimension. The strips were rehydrated with 150 µg of protein until a total of 195,000 V/h was
reached. After focusing, the strips were then placed on 18 cm x 20 cm x 1 mm 8–18.5%
polyacrylamide linear gradient gel for the separation in the second dimension. SDS-PAGE
was carried out at 40 V for 1 h, and 100 V for 21 h and stained with silver nitrate for
visualization.
3.2.6 Software Analysis of 2D Data
In order to obtain a 3D image of the electrophoretic data from the microchip, a text file
of the raw 2D run formatted into a 3D matrix was input into OriginLab (Northampton, MA,
USA). The matrix was constructed such that each column represented one MEKC cycle. The
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matrix was then plotted as a 3D surface plot. A 2D image plot was also done in ImageJ
(National Institutes of Health, Bethesda, MD) to resemble a 2D gel.
3.3

Results and Discussion

3.3.1 Results of 2D Slab Gel Separation of MCF-7 Membrane Proteins Using IEF/SDSPAGE
As it is shown in Figure 3.11, the whole cell extract gel has many more protein spots,
which is expected due to the IEF buffer incompatibility with the MCF-7 membrane proteins.

Figure 3.11 2D protein patterns from MCF-7 cell membrane extract and whole-cell extract.
The 150 µg of protein was separated first on the IPG strips and then on an 8-18.5% gradient
gel followed by silver staining. (Reproduced from Pionneau, C., Canelle, L., Bousquet, J.,
Hardouin, J., Bigeard, J., Caron, M., Joubert-Caron, R. Cancer Genomics & Proteomics 2005,
2, 199 with permission, Copyright 2013).
This confirms that it is highly possible that some membrane proteins could have been
missed and/or not separated because they never entered the gel from the IPG strips because
the proteins are hydrophobic and the buffers are aqueous (hydrophilic). There is also more
band smearing in the membrane protein gel as opposed to the whole cell extract that could
also be due to the native characteristics of the hydrophobic membrane proteins and their
insolubility, post-translational modifications, and/or nucleic acid contamination. The average
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spot size was determined to be ~200 (±4.6) pixel2, a peak area of 117,924 pixel2, and a peak
capacity of 589 (±5.1) pixel2.
3.3.2 1D µ-CGE of MCF-7 Membrane Protein Fraction Employing SDS-PAGE
The use of a highly viscous gel can alter a separation to become a size-based
separation, minimize the diffusion of solutes, prevent analyte adsorption onto the microchip
walls, and aid in EOF suppression.29 Separating proteins in their native state (non-denatured)
can result in band smears, poor migration time, poor reproducibility, and less distinct protein
spots.30 In addition, the electrophoretic mobilities of native proteins are dependent upon the
mass-to-charge ratios rather than their molecular weight solely;31 therefore, the formation of
SDS-protein complexes after denaturing establishes the foundation for performing
electrokinetic protein transfer due to the overall negative charge of the proteins but also
prepares the proteins for a size-based separation.14
We were interested in analyzing the peak capacity for a 1D µ-CGE separation of the
MCF-7 membrane proteins using Leff = 30 mm with SDS as the denaturing and complexing
agent and polyacrylamide gel electrophoresis sizing matrix. The results of the SDS µ-CGE
analysis using the PMMA microchip are shown in Figure 3.12. As seen in the
electropherogram, approximately 22 bands could be observed with varying degrees of
resolution and widths due to potential peak overlap arising from proteins with similar
molecular weights. From the data, (see bands marked with an asterisk in Figure 3.12), we
determined the average peak width was estimated to be 3.1 ±2.3 s, producing a plate number
of 4.8 x 105 ±1.6. From these values and a separation window of ~25 min (defined by the
migration time difference between the last and first migrating components), we estimated a
peak capacity for the 1D separation to be 55 ±3.3 (n = 3).
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Figure 3.12 SDS µ-CGE 1D separation of MCF-7 membrane proteins from whole cell lysate.
The protein sample, which was labeled with an amine-reactive fluorescent dye, DyLight 550,
was placed into reservoir A of the microchip (see Figure 3.7A) and electrokinetically injected
into the separation channel at 200 V/cm. The 1D SDS µ-CGE was performed at E = 350
V/cm. The total separation length was 4 cm with an effective length of 3 cm.
Obviously, this is well below the level necessary to analyze a sample as complex as
that projected for a mammalian proteome. The average peak width determined above from the
SDS-PAGE dimension was then used to select the appropriate sampling time into the second
dimension, which was set at 3 s.
3.3.3 2D µ-SDS-PAGE/ µ-MEKC Separation of MCF-7 Membrane Proteins
In the 2D electrophoretic separation, SDS-PAGE was used as the first dimension and
MEKC as the second dimension. SDS forms complexes with proteins, which are subsequently
electrophoresed through a sieving matrix allowing for the separation of species primarily
based on differences in the molecular weights. MEKC utilizes micelles as a pseudo-stationary
phase with separation based upon selective partitioning of solutes to the micelles. In the case
here, we are employing SDS micelles as a pseudo-stationary phase, which provides an
attractive interface to SDS-PAGE due to the fact that both dimensions use SDS. Shadpour et
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al.24 from our group has previously demonstrated the orthogonality of SDS-MEKC to SDS µCGE, making it an elegant format for producing high peak capacities for multi-dimensional
electrophoretic analysis of intact proteins. Using the migration order and migration times of
10 model proteins, the degree of orthogonality was evaluated and a plot of the normalized
migration time for a SDS-PAGE 1D separation versus that of the SDS MEKC 1D separation
produced a scatter plot with minimal data points occurring along the diagonal (slope = 1.0,
intercept = 0.0) providing an orthogonality value between the two separation mechanisms of
77%.
In the 2D format utilized for this work, electrophoretic zones are “parked” in the first
dimension while the second dimension is affected in a serial fashion. Therefore, issues with
zonal dispersion due to longitudinal diffusion should be considered because it can have a
significant impact on the peak capacity of the separation for the 2D analysis. This was
achieved by calculating the height equivalent to a theoretical plate for longitudinal diffusion
only (HD) of the 1D SDS µ-CGE dimension and comparing that value to HTOT secured from
the complete 2D separation. A representative diffusion coefficient for proteins in a sieving
matrix as used herein was taken as ~10-8 cm2 s-1, which is the measured diffusion coefficient
of cytochrome C in polyacrylamides,32 resulting in HD = 3.24 x 10-6 cm (HD = 2Dt/L; t =
time; L = column length, cm). The number of plates for a typical band migrating from the 2D
separation (see Figure 3.12) was 3.47 x 105, resulting in HTOT = 1.15 x 10-5 cm. Therefore, the
diffusional component to HTOT was calculated to be approximately 28%.
For 47 10 s MEKC cycles, which represents the parking time (470 s; time that is
allocated to performing the MEKC separations) and a total separation time of 3,300 s, the
percent contribution of diffusional spreading during the parking phases of the separation to
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HD is roughly 85%. Reductions in the development time for the MEKC cycles can reduce H D
stemming from the parking phases of the separation, potentially producing higher peak
capacities. However, due the inherent nature of these proteins being very hydrophobic (i.e.
membrane proteins), shorter development times for the MEKC dimension is inadvisable
because the proteins need time to separate in the pseudo-stationary phase. Higher field
strengths could be utilized but issues of bubble formation from Joule heating could arise.
In order to sample all components migrating from the 1st dimension to the 2nd
dimension, 47 MEKC cycles were required with each cycle run for 10 s (E = 400V/cm). The
development time for the full 2D separation was estimated to be ~55 min. Although the
analysis time is long from a capillary electrophoresis standpoint, this is a significant
improvement compared to the 24+ h required for a conventional 2D IEF/SDS-PAGE analysis.
A typical 2D image of the MCF-7 membrane protein separation and the corresponding 3D
landscape image are shown in Figure 3.13A. The image secured from Figure 3.13A was
imported into ImageJ for analysis. From the input data to ImageJ, the average size of each
protein spot for the µ-CE run was determined to be 133 (±7) pixel2, which yielded a peak
capacity for the 2D separation of 1,768 (±9), which was obtained by dividing the total pixel
area in the image of 235,200 pixel2 by the average spot size.
In order to ensure that the electrophoresis of membrane proteins was working
properly, we chose 3 known proteins (bovine serum albumin 66 kDa, transferrin 80 kDa, and
concanavalin A 104 kDa) to separate using the same microfluidic device. Each protein had a
concentration of 5 µM and was labeled as described in Section 3.2.3.
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Figure 3.13 (A) SDS µCGE/µ-MEKC 2D separation of a MCF-7 membrane protein fraction.
The protein sample was placed into reservoir A (see Figure 3.7A) and electrokinetically
injected into the separation channel at 200 V/cm. The 2D SDS µ-CGE × MEKC were
performed at 350 V/cm and 400 V/cm, respectively. Serial 10 s MEKC cycles were
performed with a total of 47 MEKC cycles and a 3 s transfer time from the 1st to 2nd
dimension. The bottom panel shows a 2D image of the microchip MCF-7 map, while the top
panel shows a 3D landscape image of the MCF-7 membrane protein map. (B) 2D image of a
conventional IEF/2D PAGE separation of the MCF-7 membrane protein sample (bottom
panel) and the corresponding 3D landscape (top panel). Separation conditions are provided in
the Materials and Methods section.
Figure 3.14 shows the results of the SDS µCGE/µ-MEKC 2D separation of the 3
known proteins. We utilized conditions described previously in work by Shadpour et al.24 The
2D separation required a total of 71 MEKC cycles with a MEKC cycle run time of 10 s. The
total separation time was ~750 s (12.5 min).
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Figure 3.14 3-D landscape of SDS µCGE/µ-MEKC 2D separation of 3 proteins (bovine
serum albumin, transferrin, concanavilin A) of known molecular weight. The 2-D SDS µCGE × MEKC were performed at 350 V/cm and 400 V/cm, respectively. Serial 10 s MEKC
cycles were performed and a total of 71 MEKC cycles were used with a 1 s transfer time from
the 1st to 2nd dimension.
The separation had a peak capacity of 926 (±3.4) and an average plate number of 1.01
x 103 (±2.3). The data shows that the proteins are well resolved and suggests that there are not
any issues with the electrophoretic conditions and that any peak broadening is likely a factor
of the membrane proteins aggregating and not remaining solubilized in the buffer solution
after the extraction and labeling processes.
3.4

Conclusion
Separations on microfluidic platforms have been attractive for years and are garnering

more appeal for the analysis of complex biological samples because they can easily lend
themselves to performance characteristics that rival techniques and instrumentation used on
the macro-scale, but using shorter operational times without significantly sacrificing
separation efficiency and thus, generating data production rates that are notable. In addition,
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these formats, due to their small footprint and lithographic fabrication techniques, will permit
the development of multi-channel formats that can significantly improve the production rate
of data. In the present report, we were able to demonstrate the ability to generate peak
capacities of 1,768 (±9) for a biological membrane protein sample using a 7 cm effective
separation length in both dimensions. The 2D separation platform is very attractive for
interfacing to mass spectrometry (MS) for discovery-based applications. The 2D separation
has band broadening which is likely due to the membrane proteins not being well solubilized.
In order to overcome the issue of broadening, we can perform a 2D separation on the
biotinylated MCF-7 membrane proteins that we extracted using the µ-SPE device, which we
have already shown to be well solubilized and purified from the membrane of the cell and
other contaminating species (i.e. cytosolic proteins).
As stated previously, the goal of this work is to develop an integrated system for the
analysis of proteins from a top-down perspective. We have already shown the separation of
intact proteins and now we must discuss how we plan to integrate the extraction and
separation platforms with the remaining processing steps in the proteomic pipeline for this
analysis. The next chapter will discuss our approach to how we will select cells and
biotinylate the cell surface membrane proteins on-chip before moving the membrane proteins
to the extraction bed to be purified, which we discussed in Chapter 2. After the separation of
the extracted membrane proteins, we will need to digest the proteins before the MS analysis;
therefore, we will discuss the fabrication of an on-chip bioreactor for digestion. In Chapter 4,
we will examine our approach to perform cell selection, biotinylation, and lysis. Additionally,
we will also consider how we plan to integrate each processing step into a modular platform.
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4

Summary and On-going Developments

4.1

Summary
Many researchers have been attempting to integrate various proteomic processing

steps onto a single microfluidic platform to build an autonomously operating system.
However, the ultimate goal of integrating several proteomic analysis units into one system for
building such a multifunctional system has not been realized to-date. As previously discussed
in Chapter 1, the overall goal of this work is to assemble a fully integrated fluidic system
using a novel design approach; task-specific modules will be interconnected to a fluidic
motherboard to provide full process automation for mass-limited samples using circulating
tumor cells (CTCs) as a demonstrator of the technology. The integrated system will be
directly interfaced to nanostructure-assisted laser desorption ionization MS (NALDI-MS) to
provide the ability to identify isolated protein components with little or no operator
intervention. The design strategy will employ a novel modular format with the system using 4
modules; (1) cell biotinylation and lysis module; (2) affinity selection module of a particular
sub-population of the proteome (i.e., those that have been biotinylated); (3) microchip
electrophoresis module; and (4) solid-phase bioreactor for proteolytic digestion with
subsequent deposition onto the NALDI plate for reading results via MS analysis. To reduce
sample complexity and improve the identification efficiency of the various components (i.e.,
proteins) comprising the sample via mass spectrometry (MS), we will select a particular
organelle for the analysis; in this case the sub-population we propose to focus on is membrane
proteins from the isolated cells.
Multidimensional protein separation is regarded as the workhorse of many proteomic
studies; therefore, careful attention must be paid toward the development and implementation
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of multidimensional microelectrophoresis platforms both as an independent proteomic unit
and as an integral part of a multifunctional system. We demonstrated the ability to generate
peak capacities around 1,768 (±9) within 1 h for a biological sample of membrane proteins
from an MCF-7 cell lysate using a microchip separation platform, whose effective separation
length was 7 cm. While this peak capacity is still far below the total number of protein
components found in a sample of a cell lysate, the technique remains attractive due to the fact
that a sample of membrane proteins (representing a complex biological sample) has not been
separated on a microfluidic platform to date. We were also able to perform a solid-phase
extraction of biotinylated membrane proteins from MCF-7 cell lysate.
4.2

On-going Developments and Future Work

4.2.1 Background
In Chapters 2 and 3, our efforts were focused on the extraction and separation of
membrane proteins from CTC surrogates (MCF-7; a breast cancer cell line) and the separation
of membrane proteins from CTCs, respectively. There is a wealth of literature on the
development of microfluidic devices (device in this context being units that have only one
processing step) for the analysis of proteins, including those for solid-phase extractions1,2 2D
separations,3-11 and proteolytic solid-phase bioreactions.12-17 Because complex protein
samples can require the transfer of sample from one processing step to the next and be a
source of material loss and/or contamination, it is advantageous to consider the use of a fully
integrated fluidic system (systems are defined here as units that have various devices
integrated to them). In these systems, the sample is moved hydrodynamically or
electrokinetically through the entire processing pipeline without requiring operator
intervention. This allows for the reduction of analysis time, the ability to improve result
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reproducibility, and eliminate sample handling by the operator, which can be problematic
especially for mass-limited samples or those containing proteins that have a tendency to
adhere with high propensities to surfaces, such as membrane proteins.
A schematic of the proposed integrated fluidic system we are pursuing is shown in
Figure 4.1. The system will accommodate all of the necessary processing steps of the analysis
pipeline using task-specific modules fabricated in thermoplastics with the material selected
for each module based upon the application needed to produce optimal performance. Microreplication from a metal mold master will be utilized to fabricate the modules.

Figure 4.1 Integrated and modular fluidic system for processing a sub-population of a cell
proteome that is selected via affinity techniques. The fluidic motherboard (MB) is populated
with 4 modules: (1) Cell retention, biotinylation reactor and lysis module made from PC due
to its compatibility with the PC membrane; (2) solid-phase affinity module made from
PMMA due to its high surface load of functional groups when UV-treated; (3) 2D µCE
module made from PMMA due to its propensity to generate high electrophoretic plate
numbers; and (4) solid-phase bioreactor for proteolytic digestion of protein components sorted
via 2D µCE that is also made from PMMA. The modules are interconnected to a PC-based
motherboard; selected here based on its ability to form membrane values due to its high
elongation at break threshold. Other components consist of: HV – high voltage power
supplies; CD – conductivity detectors; Vac – vacuum; SI – sample inlet; RB – release buffer;
SV – solenoid valves; LB – lysis buffer; BM – biotin reaction mixture; WB – wash buffer.
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We will integrate an affinity selection module to the protein processing system to
select CTCs directly from whole blood with high purity (no-preprocessing required). In order
to accommodate the capability to process large input volumes to select sufficient numbers of
CTCs, a series of high aspect ratio fluidic channels (narrow and deep) will be utilized in the
CTC selection module. While we have already fabricated modules for the extraction of the
biotinylated cell surface proteins and the separation of membrane proteins from MCF-7 cells,
we still need to explore how to accomplish the on-chip cell lysis of the CTCs, the label-free
detection of the proteins, protein digestion, and the mass spectrometry interface.
4.2.2 Cell Selection Module
4.2.2.1 Cell Selection, Biotinylation, and Lysis Module Design
The design of the cell selection module builds from previous experiences in the
affinity capture of rare cells from samples such as blood.18-21 The previous worked described a
platform consisting of 51 channels (width = 30 µm; depth = 150 µm) with the walls being
covalently decorated with anti-EpCAM antibodies. This module could process 1 mL of blood
in ~40 min with CTC recoveries of 98%.18 However, we anticipate the need to process larger
input volumes to increase the yield of CTCs needed to accommodate the NALDI-MS
detection/identification phases of the assay. The module design is shown in Figure 4.2.
For this module, 500 sinusoidal channels will be used so that large input volumes can
be processed within reasonable timeframes using an optimized linear flow velocity (in terms
of recovery) of 2.0 mm/s for the EpCAM antigen/antibody pair.18 Each channel of the
selection bed will be 30 µm wide, which is close to the diameter of a CTC and will improve
recovery, and 250 µm deep, which will improve throughput.
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Figure 4.2 (A) Schematic of rare cell selection module that can process large input samples
(~10 mL) with high throughput (<40 min) and a SEM of the molded module, which is made
from PMMA, is shown in the bottom right. The input/output channels are much larger than
the cell selection channels, and thus there is a lower pressure drop in these channels; the input
channel fills before the selection channels. (B&C) Images of cells captured in selection
channels.
Channels (feed and selection channels) are arranged in a Z-configuration to provide
the single-channel inlet and outlet. This configuration has been found to minimize bubble
formation compared to the previous designs that were used during blood filling.18-21 A
volumetric flow rate of 0.45 mL/min will be utilized to generate the linear velocity that is
needed in each channel (2 mm/s) for CTC recoveries >90%.18
Once the rare cells have been selected, they are essentially “attached” to the channel
walls of the selection bed. In this state, we will seek to biotinylate the membrane proteins of
the selected cells. We will covalently attach biotin to the extracellular primary amine groups
of the membrane proteins, but other functionalities, such as sulfhydryls, can be tagged as well.
Membrane protein biotinylation provides an anchoring group for the affinity SPE of this subpopulation (as discussed in Chapter 2). Following biotinylation, cells will be washed and then
lysed with the membrane proteins delipidized and solubilized. Biological membranes are
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composed of ~50 lipid molecules per protein molecule.22 Therefore, the removal of the lipids
is vital because it can assist in the solubilization of the membrane proteins. The lysis,
delipidization, and solubilization of the cells will be done using a buffer containing 4%
CHAPS, Tris, 7M urea, 2M thiourea, and magnesium acetate. Because the SPE of the
membrane proteins is affinity-based, the buffer will not be carried downstream and will not
interfere with subsequent processing steps.
4.2.3 Detection of Proteins Employing Contact Conductivity Detection
4.2.3.1 Electrochemical Detection (ECD)
The readout strategy that is most commonly used for detection methods in
microfluidic devices is laser-induced fluorescence (LIF) due to the fact that it provides superb
sensitivity with detection limits approaching the single-molecule level.23-26 Regrettably, most
LIF systems do not lend themselves to developing miniaturized systems with the detector
components often times requiring much larger footprints compared to those of microfluidic
devices and also, in most cases the proteins are themselves not fluorescent. As such,
fluorescent dyes must be appended to the proteins to make them detectable. There have been
attempts to fabricate miniaturized LIF detectors with integrated capabilities;27,28 however, LIF
requires analytes that either show intrinsic fluorescence or can be readily associated with
(either covalently or non-covalently) labeling chromophores as noted above; this can
complicate sample processing.
Another strategy that has shown promise in microfluidic applications is the use of
electrochemical detection (ECD), such as amperometric or potentiometric detection
systems.29-39 Some of the features that make ECD attractive are the simple instrumentation
that is needed to perform the detection and the favorable sensitivity and limits of detection it
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offers. However, the target analyte must be intrinsically electroactive or have an electroactive
species appended to it in order to carry out detection with amperometric or potentiometric
methods. Conductivity detection can also be considered an electrochemical technique as well.
It has the ability to detect any analyte irrespective of whether it contains an electroactive
species or not. The only requirement is that the migrating analyte zones possess a conductivity
that is different from that of the carrier electrolyte. An additional advantage of conductivity is
that the performance improves with reduced detection volumes, making it an appealing
detector for microelectrophoretic separations. There have been reports of detection limits ~107

M using an integrated conductivity detector for a volume of ~30 pL.40,41
Galloway and co-workers42 from our group have demonstrated the use of a simple,

bipolar-pulse, contact conductivity detector that was integrated directly into a PMMA
microfluidic device performing electrophoresis for the detection of various mono- or
polyanionic molecules (i.e., amino acids, peptides, proteins or oligonucleotides) was
achieved. In this format, voltage pulses of equal amplitude and duration but opposite polarity
were applied to the conductivity electrodes with the current passing between the electrodes
measured at the end of the second pulse. The Faradaic reactions that occur at the electrodes
could be minimized because the pulse frequency was appropriately chosen with respect to the
cell constant (the time to charge the double layer) and the electrical double layer does not
have sufficient time to form. The layout of the PMMA device employed for the studies is
shown in Figure 4.3.
Several different electrophoresis formats such as MEKC (proteins), free-solution zone
electrophoresis (FSE) (amino acids and peptides), and reverse-phase ion-pair open channel
capillary electrochromatography (RP-IPOCCEC) (oligonucleotides) were utilized to separate
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ionic materials in a 3 cm effective length fluidic channel within the configured PMMA
device.

Figure 4.3 (A) Topographical layout of an assembled microfluidic device with an integrated
conductivity detector. Injection channel length was 1.0 cm; separation channel was 4.0 cm
(Leff = 3.0 cm). The separation channel was 15 µm wide and 85 µm deep. The solution
reservoirs are: (1) sample reservoir; (2) electrolyte reservoir; (3) waste reservoir; and (4)
receiving reservoir. (B) Optical micrograph of the assembled device cut near the conductivity
cell using microtoming. (C) Optical micrograph of the integrated conductivity detector (Tcell, electrode gap ~20 µm). In this micrograph, the cover plate was not assembled to the
fluidic device. Working and reference electrodes were 127 µm in diameter and were placed
0.5 cm upstream from the receiving reservoir. (D) SEM of Ni electroform embossing tool
taken near the receiving electrode. (Reproduced from Galloway, M.; Stryjewski, W.; Henry,
A.; Ford, S. M.; Llopis, S.; McCarley, R. L.; Soper, S. A. Anal. Chem. 2002, 74, 2407 with
permission, Copyright 2013).
Figure 4.4 shows the results from a separation of nine peptides using the PMMA
microdevice for FSE. The solid line represents the 3rd electrophoretic run and the dotted line
is the 35th electrophoretic run on the same chip. The electrophoretic conditions were as
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follows: carrier electrolyte was 100 μM phosphate (pH 5.0) with a 3 s electrokinetic injection
time and field strength 150 V/cm for the electrophoresis.

Figure 4.4 FSE separation of a peptide mixture (~0.23 μM total peptide concentration)
consisting of (1) bradykinin, (2) bradykinin fragment 1-5, (3) substance P, (4) [Arg8]vasopressin, (5) luteinizing hormone, (6) bombesin, (7) leucine enkephalin, (8) methionine
enkephalin, and (9) oxytocin in a PMMA device using contact conductivity detection.
(Reproduced from Galloway, M.; Stryjewski, W.; Henry, A.; Ford, S. M.; Llopis, S.;
McCarley, R. L.; Soper, S. A. Anal. Chem. 2002, 74, 2407 with permission, Copyright 2013).
The detector was operated at 5.0 kHz with bipolar pulse amplitude of ± 0.5 V.
Baseline separation of all 9 peptides was achieved in the 3 cm length channel with the
separation requiring <250 s. The sensing system we will use consists of a pair of electrodes to
measure the change in the bulk solution conductance created by an electrophoretic band
migrating through the electrodes.
We have shown that conductivity sensing can provide a label-less readout modality for
a variety of materials, including proteins and peptides,42,43 but with a limit-of-detection (LOD)
somewhat inferior to laser-induced fluorescence. To optimize the LOD by increasing the
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sampling efficiency generated by an electrode pair whose field extends across the entire
fluidic channel,42 we will investigate two approaches, labeled Type I and II (see Figure 4.5).
We will employ Pt wires placed orthogonal to the output channel in the Type I configuration
(see Figure 4.5A). This will provide high signal-to-noise ratios, but it also requires the
placement of the microelectrodes into guide channels by hand using microscopic inspection
and thus, is not conducive to simple production.

Figure 4.5 Conductivity detectors consisting of Type I (A, B) and Type II (C, D). The Type I
detector is constructed with Pt wires inserted into guide channels embossed into the fluidic
structure. The Type II detector use thin-film electrodes lithographically patterned on the cover
and bottom plates. In both cases, the sampling efficiency is 100%.
Our initial studies have used this conductivity format for rapid system evaluation. The
Type II configuration is more amenable to simple production through the lithographic
patterning of thin film metal electrodes and consists of placing electrodes on the top and
bottom faces of a fluidic channel (see Figure 4.5C). Thin film electrodes can be produced via
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deposition (sputtering or evaporation) through a shadow mask, lithographically through
selective etching of a deposited metal layer, or electroplated onto UV modified polymers.44,45
Figure 4.5D schematically shows the assembly process of the Type II detector. The detector
cell is an integral part of the fluidic module and is replicated during the same embossing step
used to create the fluid channels by double-sided hot embossing.46 In the next step, the bottom
of the detector cell will be cut through using, for example, laser ablation or high precision
micromilling. This two-step process can be done in a single step with the use of double-sided
micro-injection molding, which is capable of making through-holes directly and will be used
in future efforts.47 During module assembly, the detector cell is covered on the top and the
bottom with polymer films pre-patterned with platinum or other noble metal thin-film
electrodes.
Highly sensitive electronic circuitry for conductivity measurements developed by our
group will be used for this application.18 The conductivity measurement circuit has been
specially designed for applications in micro-environments and uses a gyrator sub-circuit to
reduce the effects of parasitic capacitance due to wiring and the electrode configuration,
which otherwise would dominate changes in electrical properties of the solution and degrade
the LOD of the conductivity measurement. The dimensions of the conductivity detector cell
and the electrodes will be optimized to provide favorable LODs and sampling efficiencies
without degrading plate number through zonal dispersion induced by the finite detection
volume.
In general, the LOD of conductivity detection is inversely proportional to the detector
cell constant (K) defined as K = L/A, where L is the distance between the electrodes and A is
the sensing area of the electrodes. Thus, better LODs are generated by closely spaced
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electrodes with large surface area. For initial studies, we will use 50 µm electrodes placed
over 50 µm wide and 50 µm deep microchannels at the sensing area with a gap of 50 μm, but
these can be reduced to further optimize the LOD for conductivity sensing. Specifically, we
will also look at various buffer compositions, separation channel lengths and field strengths to
optimize separation performance (i.e., resolution) and at the same time, reduce development
time. The effects of these separation conditions on the conductivity detection limit will be
evaluated as well.
4.2.3.2 Heart-cut 2D Separation of Membrane Proteins
In a heart-cut transfer protocol securing readout results from the first dimension of the
2D electrophoresis process of the membrane proteins prior to inserting into the second
dimension would be particularly attractive because it would permit more efficient injection of
material from the first dimension into the second dimension. For example, using the methods
described in Chapter 3, <1% of the total electrophoresis band is inevitably injected into the
second dimension. With heart cutting and online detection in both the first and second
dimensions, the injection efficiency can conceivably be improved to near 100%.
Also in Chapter 3, a 1D separation was required to determine when the first peak was
expected at the end of the first dimension. In those separations, which employed “blinded”
injection of material from the first dimension into the second dimension, one peak may be
sampled multiple times into the second dimension, and the transfer efficiency can deteriorate
as well. Also, prolonged development times are apparent with the blinded injection protocol.
Figure 4.6 shows the schematic of our approach to heart cutting 2D analysis. In our heart-cut
protocol, electrode sensors are placed around the end of the first dimension and as a protein
plug transverses the electrode sensors, the signal generated by the plug above baseline (or
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background buffer) would, after a preset time, initiate protein movement from the first
dimension into the second dimension.

Figure 4.6 Schematic of the 2D heart-cut separation layout. Conductivity detectors are placed
at the end of each separation dimension with preset modes to determine the on and off times.
Therefore, a dual detection process is required. Conductivity sensing would be
particularly attractive for this due to the simple instrumentation required for the detection
process and the fact that labeling of the proteins are not required, simplifying sample preprocessing.
4.2.4 Proteolytic Digestion of Separated Membrane Proteins
4.2.4.1 Solid-phase Proteolytic Digestion
Solid-phase bioreactors are being utilized more frequently instead of solution-phase
digestion in-part because in-soluiton digestion can result in autodigestion of the proteolytic
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enzyme forming peptides, which can complicate identification of the target proteins. While
this can be minimized using low concentrations of the enzyme, it results in longer reaction
times (>24 h). Solid-phase bioreactors can eliminate this artifact as well as provide the ability
to: (i) Reuse the enzyme for subsequent analysis;48-50 (ii) enhance the stability and activity of
the enzyme;16,51,52 and (iii) simplify on-line processing in addition to allowing easier
separation of the reaction products from the enzyme.
Researchers have adopted various approaches for designing proteolytic reactors
integrated into microfluidic devices, for example the use of trypsin-coated microparticles
loaded into microchannels. Our group has generated an interesting approach for performing
solid-phase bioreactions.15,53 The solid-phase bioreactor consists of a channel populated with
microposts that contain a functional scaffold from which the proteolytic enzyme can be
covalently linked.15,53 We have also shown the use of a solid-phase bioreactor (see Figure 4.7)
that allowed for continuous deposition onto a MALDI plate, a reaction time of ~24 s, and no
noticeable loss of enzyme activity throughout the depositions.15
The attractive nature of this approach is that the fluidic module and solid support are
fabricated in a single step using micro-replication of a thermoplastic.54 Following molding of
the bioreactor and fluidic network, the solid support is exposed to UV radiation to create
carboxylic acids that can be linked through an amide bond using EDC/NHS coupling
chemistry to the proteolytic enzyme.15
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Figure 4.7 (a) Schematic of the bioreactor. (b) The assembled tryptic digest microfluidic chip
that includes: PMMA chip and cover slip, inlet and outlet connectors, capillary and stainless
steel tubing. At the end of the bioreactor are coaxial tubes that were sealed to mix digests with
a matrix solution and to deposit onto the MALDI target plate (Reproduced from Lee, J.;
Musyimi, H. K.; Soper, S. A.; Murray, K. K. J Am Soc Mass Spectrom 2008, 19, 964 with
permission, Copyright 2013, Springer Science and Business Media).
We have shown that by using this arrangement, proteolytic reactions can be carried
out in ~20 s using either hydrodynamic or electrokinetic pumping.15,55
4.2.4.2 Micropost Arrays for Solid-phase Bioreactor
Shortcomings associated with many solid-phase bioreactors are twofold. First,
diffusional kinetic barriers produced by immobilizing the reagents to the solid support can be
significant. Reducing the channel dimensions can have a profound impact on the efficiency of
conversion of the chemical reactant to product during travel through the bioreactor. The
second shortcoming associated with solid-phase bioreactors is the limited load of chemical

160

reagent to the surface, especially for non-porous materials. The load level of reagent in the
bioreactor is determined by the size of the immobilized reagent and the surface area of the
bioreactor. For example, assuming an open-bed reactor with a rectangular geometry of 5 x 5

m, the effective surface area is only (l = 1.0 cm) 2.0 x 10-3 cm2. For a molecule with a cross
sectional area of 100 Ǻ2, this would amount to ~2.0 x 1011 molecules attached to the surface
of the reactor (0.3 pmol). In order to keep an enzymatic reaction pseudo first order, only
~0.003 pmol of material could be analyzed.
To address these issues, researchers have adopted 3D architectures in open
microfluidic channels employing either polymer monoliths53,56-63 or hydrogels.49,64-71 The
challenge with these techniques is that many of the reagents required to prepare the hydrogel
or monolith are incompatible with the material used to fabricate the fluidic chip when
polymers are the substrate.57 Another consideration is the porosities of these materials, which
can create large pressure drops for material driven through the reactor hydrostatically or
exclusion effects prohibiting the entrance of large molecules into the reactor bed. Finally, the
chemical preparation of hydrogels or monoliths adds additional processing time and labor to
the chip fabrication.
We will use micropost arrays as the solid-phase bioreactors, which can provide greatly
increased surface area so that the efficiency of a chemical reaction between the solid and
fluidized materials can be improved, but do so with minimal amounts of time and labor
needed to prepare the reactor bed. These reactors consist of microchannels populated with
microposts generated using hot embossing in a single fabrication step.15 Moreover, it has been
found that micropost arrays can also be utilized to promote mixing or enhance reaction rates.
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We will use computational fluid dynamics to futher study the flow patterns around the
posts within the microchannels. We will initiate our studies using posts of 20 m diameter
and an interpost spacing of 20 m. The channel dimensions for these bioreactors will be 50
m in depth, 1 mm in width, and 7 mm in length. With these dimensions, the bioreactor
surface area is approximately 28 mm2 with a surface area to volume ratio of 103 mm-1. We
have successfully immobilized trypsin onto PMMA surfaces using microfluidic channels
populated with microposts. Results for the digestion of cytochrome c using trypsin showed
that with a residence time of ~20 s, the sequence coverage (ratio of the identified amino acid
residues to the total number of amino acid residues in the protein) was 98% compared to only
9% for an open channel reactor of the same size. We will investigate different post geometries
(e.g. squares, diamonds, circles), post sizes (lateral dimensions) and interpost spacing to
produce high loads of enzyme and attempt to further reduce the reaction time and efficiency.
If we desire smaller posts and interpost spacing, we can use UV LiGA to manufacture the
master for replicating the desired parts using hot embossing.72
We will carefully evaluate the ability of obtaining peptides from a variety of
membrane proteins using trypsin; however, trypsin cleavage is less frequent for integral
membrane proteins,73 because lysine and arginine residues are not uniformly distributed along
the protein sequence.74 Therefore, trypsin may be used in conjunction with chymotrypsin to
aid in the sequence coverage and identification of integral membrane proteins. Chymotrypsin,
although less specific than trypsin, effectively cleaves peptide bonds consisting of amino
acids with aromatic or large hydrophobic side chains.75 This will require the formation of
mixed-monolayers of enzymes or the sequential patterning of trypsin and chymotrypsin
reactor beds by masking.
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4.2.5 NALDI-MS Platform for the Analysis of Mass-limited Samples
The samples from the digestion module will be continuously depostied from the
microfluidic system onto a MALDI target for off-line analysis. To improve the mass LOD
required to further accommodate the microfluidic outputs, we will utilize engineered plates
comprised of Si nanowires grown via chemical vapor deposition (CVD) techniques onto Si
substrates (NALDI), which have been shown to improve the LOD by approximately 10-fold
compared to conventional MALDI.76-79 NALDI does not require a matrix, which also results
in less interference in the low mass range. Also, a NALDI target plate is built on a
hydrophobic surface that will create narrow lines of aqueous solvent when the chip effluent is
deposited onto the plate via direct deposition.80,81
Continous deposition from the fluidic system to the target plate will be utilized for the
NALDI analysis. The fluidic system will be fit into a stationary mount, a guide channel will
be embossed into the fluidic motherboard, and used for transporting samples onto the target.
The NALDI plate will be placed on another mount operated using linear actuators and a
motion controller interfaced to a computer running LabView. During deposition, the fluidic
system outlet will be brought into contact with the target for depositing the effluent. The rate
of target motion will be matched to the (off-line) MS readout rate. After sample deposition,
the target will be loaded into the MS and spectra acquired. We will also investigate the effects
of co-deposition of SDS onto MALDI/NALDI plates and its effects on the integrity of the
MS.
Recent studies have shown that SDS concentrations ranging from 0.3% to 1.0% (w/v)
can improve the sequence coverage for proteins analyzed via MALDI-MS,82-84 whereas
concentrations above 1% lead to loss of spectral quality due to excess Na+ and also, formation
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of SDS cluster peaks in the MS. As noted above, for our MEKC dimension of the 2D µCE,
we will be using SDS concentrations near the CMC (>0.23%), so we will be below the critical
1% level to maintain MS integrity. In all of the cited work, however, the effects of SDS were
evaluated for MALDI-MS, in which a matrix was used; the effects of co-deposition of SDS
with NALDI have not been evaluated. Therefore, we will investigate the effects of SDS
concentration on the integrity of NALDI.
4.2.6 Integration of Modules for Membrane Protein Analysis
The overall goal of this work is to integrate the previously discussed modules to a
motherboard that possesses a fluidic bus, interconnects and valves for controlling
reagent/sample flow direction that is driven hydrodynamically through the use of off-chip
pumps. The proposed integrated system is based on a modular format (see Figure 4.1) and
consists of four modules. Fluidic modules will be interconnected to the modules using the
design concept shown in Figure 4.6. An excimer laser will be employed to drill holes of the
appropriate shape and size into the fluidic motherboard and module. Then, a Tefzel tube will
be inserted into the laser-drilled holes.
Exerting pressure on the assembly allows the proper leak-free interconnection (up to
~600 psi). As can be seen from the micrograph depicted in Figure 4.6, this interconnection
produces minimal unswept or dead volumes, which is a critical performance metric when
analyzing mass-limited samples. We will use a combination of electrokinetic and
hydrodynamic pumping. For example, the cell biotinylation and SPE modules will use
hydrodynamic pumping with off-chip pumps.

164

Electrokinetic fluid drive will be used for the µ-CE with subsequent deposition onto
the MALDI plate. We have already discussed the use of COMSOL to investigate the flow
patterns around microposts for the SPE work (see Chapter 2). COMSOL and/or computational
fluid dynamics will be employed to study flow patterns around various posted architectures,
which will include the packing geometry (hexagonal, equilateral or square array), post
spacing or post diameter.

Figure 4.8 Micrographs on the left show laser drilled holes using an ArF excimer laser into a
thermoplastic (PC). The schematics on the right show the interconnect technology that will be
used to provide leak-free connections of modules to the fluidic motherboard. The micrograph
(bottom right) shows a connection between two polymer pieces with dye filling the fluidic
via, showing near zero dead volume.
We will also analyze the flow distribution85,86 within and between the module and
motherboard. The transport velocity through posted beds will be optimized with respect to
balancing the encounter and reaction rates.87,88 For electrokinetic driving, we will analyze
material discontinuities (motherboard/module interfaces and interconnects) to evaluate the
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effects of material dependent electroosmotic flows (EOFs) that may generate laminar flow
profiles and consequently, degrade plate numbers for the µ-CE phases of the processing.89
We will employ several on-chip valves (see Figure 4.1, SV1-7) poised on the fluidic
motherboard. Figure 4.9 shows drawings of the design and operation of these valves, which
consist of a two-layered structure (fluidic substrate and cover plate) as opposed to threelayered structures typically employed for PDMS-based membrane values. Valves will be
actuated with solenoids. Simplicity of fabrication, and the use of a single material
differentiates these fluid control elements from other on-chip valves, which are typically
hybrid devices consisting of glass and PDMS.90-94

Figure 4.9 Physical operation of the on-chip valve. A – valve in open position, B – valve in
closed position; 1 – PC chip body; 2 – PC membrane; 3 – inlet; 4 – outlet; 5 – solenoid
actuated plunger. Half-circle cutouts in the membrane were used for clarity of the pictures.
We have successfully tested these micro-valves with head pressures up to 105 psi with
no leakage; these valves can take more than an order of magnitude higher pressure load than
hybrid thermoplastic/elastomeric valves.95 The valving membrane (motherboard cover plate)
used here is PC, with the substrate also made from PC to allow simple thermal fusion bonding
of these materials.

166

4.3

References

(1)

Yang, W.; Sun, X.; Pan, T.; Woolley, A. T. Electrophoresis 2008, 29, 3429.

(2)

Zhao, Y.; Zhang, W.; Kho, Y.; Zhao, Y. Anal Chem 2004, 76, 1817.

(3)

Chen, H.; Fan, Z. H. Electrophoresis 2009, 30, 758.

(4)

Chen, X.; Wu, H.; Mao, C.; Whitesides, G. M. Anal Chem 2002, 74, 1772.

(5)

Erickson, D., Li, D. Analytica chimica acta 2004, 507, 11.

(6)

Molloy, M. P.; Brzezinski, E. E.; Hang, J.; McDowell, M. T.; VanBogelen, R. A.
Proteomics 2003, 3, 1912.

(7)

Osiri, J. K.; Shadpour, H.; Park, S.; Snowden, B. C.; Chen, Z. Y.; Soper, S. A.
Electrophoresis 2008, 29, 4984.

(8)

Service, R. F. Science 2001, 294, 2074.

(9)

Shadpour, H.; Soper, S. A. Anal Chem 2006, 78, 3519.

(10)

Smith, R. D. Nat Biotechnol 2000, 18, 1041.

(11)

Wang, H.; Hanash, S. Journal of chromatography. B, Analytical technologies in the
biomedical and life sciences 2003, 787, 11.

(12)

Brivio, M.; Fokkens, R. H.; Verboom, W.; Reinhoudt, D. N.; Tas, N. R.; Goedbloed,
M.; van den Berg, A. Anal Chem 2002, 74, 3972.

(13)

Duan, J.; Sun, L.; Liang, Z.; Zhang, J.; Wang, H.; Zhang, L.; Zhang, W.; Zhang, Y.
Journal of chromatography. A 2006, 1106, 165.

(14)

Jin, L. J.; Ferrance, J.; Sanders, J. C.; Landers, J. P. Lab on a chip 2003, 3, 11.

(15)

Lee, J.; Musyimi, H. K.; Soper, S. A.; Murray, K. K. J Am Soc Mass Spectrom 2008,
19, 964.

(16)

Letant, S. E.; Hart, B. R.; Kane, S. R.; Hadi, M. Z.; Shields, S. J.; Reynolds, J. G. Adv
Mater 2004, 16, 689.

(17)

Peterson, D. S.; Rohr, T.; Svec, F.; Frechet, J. M. Anal Chem 2002, 74, 4081.

(18)

Adams, A. A.; Okagbare, P. I.; Feng, J.; Hupert, M. L.; Patterson, D.; Gottert, J.;
McCarley, R. L.; Nikitopoulos, D.; Murphy, M. C.; Soper, S. A. J Am Chem Soc 2008,
130, 8633.

167

(19)

Dharmasiri, U.; Balamurugan, S.; Adams, A. A.; Okagbare, P. I.; Obubuafo, A.;
Soper, S. A. Electrophoresis 2009, 30, 3289.

(20)

Dharmasiri, U.; Njoroge, S. K.; Witek, M. A.; Adebiyi, M. G.; Kamande, J. W.;
Hupert, M. L.; Barany, F.; Soper, S. A. Anal Chem 2011, 83, 2301.

(21)

Dharmasiri, U.; Witek, M. A.; Adams, A. A.; Osiri, J. K.; Hupert, M. L.; Bianchi, T.
S.; Roelke, D. L.; Soper, S. A. Anal Chem 2010, 82, 2844.

(22)

Yates, J. R.; Ruse, C. I.; Nakorchevsky, A. Annual Review of Biomedical Engineering
2009, 11, 49.

(23)

Wabuyele, M. B.; Ford, S. M.; Stryjewski, W.; Barrow, J.; Soper, S. A.
Electrophoresis 2001, 22, 3939.

(24)

Effenhauser, C. S.; Bruin, G. J.; Paulus, A.; Ehrat, M. Anal Chem 1997, 69, 3451.

(25)

Fister, J. C.; Jacobson, S. C.; Davis, L. M.; Ramsey, J. M. Anal Chem 1998, 70, 431.

(26)

Haab, B. B.; Mathies, R. A. Anal Chem 1999, 71, 5137.

(27)

Webster, J. R.; Burns, M. A.; Burke, D. T.; Mastrangelo, C. H. Anal Chem 2001, 73,
1622.

(28)

Burns, M. A.; Johnson, B. N.; Brahmasandra, S. N.; Handique, K.; Webster, J. R.;
Krishnan, M.; Sammarco, T. S.; Man, P. M.; Jones, D.; Heldsinger, D.; Mastrangelo,
C. H.; Burke, D. T. Science 1998, 282, 484.

(29)

Baba, Y. Electrochemistry 2000, 68, 197.

(30)

Martin, R. S.; Gawron, A. J.; Lunte, S. M. Anal Chem 2000, 72, 3196.

(31)

Rossier, J. S.; Roberts, M. A.; Ferrigno, R.; Girault, H. H. Anal Chem 1999, 71, 4294.

(32)

Suzuki, H.; Arakawa, H.; Sasaki, S.; Karube, I. Anal Chem 1999, 71, 1737.

(33)

Tantra, R.; Manz, A. Anal Chem 2000, 72, 2875.

(34)

Wang, J.; Chatrathi, M. P.; Tian, B. Anal Chem 2000, 72, 5774.

(35)

Wang, J.; Tian, B.; Sahlin, E. Anal Chem 1999, 71, 5436.

(36)

Woolley, A. T.; Lao, K.; Glazer, A. N.; Mathies, R. A. Anal Chem 1998, 70, 684.

(37)

Gawron, A. J.; Martin, R. S.; Lunte, S. M. Electrophoresis 2001, 22, 242.

168

(38)

Martin, R. S.; Gawron, A. J.; Fogarty, B. A.; Regan, F. B.; Dempsey, E.; Lunte, S. M.
The Analyst 2001, 126, 277.

(39)

Lacher, N. A.; Garrison, K. E.; Martin, R. S.; Lunte, S. M. Electrophoresis 2001, 22,
2526.

(40)

Huang, X. H.; Pang, T. K. J.; Gordon, M. J.; Zare, R. N. Analytical Chemistry 1987,
59, 2747.

(41)

Huang, X. H.; Luckey, J. A.; Gordon, M. J.; Zare, R. N. Analytical Chemistry 1989,
61, 766.

(42)

Galloway, M.; Stryjewski, W.; Henry, A.; Ford, S. M.; Llopis, S.; McCarley, R. L.;
Soper, S. A. Anal. Chem. 2002, 74, 2407.

(43)

Shadpour, H.; Hupert, M. L.; Patterson, D.; Liu, C. G.; Galloway, M.; Stryjewski, W.;
Goettert, J.; Soper, S. A. Anal. Chem. 2007, 79, 870.

(44)

Henry, A. C.; Tutt, T. J.; Galloway, M.; Davidson, Y. Y.; McWhorter, C. S.; Soper, S.
A.; McCarley, R. L. Anal Chem 2000, 72, 5331.

(45)

Vaidya, B.; Soper, S. A.; McCarley, R. L. The Analyst 2002, 127, 1289.

(46)

Xu, F.; Datta, P.; Wang, H.; Gurung, S.; Hashimoto, M.; Wei, S.; Goettert, J.;
McCarley, R. L.; Soper, S. A. Anal Chem 2007, 79, 9007.

(47)

Yin, H., Qu, X. and Jia, C. Journal of University of Science and Technology Beijing
2008, 15, 480.

(48)

Mao, H.; Yang, T.; Cremer, P. S. Anal Chem 2002, 74, 379.

(49)

Seong, G. H.; Zhan, W.; Crooks, R. M. Anal Chem 2002, 74, 3372.

(50)

Davidson, Y. Y., Soper, S. A., Margolis, S., Sander, L. C. Journal of separation
science 2001, 24, 10.

(51)

Laurell, T., Drott, J. Rosengren, L., Lindstrom, K. Sensors and Actuators B: Chemical
1996, 31, 161.

(52)

Manjón, A., Obón, J. M., Casanova, P., Fernández, V. M., Ilborra, J. L. Biotechnology
letters 2002, 24, 1227.

(53)

Hasselbrink, E. F., Jr.; Shepodd, T. J.; Rehm, J. E. Anal Chem 2002, 74, 4913.

169

(54)

Hupert, M. L., Guy, W. J., Llopis, S. D., Shadpour, H., Sudheer, R., Nikitopoulos, D.
E., Soper, S. A. Microfluidics and Nanofluidics 2007, 3, 1.

(55)

Lee, C. S.; Lee, S. H.; Kim, Y. G.; Lee, J. H.; Kim, Y. K.; Kim, B. G. Biosensors &
bioelectronics 2007, 22, 891.

(56)

Peters, E. C., Svec, F., Fréchet, J. M. Adv Mater 1999, 11, 1169.

(57)

Stachowiak, T. B.; Rohr, T.; Hilder, E. F.; Peterson, D. S.; Yi, M.; Svec, F.; Frechet, J.
M. Electrophoresis 2003, 24, 3689.

(58)

Svec, F., Fréchet, J. M. Ind Eng Chem Res 1999, 38, 34.

(59)

Yu, C., Svec, F., Fréchet, J. M. Abstr Pap Am Chem S 2001, 222, U84.

(60)

Yu, C., Xu, M., Svec, F., Fréchet, J. M. Journal of Polymer Science Part A-Polymer
Chemistry 2002, 40, 755.

(61)

Yu, C.; Davey, M. H.; Svec, F.; Frechet, J. M. Anal Chem 2001, 73, 5088.

(62)

Yu, C.; Svec, F.; Frechet, J. M. Electrophoresis 2000, 21, 120.

(63)

Xie, S., Svec, F., Fréchet, J. M. J. Biotechnology & Bioengineering 1999, 62, 30.

(64)

Burdick, J. A.; Khademhosseini, A.; Langer, R. Langmuir : the ACS journal of
surfaces and colloids 2004, 20, 5153.

(65)

Harmon, M. E., Tang, M., Frank, C. W. Polymer 2003, 44, 4547.

(66)

Neidhart, M., Rethage, J., Kuchen, S., Künzler, P., Crowl, R., Billingham, M., Gay,
R., Gay, S. Arthritis & Rheumatism 2000, 43, 2634.

(67)

Hoffmann, J., Plötner, M., Kuckling, D., Fischer, W. J. Sens. Actuator A-Phys. 1999,
77, 139.

(68)

Khoury, C., Adalsteinsson, T., Johnson, B., Crone, W. C., Beebe, D. J. Biomedical
Microdevices 2003, 5, 35.

(69)

Siegal, R. A., Gu, Y. D., Baldi, A., Ziaie, B. Macromolecular Symposia 2004, 207,
249.

(70)

Campbell, T. D., Washington, R. P., Ginn, B. T., Blakemore, L. J., Trombley, P. Q.,
and Steinbock,O. Abstr Pap Am Chem S 2003, 225, U512.

(71)

Lesho, M. J., Sheppard, N. F. Abstr Pap Am Chem S 1994, 208, 423.

170

(72)

Witek, M. A.; Hupert, M. L.; Park, D. S. W.; Fears, K.; Murphy, M. C.; Soper, S. A.
Analytical Chemistry 2008, 80, 3483.

(73)

Kyte, J.; Doolittle, R. F. Journal of molecular biology 1982, 157, 105.

(74)

Sipos, L.; von Heijne, G. European journal of biochemistry / FEBS 1993, 213, 1333.

(75)

Lu, B.; McClatchy, D. B.; Kim, J. Y.; Yates, J. R., 3rd Proteomics 2008, 8, 3947.

(76)

Daniels, R. H.; Dikler, S.; Li, E.; Stacey, C. JALA 2008, 314.

(77)

Go, E. P.; Apon, J. V.; Saghatelian, A.; Daniels, R. H.; Sahi, V.; Dubrow, R.; Cravatt,
B. F.; Vertes, A.; Siuzdak, G. Anal. Chem. 2005, 77, 1641.

(78)

Kang, M.-J.; Pyun, J.-C.; Lee, J.-C.; Park, J.-H.; Park, J.-G.; Lee, J.-G.; Choi, H.-J.
Rapid Commun. Mass Spectrom. 2005, 19, 3166.

(79)

Vidova, V.; Novak, P.; Strohalm, M.; Pol, J.; Havlicek, V.; Volny, M. Anal Chem
2010, 82, 4994.

(80)

Lee, J.; Musyimi, H. K.; Soper, S. A.; Murray, K. K. J. Am. Soc. Mass Spectrom.
2008, 19, 964.

(81)

Lee, J.; Soper, S. A.; Murray, K. K. Analyst 2009, 134, 2426.

(82)

Zhang, N.; Li, L. Rapid Commun. Mass Spectrom. 2004, 18, 889.

(83)

Tummala, R.; Green-Church, K. B.; Limbach, P. A. American Society for Mass
Spectrometry 2005, 16, 1438.

(84)

Tummala, R.; Limbach, P. A. Rapid Commun. Mass Spectrom. 2004, 18, 2031.

(85)

Drummond, J. E.; Tahir, M. I. International Journal of Multiphase Flow 1984, 10,
515.

(86)

Gordon, D. Computational Fluids 1978, 6, 1.

(87)

Adams, A. A.; Okagbare, P. I.; Feng, J.; Hupert, M. L.; Patterson, D.; Gottert, J.;
McCarley, R. L.; Nikitopoulos, D.; Murphy, M. C.; Soper, S. A. J. Am. Chem. Soc.
2008, 130, 8633.

(88)

Chang, K. C.; Hammer, D. A. BIophysical Journal 1999, 76, 1280.

(89)

Shadpour, H.; Musyimi, H.; Chen, J.; Soper, S. A. J. Chromatogr. A 2006, 1111, 238.

171

(90)

Lagally, E. T.; Sintegral membrane proteinson, P. C.; Mathies, R. A. Sens. Actuator BChem. 2000, 63, 138.

(91)

Grover, W. H.; Skelley, A. M.; Liu, C. N.; Lagally, E. T.; Mathies, R. A. Sens.
Actuator B-Chem. 2003, 89, 315.

(92)

Lagally, E. T.; Scherer, J. R.; Blazej, R. G.; Toriello, N. M.; Diep, B. A.;
Ramchandani, M.; Sensabaugh, G. F.; Riley, L. W.; Mathies, R. A. Analytical
Chemistry 2004, 76, 3162.

(93)

Skelley, A. M.; Scherer, J. R.; Aubrey, A. D.; Grover, W. H.; Ivester, R. H. C.;
Ehrenfreund, P.; Grunthaner, F. J.; Bada, J. L.; Mathies, R. A. Proc. Natl. Acad. Sci.
U. S. A. 2005, 102, 1041.

(94)

Grover, W. H.; Ivester, R. H. C.; Jensen, E. C.; Mathies, R. A. Lab On A Chip 2006, 6,
623.

(95)

Zhang, W.; Lin, S.; Wang, C.; Hu, J.; Li, C.; Zhuang, Z.; Zhou, Y.; Mathies, R. A.;
Yang, C. J. Lab Chip 2009, 9, 3088.

172

Appendix: Permissions
JOHN WILEY AND SONS LICENSE TERMS AND CONDITIONS
Aug 28, 2013
This is a License Agreement between Katrina N Battle ("You") and John Wiley and Sons
("John Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license
consists of your order details, the terms and conditions provided by John Wiley and Sons, and
the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see information
listed at the bottom of this form.
License Number 3217821263929
License date Aug 28, 2013
Licensed content publisher John Wiley and Sons
Licensed content publication Proteomics
Licensed content title Technologies for plasma membrane proteomics
Licensed copyright line Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA,
Weinheim
Licensed content author Stuart J. Cordwell,Tine E. Thingholm
Licensed content date Oct 15, 2009
Start page 611
End page 627
Type of use Dissertation/Thesis
Requestor type University/Academic
Format Print and electronic
Portion Figure/table
Number of figures/tables 2
Original Wiley figure/table number(s) Figure1, Figure 3
Will you be translating? No
Total 0.00 USD
AMERICAN CHEMICAL SOCIETY LICENSE TERMS AND CONDITIONS
Title: Protein Digestion: An Overview of the Available Techniques and Recent Developments
Author: Linda Switzar, Martin Giera, and Wilfried M. A. Niessen
Publication: Journal of Proteome Research
Publisher: American Chemical Society
Date: Mar 1, 2013 Copyright © 2013, American Chemical Society
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following:
Permission is granted for your request in both print and electronic formats, and translations.
If figures and/or tables were requested, they may be adapted or used in part.
Please print this page for your records and send a copy of it to your publisher/graduate school.
Appropriate credit for the requested material should be given as follows: "Reprinted (adapted)

173

with permission from (COMPLETE REFERENCE CITATION). Copyright (YEAR)
American Chemical Society." Insert appropriate information in place of the capitalized words.
One-time permission is granted only for the use specified in your request. No additional uses
are granted (such as derivative works or other editions). For any other uses, please submit a
new request. If credit is given to another source for the material you requested, permission
must be obtained from that source.
ELSEVIER LICENSE TERMS AND CONDITIONS
Aug 28, 2013
This is a License Agreement between Katrina N Battle ("You") and Elsevier ("Elsevier")
provided by Copyright Clearance Center ("CCC"). The license consists of your order details,
the terms and conditions provided by Elsevier, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see information
listed at the bottom of this form.
Supplier Elsevier Limited The Boulevard,Langford Lane Kidlington,Oxford,OX5 1GB,UK
Registered Company Number 1982084
Customer name Katrina N Battle
Customer address 116 Manning Drive CHAPEL HILL, NC 27599
License number 3217930781023
License date Aug 28, 2013
Licensed content publisher Elsevier
Licensed content publication Current Opinion in Chemical Biology
Licensed content title Mass spectrometry for proteomics
Licensed content author Xuemei Han,Aaron Aslanian,John R Yates
Licensed content date October 2008
Licensed content volume number 12
Licensed content issue number 5
Number of pages 8
Start Page 483
End Page 490
Type of Use reuse in a thesis/dissertation
Intended publisher of new work other
Portion figures/tables/illustrations
Number of figures/tables/illustrations 1
Format both print and electronic
Are you the author of this Elsevier article? No
Will you be translating? No
Order reference number
Title of your thesis/dissertation Microfluidics for the Analysis of Integral Membrane Proteins:
A Top-down Approach
Expected completion date Dec 2013
Estimated size (number of pages) 157
Elsevier VAT number GB 494 6272 12
Permissions price 0.00 USD
VAT/Local Sales Tax 0.0 USD / 0.0 GBP

174

AMERICAN CHEMICAL SOCIETY LICENSE TERMS AND CONDITIONS
Title: Proteomics on Full-Length Membrane Proteins Using Mass Spectrometry
Author: Johannes le Coutre et al.
Publication: Biochemistry
Publisher: American Chemical Society
Date: Apr 1, 2000 Copyright © 2000, American Chemical Society
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following:
Permission is granted for your request in both print and electronic formats, and translations.
If figures and/or tables were requested, they may be adapted or used in part. Please print this
page for your records and send a copy of it to your publisher/graduate school. Appropriate
credit for the requested material should be given as follows: "Reprinted (adapted) with
permission from (COMPLETE REFERENCE CITATION). Copyright (YEAR) American
Chemical Society." Insert appropriate information in place of the capitalized words. One-time
permission is granted only for the use specified in your request. No additional uses are
granted (such as derivative works or other editions). For any other uses, please submit a new
request. If credit is given to another source for the material you requested, permission must be
obtained from that source.
AMERICAN CHEMICAL SOCIETY LICENSE TERMS AND CONDITIONS
Title: Preconcentration of Proteins on Microfluidic Devices Using Porous Silica Membranes
Author: Robert S. Foote,*, Julia Khandurina,†, Stephen C. Jacobson,‡ and, and J. Michael
Ramsey§
Publication: Analytical Chemistry
Publisher: American Chemical Society
Date: Jan 1, 2005 Copyright © 2005, American Chemical Society
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following: Permission is
granted for your request in both print and electronic formats, and translations. If figures
and/or tables were requested, they may be adapted or used in part. Please print this page for
your records and send a copy of it to your publisher/graduate school. Appropriate credit for
the requested material should be given as follows: "Reprinted (adapted) with permission from
(COMPLETE REFERENCE CITATION). Copyright (YEAR) American Chemical Society."
Insert appropriate information in place of the capitalized words. One-time permission is
granted only for the use specified in your request. No additional uses are granted (such as
derivative works or other editions). For any other uses, please submit a new request. If credit
is given to another source for the material you requested, permission must be obtained from
that source.

175

AMERICAN CHEMICAL SOCIETY LICENSE TERMS AND CONDITIONS
Title: Poly(dimethylsiloxane)-Based Microchip for Two-Dimensional Solid-Phase Extraction
Capillary Electrophoresis with an Integrated Electrospray Emitter Tip
Author: Andreas P. Dahlin et al.
Publication: Analytical Chemistry
Publisher: American Chemical Society
Date: Aug 1, 2005 Copyright © 2005, American Chemical Society
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following:
Permission is granted for your request in both print and electronic formats, and translations.
If figures and/or tables were requested, they may be adapted or used in part.
Please print this page for your records and send a copy of it to your publisher/graduate school.
Appropriate credit for the requested material should be given as follows: "Reprinted (adapted)
with permission from (COMPLETE REFERENCE CITATION). Copyright (YEAR)
American Chemical Society." Insert appropriate information in place of the capitalized words.
One-time permission is granted only for the use specified in your request. No additional uses
are granted (such as derivative works or other editions). For any other uses, please submit a
new request. If credit is given to another source for the material you requested, permission
must be obtained from that source.
AMERICAN CHEMICAL SOCIETY LICENSE TERMS AND CONDITIONS
Title: Integrated Microfluidic Device for Mass Spectrometry-Based Proteomics and Its
Application to Biomarker Discovery Programs
Author: Marie-Helene Fortier,†, Eric Bonneil,‡,§, Paul Goodley,! and, and Pierre
Thibault*,†,‡,§
Publication: Analytical Chemistry
Publisher: American Chemical Society
Date: Mar 1, 2005 Copyright © 2005, American Chemical Society
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following: Permission is
granted for your request in both print and electronic formats, and translations. If figures
and/or tables were requested, they may be adapted or used in part. Please print this page for
your records and send a copy of it to your publisher/graduate school. Appropriate credit for
the requested material should be given as follows: "Reprinted (adapted) with permission from
(COMPLETE REFERENCE CITATION). Copyright (YEAR) American Chemical Society."
Insert appropriate information in place of the capitalized words. One-time permission is
granted only for the use specified in your request. No additional uses are granted (such as
derivative works or other editions). For any other uses, please submit a new request. If credit
is given to another source for the material you requested, permission must be obtained from
that source.

176

ELSEVIER LICENSE TERMS AND CONDITIONS
Aug 28, 2013
This is a License Agreement between Katrina N Battle ("You") and Elsevier ("Elsevier")
provided by Copyright Clearance Center ("CCC"). The license consists of your order details,
the terms and conditions provided by Elsevier, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see information
listed at the bottom of this form.
Supplier Elsevier Limited The Boulevard,Langford Lane Kidlington,Oxford,OX5 1GB,UK
Registered Company
Customer name Katrina N Battle
Customer address 116 Manning Drive CHAPEL HILL, NC 27599
License number 3217921349499
License date Aug 28, 2013
Licensed content publisher Elsevier
Licensed content publication Analytica Chimica Acta
Licensed content title Protein digestion and phosphopeptide enrichment on a glass microchip
Licensed content author Guihua Eileen Yue, Michael G. Roper, Catherine Balchunas, Abigail
Pulsipher, Joshua J. Coon, Jeffery Shabanowitz, Donald F. Hunt, James P. Landers, Jerome P.
Ferrance
Licensed content date 30 March 2006
Licensed content volume number 564
Licensed content issue number 1
Number of pages 7
Start Page 116
End Page 122
Type of Use reuse in a thesis/dissertation
Intended publisher of new work other
Portion figures/tables/illustrations
Number of figures/tables/illustrations 1
Format both print and electronic
Are you the author of this Elsevier article? No
Will you be translating? No
Order reference number
Title of your thesis/dissertation
Microfluidics for the Analysis of Integral Membrane Proteins: A Top-down Approach
Expected completion date Dec 2013
Estimated size (number of pages) 157
Elsevier VAT number GB 494 6272 12
Permissions price 0.00 USD
VAT/Local Sales Tax 0.0 USD / 0.0 GBP
Total 0.00 USD

177

JOHN WILEY AND SONS LICENSE TERMS AND CONDITIONS
Aug 28, 2013
This is a License Agreement between Katrina N Battle ("You") and John Wiley and Sons
("John Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license
consists of your order details, the terms and conditions provided by John Wiley and Sons, and
the payment terms and conditions. All payments must be made in full to CCC. For payment
instructions, please see information listed at the bottom of this form.
License Number 3217920921415
License date Aug 28, 2013
Licensed content publisher John Wiley and Sons
Licensed content publication Proteomics
Licensed content title Analysis of outer membrane proteome of Escherichia coli related to
resistance to ampicillin and tetracycline
Licensed copyright line Copyright © 2006 WILEY-VCH Verlag GmbH & Co. KGaA,
Weinheim
Licensed content author Changxin Xu,Xiangmin Lin,Haixia Ren,Yueling Zhang,Sanying
Wang,Xuanxian Peng
Licensed content date Dec 21, 2005
Start page 462
End page 473
Type of use Dissertation/Thesis
Requestor type University/Academic
Format Print and electronic
Portion Figure/table
Number of figures/tables 1
Original Wiley figure/table number(s) Figure 4
Will you be translating? No
Total 0.00 USD
JOHN WILEY AND SONS LICENSE TERMS AND CONDITIONS
Aug 29, 2013
This is a License Agreement between Katrina N Battle ("You") and John Wiley and Sons
("John Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license
consists of your order details, the terms and conditions provided by John Wiley and Sons, and
the payment terms and conditions. All payments must be made in full to CCC. For payment
instructions, please see information listed at the bottom of this form.
License Number 3218551499370
License date Aug 29, 2013
Licensed content publisher John Wiley and Sons
Licensed content publication Electrophoresis
Licensed content title A proteomic approach to investigate potential biomarkers directed
against membrane-associated breast cancer proteins
Licensed copyright line Copyright © 2006 WILEY-VCH Verlag GmbH & Co. KGaA,
Weinheim

178

Licensed content author Ludovic Canelle,Jordane Bousquet,Cedric Pionneau,Julie
Hardouin,Genevieve Choquet-Kastylevsky,Raymonde Joubert-Caron,Michel Caron
Licensed content date Mar 20, 2006
Start page 1609
End page 1616
Type of use Dissertation/Thesis
Requestor type University/Academic
Format Print and electronic
Portion Figure/table
Number of figures/tables 1
Original Wiley figure/table number(s) Figure 2
Will you be translating? No
Total 0.00 USD
JOHN WILEY AND SONS LICENSE TERMS AND CONDITIONS
Aug 29, 2013
This is a License Agreement between Katrina N Battle ("You") and John Wiley and Sons
("John Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license
consists of your order details, the terms and conditions provided by John Wiley and Sons, and
the payment terms and conditions. All payments must be made in full to CCC. For payment
instructions, please see information listed at the bottom of this form.
License Number 3218541268418
License date Aug 29, 2013
Licensed content publisher John Wiley and Sons
Licensed content publication Electrophoresis
Licensed content title Generating high peak capacity 2-D maps of complex proteomes using
PMMA microchip electrophoresis
Licensed copyright line Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA,
Weinheim
Licensed content author John K. Osiri, Hamed Shadpour, Sunjung Park, Brandy C. Snowden,
Zhi Yuan Chen, Steven A. Soper
Licensed content date Jan 7, 2009
Start page 4984
End page 4992
Type of use Dissertation/Thesis
Requestor type University/Academic
Format Print and electronic
Portion Figure/table
Number of figures/tables 1
Original Wiley figure/table number(s) Figure 3
Will you be translating? No
Total 0.00 USD

179

AMERICAN CHEMICAL SOCIETY LICENSE TERMS AND CONDITIONS
Title: High-Efficiency, Two-Dimensional Separations of Protein Digests on Microfluidic
Devices
Author: Jeremy D. Ramsey,†, Stephen C. Jacobson, Christopher T. Culbertson,‡ and, and J.
Michael Ramsey*
Publication: Analytical Chemistry
Publisher: American Chemical Society
Date: Aug 1, 2003 Copyright © 2003, American Chemical Society
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following: Permission is
granted for your request in both print and electronic formats, and translations. If figures
and/or tables were requested, they may be adapted or used in part. Please print this page for
your records and send a copy of it to your publisher/graduate school. Appropriate credit for
the requested material should be given as follows: "Reprinted (adapted) with permission from
(COMPLETE REFERENCE CITATION). Copyright (YEAR) American Chemical Society."
Insert appropriate information in place of the capitalized words. One-time permission is
granted only for the use specified in your request. No additional uses are granted (such as
derivative works or other editions). For any other uses, please submit a new request. If credit
is given to another source for the material you requested, permission must be obtained from
that source.
AMERICAN CHEMICAL SOCIETY LICENSE TERMS AND CONDITIONS
Title: Two-Dimensional Electrophoretic Separation of Proteins Using Poly(methyl
methacrylate)
Microchips
Author: Hamed Shadpour† and Steven A. Soper*†,‡
Publication: Analytical Chemistry
Publisher: American Chemical Society
Date: Jun 1, 2006 Copyright © 2006, American Chemical Society
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following: Permission is
granted for your request in both print and electronic formats, and translations. If figures
and/or tables were requested, they may be adapted or used in part. Please print this page for
your records and send a copy of it to your publisher/graduate school. Appropriate credit for
the requested material should be given as follows: "Reprinted (adapted) with permission from
(COMPLETE REFERENCE CITATION). Copyright (YEAR) American Chemical Society."
Insert appropriate information in place of the capitalized words. One-time permission is
granted only for the use specified in your request. No additional uses are granted (such as
derivative works or other editions). For any other uses, please submit a new request. If credit
is given to another source for the material you requested, permission must be obtained from
that source.

180

SPRINGER LICENSE TERMS AND CONDITIONS
Sep 02, 2013
This is a License Agreement between Katrina N Battle ("You") and Springer ("Springer")
provided by Copyright Clearance Center ("CCC"). The license consists of your order details,
the terms and conditions provided by Springer, and the payment terms and conditions. All
payments must be made in full to CCC. For payment instructions, please see information
listed at the bottom of this form.
License Number 3221020531492
License date Sep 02, 2013
Licensed content publisher Springer
Licensed content publication Analytical and Bioanalytical Chemistry
Licensed content title Ultra-fast two-dimensional microchip electrophoresis using SDS μCGE and microemulsion electrokinetic chromatography for protein separations
Licensed content author John K. Osiri
Licensed content date Jan 1, 2010
Volume number 398
Issue number 1
Type of Use Thesis/Dissertation
Portion Figures
Author of this Springer article No
Order reference number
Title of your thesis /dissertation Microfluidics for the Analysis of Integral Membrane
Proteins: A Top-down Approach
Expected completion date Dec 2013
Estimated size (pages) 157
Total 0.00 USD
Limited License
With reference to your request to reprint in your thesis material on which Springer Science
and Business Media control the copyright, permission is granted, free of charge, for the use
indicated in your enquiry. Licenses are for one-time use only with a maximum distribution
equal to the number that you identified in the licensing process. This License includes use in
an electronic form, provided its password protected or on the university’s intranet or
repository, including UMI (according to the definition at the Sherpa website:
http://www.sherpa.ac.uk/romeo/). For any other electronic use, please contact Springer at
(permissions.dordrecht@springer.com or permissions.heidelberg@springer.com). The
material can only be used for the purpose of defending your thesis, and with a maximum of
100 extra copies in paper. Although Springer holds copyright to the material and is entitled to
negotiate on rights, this license is only valid, subject to a courtesy information to the author
(address is given with the article/chapter) and provided it concerns original material which
does not carry references to other sources (if material in question appears with credit to
another source, authorization from that source is required as well). Permission free of charge
on this occasion does not prejudice any rights we might have to charge for reproduction of our
copyrighted material in the future.

181

Copyright Permission Request
TO WHOM IT MAY CONCERN:
I am not an author of the Science article entitled, Structural origins of high-affinity biotin
binding to streptavidin by Weber P. C., Ohlendorf D. H., Wendoloski J. J., Salemme F. R.
(Science, 1989, 243, 85), but I would like to obtain permission to incorporate a figure
presented in the article (shown below) in my dissertation entitled, Microfluidics for the
Analysis of Integral Membrane Proteins: A Top-down Approach.
Thanks,
Katrina Battle
Dear Katrina: Re: 1 fig from “Structural origins of high-affinity biotin binding to streptavidin”
Science 6 January 1989: Vol. 243 no. 4887 pp. 85-88, DOI: 10.1126/science.2911722
Thank you very much for your request and for your interest in our content.
Please feel free to include the figure in your thesis or dissertation subject to the guidelines
listed on our website. Permission covers the distribution of your dissertation or thesis on
demand by a third party distributor (e.g. ProQuest/UMI), provided the AAAS material
covered by this permission remains in situ and is not distributed by that third party outside of
the context of your Thesis/Dissertation. Permission does not apply to figures/photos/artwork
or any other content or materials included in your work that are credited to non-AAAS
sources. If the requested material is sourced to or references non-AAAS sources, you must
obtain authorization from that source as well before using that material. You agree to hold
harmless and indemnify AAAS against any claims arising from your use of any content in
your work that is credited to non-AAAS sources. By using the AAAS Material identified in
your request, you agree to abide by all the terms and conditions herein. AAAS makes no
representations or warranties as to the accuracy of any information contained in the AAAS
material covered by this permission, including any warranties of merchantability or fitness for
a particular purpose. If how you wish to use our content falls outside of these guidelines or if
you have any questions please just let me know.
Best regards,
Liz Sandler (Ms) Elizabeth Sandler
Rights and Permissions The American Association for the Advancement of Science 1200
New York Ave., NW Washington, DC 20005
+1-202-326-6765 (tel) esandler@aaas.org
SPRINGER LICENSE TERMS AND CONDITIONS
Sep 03, 2013
This is a License Agreement between Katrina N Battle ("You") and Springer ("Springer")
provided by Copyright Clearance Center ("CCC"). The license consists of your order details,
the terms and conditions provided by Springer, and the payment terms and conditions. All
payments must be made in full to CCC. For payment instructions, please see information
listed at the bottom of this form.
182

License Number 3221461465685
License date Sep 03, 2013
Licensed content publisher Springer
Licensed content publication Journal of The American Society for Mass Spectrometry
Licensed content title Development of an automated digestion and droplet deposition
microfluidic chip for MALDI-TOF MS
Licensed content author Jeonghoon Lee
Licensed content date Jan 1, 2008
Volume number 19
Issue number 7
Type of Use Thesis/Dissertation
Portion Figures
Author of this Springer article No
Order reference number
Title of your thesis/dissertation Microfluidics for the Analysis of Integral Membrane Proteins:
A Top-down Approach
Expected completion date Dec 2013
Estimated size(pages) 157
Total 0.00 USD
Terms and Conditions
Limited License
With reference to your request to reprint in your thesis material on which Springer Science
and Business Media control the copyright, permission is granted, free of charge, for the use
indicated in your enquiry. Licenses are for one-time use only with a maximum distribution
equal to the number that you identified in the licensing process. This License includes use in
an electronic form, provided its password protected or on the university’s intranet or
repository, including UMI (according to the definition at the Sherpa website:
http://www.sherpa.ac.uk/romeo/). For any other electronic use, please contact Springer at
(permissions.dordrecht@springer.com or permissions.heidelberg@springer.com). The
material can only be used for the purpose of defending your thesis, and with a maximum of
100 extra copies in paper. Although Springer holds copyright to the material and is entitled to
negotiate on rights, this license is only valid, subject to a courtesy information to the author
(address is given with the article/chapter) and provided it concerns original material which
does not carry references to other sources (if material in question appears with credit to
another source, authorization from that source is required as well). Permission free of charge
on this occasion does not prejudice any rights we might have to charge for reproduction of our
copyrighted material in the future. Altering/Modifying Material: Not Permitted
You may not alter or modify the material in any manner. Abbreviations, additions, deletions
and/or any other alterations shall be made only with prior written authorization of the
author(s) and/or Springer Science + Business Media. (Please contact Springer at
(permissions.dordrecht@springer.com or permissions.heidelberg@springer.com) Reservation
of Rights Springer Science + Business Media reserves all rights not specifically granted in the
combination of (i) the license details provided by you and accepted in the course of this
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions. Copyright Notice: Disclaimer You must include the following copyright
and permission notice in connection with an reproduction of the licensed material: "Springer

183

and the original publisher /journal title, volume, year of publication, page, chapter/article title,
name(s) of author(s), figure number(s), original copyright notice) is given to the publication in
which the material was originally published, by adding; with kind permission from Springer
Science and Business Media"
Title: Contact Conductivity Detection in Poly(methyl methacylate)-Based Microfluidic
Devices for Analysis of Mono- and Polyanionic Molecules
Author: Michelle Galloway et al.
Publication: Analytical Chemistry
Publisher: American Chemical Society
Date: May 1, 2002
Copyright © 2002, American Chemical Society
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following: Permission is
granted for your request in both print and electronic formats, and translations. If figures
and/or tables were requested, they may be adapted or used in part. Please print this page for
your records and send a copy of it to your publisher/graduate school. Appropriate credit for
the requested material should be given as follows: "Reprinted (adapted) with permission from
(COMPLETE REFERENCE CITATION). Copyright (YEAR) American Chemical Society."
Insert appropriate information in place of the capitalized words. One-time permission is
granted only for the use specified in your request. No additional uses are granted (such as
derivative works or other editions). For any other uses, please submit a new request. If credit
is given to another source for the material you requested, permission must be obtained from
that source.
DATE: 29/08/2013
Full name: Katrina Battle
Comments: Hello! I would like to use a Figure from an article published in your journal in
my dissertation in both electronic and print formats. The figure is Figure 3 from the article
titled: Proteomic Analysis of Membrane- associated Proteins from the Breast Cancer Cell
Line MCF7 from CANCER GENOMICS & PROTEOMICS 2: 199-208 (2005).
Dear Mrs. Battle:
Following your request we are pleased to permit reproduction of Figure 3 of the paper
entitled: “Proteomic Analysis of Membrane-associated Proteins from the Breast Cancer
Cell Line MCF7” by C. Pionneau et al. which was published in CANCER GENOMICS &
PROTEOMICS Volume 2, No. 4, pp. 199-208 (July-August 2005), provided that you
mention the source of information.
With best regards,
Yours sincerely,
John G. Delinasios

184

Managing Editor

International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS
1st km Kapandritiou-Kalamou Road P.O. Box 22, GR-19014 Kapandriti, Attiki Greece

Tel: +30-22950-52945 Tel/Fax:+30-22950-53389
e-mail: iiar@iiar-anticancer.org
web: www.iiar-anticancer.org / http://iiarjournals.org

From: editor@cgp-journal.com [mailto:editor@cgp-journal.com] Sent: Friday,
August 30, 2013 6:25 AM To: editor@cgp-journal.com Subject: Contact e-mail
from www.cgp-journal.com
JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS
Nov 09, 2013
This is a License Agreement between Katrina N Battle ("You") and John Wiley and Sons
("John Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license
consists of your order details, the terms and conditions provided by John Wiley and Sons, and
the payment terms and conditions. All payments must be made in full to CCC. For payment
instructions, please see information listed at the bottom of this form.
License Number 3264830399756
License date Nov 09, 2013
Licensed content publisher John Wiley and Sons
Licensed content publication Proteomics
Licensed content title Digital microfluidic hydrogel microreactors for proteomics
Licensed copyright line © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Licensed content author Vivienne N. Luk, Lindsey K. Fiddes,Victoria M. Luk, Eugenia
Kumacheva, Aaron R. Wheeler
Licensed content date May 16, 2012
Start page 1310
End page 1318
Type of use Journal
Requestor type University/Academic
Is the reuse sponsored by or associated with a pharmaceutical or medical no
Format Print and electronic
Portion Figure/table
Number of figures/tables 1
Original Wiley figure/table number(s) Figure 2
Will you be translating? No
Title of new article Microfluidic Analysis of Integral Membrane Proteins: How do we get
there?
Publication the new article is in Electrophoresis
Publisher of new article John Wiley and Sons
Author of new article Katrina Battle, Franklin Uba, and Steve A. Soper
Expected publication date of new article Mar 2014
Estimated size of new article (pages) 8
Total 0.00 USD

185

Terms and Conditions
TERMS AND CONDITIONS
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or
one of its group companies (each a "Wiley Company") or a society for whom a Wiley
Company has exclusive publishing rights in relation to a particular journal (collectively
"WILEY"). By clicking "accept" in connection with completing this licensing transaction,
you agree that the following terms and conditions apply to this transaction (along with the
billing and payment terms and conditions established by the Copyright Clearance Center
Inc., ("CCC's Billing and Payment terms and conditions"), at the time that you opened your
RightsLink account (these are available at any time at http://myaccount.copyright.com).
Terms and Conditions
1. The materials you have requested permission to reproduce (the "Materials") are protected
by copyright.
2.You are hereby granted a personal, non-exclusive, non-sublicensable, non-transferable,
worldwide, limited license to reproduce the Materials for the purpose specified in the
licensing process. This license is for a one-time use only with a maximum distribution equal
to the number that you identified in the licensing process. Any form of republication granted
by this license must be completed within two years of the date of the grant of this license
(although copies prepared before may be distributed thereafter). The Materials shall not be
used in any other manner or for any other purpose. Permission is granted subject to an
appropriate acknowledgement given to the author, title of the material/book/journal and the
publisher. You shall also duplicate the copyright notice that appears in the Wiley publication
in your use of the Material. Permission is also granted on the understanding that nowhere in
the text is a previously published source acknowledged for all or part of this Material. Any
third party material is expressly excluded from this permission.
NATURE PUBLISHING GROUP LICENSE
TERMS AND CONDITIONS
Nov 09, 2013
This is a License Agreement between Katrina N Battle ("You") and Nature Publishing Group
("Nature Publishing Group") provided by Copyright Clearance Center ("CCC"). The license
consists of your order details, the terms and conditions provided by Nature Publishing Group,
and the payment terms and conditions. All payments must be made in full to CCC. For
payment instructions, please see information listed at the bottom of this form.
License Number 3264830553161
License date Nov 09, 2013
Licensed content publisher Nature Publishing Group
Licensed content publication Nature Medicine
Licensed content title Clinical microfluidics for neutrophil genomics and proteomics
Licensed content author Kenneth T Kotz, Wenzong Xiao, Carol Miller-Graziano, Wei-Jun
Qian, Aman Russom, Elizabeth A Warner
Licensed content date Aug 29, 2010
Volume number 16
Issue number 9
Type of Use reuse in a journal/magazine
Requestor type academic/university or research institute

186

Format print and electronic
Portion figures/tables/illustrations
Number of figures/tables/illustrations 1
High-res required no
Figures a and b from Figure 1
Author of this NPG article no
Your reference number
Title of the article Microfluidic Analysis of Integral Membrane Proteins: How do we get
there?
Publication the new article is in Electrophoresis
Publisher of your article John Wiley and Sons
Author of the article Katrina Battle, Franklin Uba, and Steve A. Soper
Expected publication date Mar 2014
Estimated size of new article (number of pages) 8
Total 0.00 USD
Terms and Conditions
Terms and Conditions for Permissions
Nature Publishing Group hereby grants you a non-exclusive license to reproduce this material
for this purpose, and for no other use, subject to the conditions below:
1. NPG warrants that it has, to the best of its knowledge, the rights to license reuse of this
material. However, you should ensure that the material you are requesting is original to
Nature Publishing Group and does not carry the copyright of another entity (as credited in the
published version). If the credit line on any part of the material you have requested indicates
that it was reprinted or adapted by NPG with permission from another source, then you should
also seek permission from that source to reuse the material.
2. Permission granted free of charge for material in print is also usually granted for any
electronic version of that work, provided that the material is incidental to the work as a whole
and that the electronic version is essentially equivalent to, or substitutes for, the print version.
Where print permission has been granted for a fee, separate permission must be obtained for
any additional, electronic re-use (unless, as in the case of a full paper, this has already been
accounted for during your initial request in the calculation of a print run).NB: In all cases,
web-based use of full-text articles must be authorized separately through the 'Use on a Web
Site' option when requesting permission.
Once you receive your invoice for this order, you may pay your invoice by credit card.
Please follow instructions provided at that time.
Make Payment To:
Copyright Clearance Center
Dept 001
P.O. Box 843006
Boston, MA 02284-3006
For suggestions or comments regarding this order, contact RightsLink Customer
Support: customercare@copyright.com or +1-877-622-5543 (toll free in the US) or +1978-646-2777.
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable
license for your reference. No payment is required.

187

JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS
Nov 09, 2013
This is a License Agreement between Katrina N Battle ("You") and John Wiley and Sons
("John Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license
consists of your order details, the terms and conditions provided by John Wiley and Sons, and
the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see information
listed at the bottom of this form.
License Number 3264820629885
License date Nov 09, 2013
Licensed content publisher John Wiley and Sons
Licensed content publication Electrophoresis
Licensed content title Integrated electrokinetic sample fractionation and solid-phase extraction
in microfluidic devices
Licensed copyright line © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Licensed content author Zhen Wang, Abebaw B. Jemere, D. Jed Harrison
Licensed content date Sep 5, 2012
Start page 3151
End page 3158
Type of use Journal
Requestor type University/Academic
Is the reuse sponsored by or associated with a pharmaceutical or medical products company?
no
Format Print and electronic
Portion Figure/table
Number of figures/tables 2
Original Wiley figure/table number(s) Figure 5, Figure 6
Will you be translating? No
Title of new article Microfluidic Analysis of Integral Membrane Proteins: How do we get
there?
Publication the new article is in Electrophoresis
Publisher of new article John Wiley and Sons
Author of new article Katrina Battle, Franklin Uba, and Steve A. Soper
Expected publication date of new article Mar 2014
Estimated size of new article (pages) 8
Total 0.00 USD
Terms and Conditions
TERMS AND CONDITIONS
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or
one of its group companies (each a "Wiley Company") or a society for whom a Wiley
Company has exclusive publishing rights in relation to a particular journal (collectively
"WILEY"). By clicking "accept" in connection with completing this licensing transaction, you
agree that the following terms and conditions apply to this transaction (along with the billing
and payment terms and conditions established by the Copyright Clearance Center
Inc., ("CCC's Billing and Payment terms and conditions"), at the time that you opened your

188

RightsLink account (these are available at any time at http://myaccount.copyright.com).
Terms and Conditions
1. The materials you have requested permission to reproduce (the "Materials") are protected
by copyright.
2.You are hereby granted a personal, non-exclusive, non-sublicensable, non-transferable,
worldwide, limited license to reproduce the Materials for the purpose specified in the
licensing process. This license is for a one-time use only with a maximum distribution equal
to the number that you identified in the licensing process. Any form of republication granted
by this license must be completed within two years of the date of the grant of this license
(although copies prepared before may be distributed thereafter). The Materials shall not be
used in any other manner or for any other purpose. Permission is granted subject to an
appropriate acknowledgement given to the author, title of the material/book/journal and the
publisher. You shall also duplicate the copyright notice that appears in the Wiley publication
in your use of the Material. Permission is also granted on the understanding that nowhere in
the text is a previously published source acknowledged for all or part of this Material. Any
third party material is expressly excluded from this permission.
Once you receive your invoice for this order, you may pay your invoice by credit card.
Please follow instructions provided at that time.
Make Payment To:
Copyright Clearance Center
Dept 001
P.O. Box 843006
Boston, MA 02284-3006
For suggestions or comments regarding this order, contact RightsLink Customer
Support: customercare@copyright.com or +1-877-622-5543 (toll free in the US) or +1978-646-2777.
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable
license for your reference. No payment is required.
AMERICAN CHEMICAL SOCIETY LICENSE TERMS AND CONDITIONS
Title: Fabrication of High-Quality Microfluidic Solid-Phase Chromatography Columns
Author: Jens Huft, Charles A. Haynes, and Carl L. Hansen
Publication: Analytical Chemistry
Publisher: American Chemical Society
Date: Feb 1, 2013
Copyright © 2013, American Chemical Society
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following:
Permission is granted for your request in both print and electronic formats, and translations.
If figures and/or tables were requested, they may be adapted or used in part. Please print this
page for your records and send a copy of it to your publisher/graduate school.
Appropriate credit for the requested material should be given as follows: "Reprinted (adapted)
with permission from (COMPLETE REFERENCE CITATION). Copyright
(YEAR) American Chemical Society." Insert appropriate information in place of the

189

capitalized words. One-time permission is granted only for the use specified in your request.
No additional uses are granted (such as derivative works or other editions). For any other
uses, please submit a new request.
If credit is given to another source for the material you requested, permission must be
obtained from that source. Copyright © 2013 Copyright Clearance Center, Inc. All Rights
Reserved. Privacy statement. Comments? We would like to hear from you. E-mail us at
customercare@copyright.com
AMERICAN CHEMICAL SOCIETY LICENSE TERMS AND CONDITIONS
Title: A Digital Microfluidic Approach to Proteomic Sample Processing
Author: Vivienne N. Luk and Aaron R. Wheeler
Publication: Analytical Chemistry
Publisher: American Chemical Society
Date: Jun 1, 2009
Copyright © 2009, American Chemical Society
PERMISSION/LICENSE IS GRANTED FOR YOUR ORDER AT NO CHARGE
This type of permission/license, instead of the standard Terms & Conditions, is sent to you
because no fee is being charged for your order. Please note the following:
Permission is granted for your request in both print and electronic formats, and translations.
If figures and/or tables were requested, they may be adapted or used in part.
Please print this page for your records and send a copy of it to your publisher/graduate school.
Appropriate credit for the requested material should be given as follows: "Reprinted (adapted)
with permission from (COMPLETE REFERENCE CITATION). Copyright
(YEAR) American Chemical Society." Insert appropriate information in place of the
capitalized words. One-time permission is granted only for the use specified in your request.
No additional uses are granted (such as derivative works or other editions). For any other
uses, please submit a new request.
If credit is given to another source for the material you requested, permission must be
obtained from that source. Copyright © 2013 Copyright Clearance Center, Inc. All Rights
Reserved. Privacy statement. Comments? We would like to hear from you. E-mail us at
customercare@copyright.com

190

Vita
Katrina Nychole Battle was born in Macon, Georgia to Leonard and Sherrye Battle.
She began her early education at Hubbard Elementary School, Monroe County Middle
School, and graduated with honors from Mary Persons High School in 2004. After high
school, she chose to attend Jackson State University in Jackson, MS for her undergraduate
studies in chemistry. While at Jackson State, Katrina remained active in her studies as well as
the surrounding community. She was an active participant in the Student Government
Association, the NOBCChE Chapter on Campus, and also became a member of Alpha Kappa
Alpha Sorority, Inc. As a junior at Jackson State, Katrina was chosen to be an intern at the
National Crime Lab in Qunatico, VA through participation in the Federal Bureau of
Investigation's Summer Honor's Internship Program (SHIP). Following graduation from
Jackson State, she enrolled at Lousiana State University in Baton Rouge in the fall of 2008
where she was mentored in the Soper Research Group by Professor Steven A. Soper. She has
co-authored two publications and has presented her research at national conferences. Her
dissertation is entitled "Microfluidics for the Analysis of Integral Membrane Proteins: A Topdown Approach." The degree of Doctor of Philosophy will be conferred at the December
2013 commencement ceremony.

191

